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Abstract 
The biomedical and pharmaceutical communities are experiencing a growing demand for 
new druggable targets. On the other hand, many marketed drugs are being repurposed for their 
newly uncovered pharmacological activities. In fact, off-target drug effects can either lead to 
adverse events or new marketable indications. As the healthcare industry moves closer toward 
systems biology and precision medicine, comprehensive profiling of small molecule-protein 
interactions has become increasingly crucial. Chemical proteomics is a powerful set of 
bioanalytical approaches that utilize small molecule chemical probes and affinity capture mass 
spectrometry to study proteome-wide actions of reactive small molecules like drugs, toxins, and 
metabolites.  
This dissertation discusses multiple technical and methodological aspects of chemical 
proteomics as a multidisciplinary subject. It presents two projects that exemplify the development 
of chemical probes and implementation of chemical proteomics in two distinct directions known 
as compound-centric and activity-based. Within both studies, the modification-specific data 
processing principle has provoked awareness and thoughts on tailoring bioinformatics tools for 
chemical proteomics. 




The 2-nitroimidazole-indocyanine green (2-nitro-ICG) project features the deployment of 
a novel compound-centric chemical probe that answers how 2-nitroimidazole targets tumor 
hypoxia. This study concludes that 2-nitro-ICG and its reduced fragments modify mouse albumin 
as the primary target, but at two distinct sites via two different mechanisms. The development and 
application of 2-nitro-ICG also demonstrate various analytical benefits, challenges, and pitfalls in 
the compound-centric direction of chemical proteomics. 
The α-methylene-β-lactone (MeLac) project presents an innovative activity-based probe 
with multiple electrophilic sites. This study explores the significance of broad probe reactivity in 
activity-based chemical proteomics. It concludes that MeLac is reactive to amino, hydroxyl, and 
thiol groups on proteins. Moreover, the discovery of MeLac-alkyne glutathione adduct reveals a 
potential shortcut for customizing compound-centric probes. Therefore, the multi-electrophilic 
MeLac moiety creates both a versatile activity-based probe and a scaffold for assembling 
compound-centric probes. 
Overall, chemical proteomics has established its irreplaceable position in chemical biology. 
Researchers exert efforts to make chemical proteomics technologies more applicable. The 
chemical tools, analytical workflows, and bioinformatics support continue to improve. The field 
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Chapter 1 Introduction to Chemical Proteomics 
This chapter begins with a briefly introduction to the omics concept and its application in 
modern biomedical and pharmaceutical research. Afterwards, it mainly focuses on a 
comprehensive overview of bottom-up proteomics. The discussion touches multiple technical 
aspects on sample preparation, analytical instrumentation, chemical tools, analytical 
methodologies, and bioinformatics throughout a typical mass spectrometry-based bottom-up 
proteomics workflow. Finally, the discussion extends to the introduction to chemical proteomics 
involving application of these chemical tools and analytical approaches for studying proteome-
wide activity of small molecule compounds. The final discussion covers several challenges and 





1.1 Multi-Omics as a Promising Path to Precision Healthcare 
The universal detection and measurement of whole sets of biomolecules shape the 
technological fundamental of omics research. The principle that a complex biological system can 
be understood better if treated as a whole defines the characteristic methodology of the omics 
approach.  
Modern biomedical and pharmaceutical research often generates and tests hypotheses by 
exploring the context of organelles, cells, tissues, organs, and organisms at the molecular level. 
These explorations scrutinize functions and compositions of individual biological molecules and 
address their interactions, relationships, and combined influence on an organism’s growth and 
development. The omics approach is particularly suitable for those explorations. In hypothesis-
generating experiments, the omics approach acquires and analyzes all available data to construct 
a hypothesis. In hypothesis-testing experiments, the omics approach highlights nuance, models 
trends, and builds connections among various subsets of multiple complex biological samples. It 
often discovers missing pieces from the existing knowledgebase. Moreover, the holistic datasets 
accumulated in omics research are ready for retrograde analyses if necessary, even for completely 
irrelevant objectives.  
Thus, omics research naturally produces archivable data with great long-term values. A 
complete biological sample only provides four sets of biological molecules, DNA/genes (genome), 
mRNA (transcriptome), proteins (proteome), and metabolites (metabolome). From the genome to 
metabolome, the volume of information expands as molecular diversity increases. (Figure 1.1) 
Given the biological and chemical differences and similarities among these molecules, omics 
research uses a variety of bioanalytical strategies and techniques. While genomics and 




detection, proteomics and metabolomics employ liquid chromatography-tandem mass 
spectrometry (LC-MS/MS) as the main analytical platform. 
The principle of omics dates to the early 2000s with the completion of the Human Genome 
Project.1 The establishment of automated high-throughput DNA sequencing and synthesis 
pipelines formed the technological foundation for modern genomics research.2,3 Meanwhile, the 
introduction of complementary DNA (cDNA) microarray and mass spectrometry-based protein 
profiling technologies also enabled the quantitative analysis of the differential global gene 
expression at messenger RNA level and protein level.4 These powerful tools marked a historical 
milestone in transcriptomics and proteomics research. On the other hand, the growing availability 
of spectroscopy, mass spectrometry, and nuclear magnetic resonance instruments allowed 
functional analysis at the metabolite level, which was initially referred to as metabolic profiling 
and metabolic control analysis.5 It was remarkable that the concept of complete multi-omics study 
on the yeast model was reported as early as 1998.5,6 
Nowadays, proteomics and metabolomics research frequently contribute to the 
development of biomolecular indicators known as biomarkers7,8 for disease diagnosis9, 
progression monitoring10, drug absorption, distribution, metabolism, and excretion (ADME) in 
pharmacokinetics and pharmacology (PK/PD)11 studies. (Figure 1.2) Moreover, proteomics 
platforms are also implemented with chemical tools that facilitate the analyses of intermolecular 
interactions of proteins with other molecules. For instance, covalent chemical probes that react and 
label proteins can analyze small molecule drug candidates’ effects on the target protein activity in 
various stages of drug development, such as evaluating drug-target engagement, revealing off-
target effect, and assessing drug toxicity.12 Protein cross-linking reagents that react and conjugate 




biological roles of protein complexes.13 Complementary to genomics and proteomics platforms, 
advanced metabolomics platforms rapidly expand knowledgebase of biochemical pathways and 
metabolic networks in various organisms, which has led to recent achievements in studies on gut 
microbiome-related regulations of human immune system.14 
Analytically, omics samples are essentially mixtures of diverse biomolecules that require 
pre-analysis preparation. Depending on the specific analytical goal, separation/extraction 
techniques, which preserve a subgroup of these biomolecules as analytes of interest and remove 
the rest as interference, are practiced accordingly. The protein or metabolite analytes in the 
prepared samples are then resolved and measured at molecular level on liquid or gas 
chromatography-mass spectrometry (LC-MS or GC-MS) systems. While high-resolving 
power/accurate-mass (HR/AM) mass spectrometers enable unambiguous measurements of 
biomolecules, ultra-high-performance liquid chromatography (UHPLC) systems provide extra 
separation of various analytes online. Advanced mass spectrometers are often equipped with 
instrumental components that can break down ions of analytes into fragments for tandem mass 
spectrometry (MS/MS) measurements. These fragments contain more useful information as 
molecular fingerprints. The capability of generating and measuring gas-phase fragments further 
reinforces the analytical impact of mass spectrometers on the omics research. In fact, researchers 
routinely use selective measurement of fragment ions generated in the gas phase as the method of 
choice for quantifying biomolecules of interest in quantitative proteomics and metabolomics. 
Apparently, the LC-MS/MS, a hyphenated analytical technology, has become the technological 
core of the proteomics and metabolomics research.  
Overall, contemporary multi-omics platforms (genomics, transcriptomics, proteomics, and 




systems are driving the fast advancement of multidisciplinary biomedical subjects such as systems 
biology, synthetic biotics8 and translational medicine15, which ultimately enact precision and 





1.2 The Bottom-up Proteomics Workflow 
1.2.1 Overview of proteomics 
Proteomics is the comprehensive study of proteins. It deciphers protein structures, post-
translational modifications (PTMs), cellular functions, biological/pathological significances, and 
interactions with other molecules. Since proteins are the most important cellular machinery and 
building blocks, proteomics investigations are being conducted at an escalating rate to explore 
pathologies of a wide range of diseases and medical conditions including but not limited to 
cancer7,16,17, neuro-degenerative disease18,19, infectious disease20,21, metabolic disorders22,23, 
autoimmune disease24,25, and cardiovascular disease26. Proteomics studies routinely involve the 
large-scale experimental analysis of proteins.  
Depending on the specific study objective, proteins are analyzed either in their original 
forms (native, slightly reduced, or denatured) or proteolytically cleaved forms. This analytical 
choice further splits proteomics into two strategic divisions as top-down proteomics and bottom-
up proteomics (also known as shotgun proteomics27). Each of them has its unique sets of 
experimental practices and analytical emphases. In general, the top-down strategy is more suitable 
for protein structure elucidation of purified protein samples. It has the potential to access complete 
protein sequences and ability to locate and characterize PTMs. It also eliminates the protein 
digestion step that is most time-consuming but mandatory part of the sample preparation for 
bottom-up proteomics. However, top-down proteomics is a relatively young field.28 It requires the 
most advanced instrumentation and higher operation costs while suffering from a large number of 
analytical limitations. In comparison to the top-down strategy, the bottom-up strategy is the 




Nevertheless, all proteomics experiments often require constant development and 
implementation of effective analytical techniques. The present collection of various technical 
disciplines that contributes to proteomics include gel electrophoresis, chromatography, affinity 
pull-down/immunoprecipitation, spectrophotometry, fluorophotometry, fluorescence imaging, 
immunoblotting, and most importantly mass spectrometry. In general, a typical bottom-up 
proteomics workflow (Figure 1.3) consists of three major steps as sample preparation, 
instrumental sample analysis, and data processing for biological inferences.  
1.2.2 Sample preparation 
The proteomics workflow begins with preparation of complex biological samples. The 
overall purpose of proteomics sample preparation is to collect analytes of interest from the samples 
and convert them into instrument-compatible forms. The implementation of a specific sample 
preparation workflow entails a balance of method efficiency, reproducibility, and cost. A typical 
proteomics sample preparation workflow is a four-step procedure that involves a series of physical 
and chemical processes. These four steps are cell lysis, protein separation/clean-up, proteolytic 
cleavage/digestion, and peptide separation/clean-up. 
1.2.2.1 Cell lysis 
As the first step, crude biological samples, such as cell culture pellets, animal tissues, and 
organs, are physically homogenized in a lysis buffer that consists of buffering agents, protease 
inhibitors, and a surfactant such as octyl phenoxypolyethoxylethanol (NP-40) or Triton X-100 at 
refrigeration temperature. Although homogenization can be a manual process that takes place in a 
Dounce tissue grinder, advanced mechanical forces introduced by focused bursts of ultrasonic 
waves or high-frequency bead beating are usually preferred for extraction of whole-cell protein 




cellular protein contents. Particulates are usually removed from the samples either via high-speed 
centrifugation or filtration through 0.2 μm filters. Additional cell fractionation is necessary for 
more efficient extraction of low-abundance proteins. Mild surfactants such as saponin and 
digitonin are suitable for the extraction of cytosolic proteins. In contrast, strong ionic surfactants 
such as sodium dodecyl sulfate and sodium deoxycholate are required for the extraction of nuclear 
proteins. However, these ionic surfactants can denature proteins and are incompatible with 
experiments that require protein integrity.  
For some special human or animal proteome samples such as plasma and sera, the initial 
preparation steps generally focus on the depletion of high-abundant proteins rather than 
solubilization of the whole proteome. Plasma samples consist of mainly high-abundance proteins 
such as albumin, haptoglobin, hemopexin, immunoglobulins, which are usually not the target 
proteins of interest. Large quantities of immobilized antibodies on agarose resins are usually used 
to scavenge these high-abundance inference proteins. These immunodepleting materials are 
commercially available at relatively high costs. 
1.2.2.2 Total protein quantitation assay 
It is crucial to measure the total protein concentration of lysates. Although the 
concentration of a protein solution can be directly determined from spectrophotometric 
measurements at 280 nm for its UV absorption, reagent and dye-based assays are preferred for 
higher analytical performance. Several conventional protein assay techniques are available. The 
bicinchoninic acid (BCA) assay29 and Lowry assay30 are redox reaction-based assays, where the 
protein reduces copper(II) ions to copper(I) ions that form a colored complex. It strongly absorbs 
light at a specific wavelength (562 nm for BCA assays and 660 nm for Lowry assays). 




Blue G-250 dye undergoes a light absorption spectrum shift upon binding to proteins. Therefore, 
the absorbance at 595 nm is proportional to the amount of protein-bound dye, and thus to the 
sample’s protein concentration. Reagents for these assays are commercialized and used routinely 
in proteomics research. In a total protein quantification assay experiment, reagents are mixed with 
protein solutions to produce a measurable color change in proportion to the protein amount. The 
total protein concentration of a lysate is determined by referring to a calibration curve constructed 
with the assay readout of several known concentrations of a purified reference protein, such as 
bovine serum albumin. The BCA assay features compatibility with surfactants and less protein-to-
protein variation while the Bradford assay features easy preparation and compatibility with 
chaotropic and reducing agents. Therefore, the BCA assay is the most popular choice in lysate 
protein quantitation because of the surfactants in lysate samples. 
1.2.2.3 Size-exclusion chromatography 
Frequently, it is necessary to remove certain small molecule interference, such as assay 
incompatible surfactants, buffering agents/salts, excessive reagents, reducing agents, and 
chaotropic agents, from the lysate sample matrix while retaining its protein content. The size-
exclusion chromatography (SEC) is the most efficient technique to perform a buffer exchange, 
which replaces the entire sample matrix of small molecules with one compatible to downstream 
processes. The buffer exchange SEC is usually performed in spin column format. The lysate 
sample is gradually loaded to the resins packed in a spin column, where small molecules will enter 
the resin matrix and become retained while large molecules will bypass the resin matrix and elute 
early. Alternative techniques, including molecular filtration using micro-spin filters and dialysis 
using semi-permeable membrane inside a cassette, are also available. However, compared to SEC, 




1.2.2.4 Gel electrophoresis 
Within the polyacrylamide gel, the porous gel matrix retains proteins and isolates them 
from the sample matrix. Driven by electrophoretic forces in the electric field, proteins undergo 
differential migration and thus separation in the polyacrylamide gel matrix with an appropriate 
buffer composition according to their size (sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis, SDS-PAGE), charge (isoelectric focusing-polyacrylamide gel electrophoresis, 
IEF-PAGE), or a mixed factor of the size, charge, and shape (native polyacrylamide gel 
electrophoresis, native PAGE). The two-dimensional gel electrophoresis is essentially a serial 
implementation of IEF-PAGE and SDS-PAGE as orthogonal separation techniques to resolve 
different proteins in a lysate sample. Gel electrophoresis techniques are used for both analytical 
and preparative purposes in proteomics research. Analytical protein gel electrophoresis provides 
an expedited way to visualize the global protein composition of the sample upon colorimetric 
staining and validate target proteins upon affinity/reaction-based fluorescence detection, which 
can be used as both an upstream sample preparation checkpoint and supplementary data to the 
mass spectrometry-based proteomics profiling result. On the other hand, preparative protein gel 
electrophoresis provides an interactive approach to purify protein analytes and isolate proteins of 
interest with on-spot verification. The (fluorescence imaging) verified target protein gel bands or 
spots can be excised and undergo the in-gel protein digestion process to prepare enriched MS-
compatible analytes. 
1.2.2.5 Affinity capture 
When proteins of interest are distinguishable from the rest of proteins within the sample 
matrix, affinity capture (also known as affinity pull-down or affinity enrichment) techniques can 




on agarose or magnetic beads can enrich proteins chemically labeled with the biotin affinity tag. 
Monoclonal antibodies immobilized on magnetic beads can also capture specific target proteins 
with or without engineered amino acid sequence tags (such as polyhistidine tags) via 
immunoprecipitation (IP) or protein complex immunoprecipitation (Co-IP) processes. 
The biotin-(strept)avidin system serves as the technological core of an enormous number 
of approaches to analyze and manipulate molecular interactions within complex biological 
matrices. It has been decades since the discovery and first laboratory application of this tightest 
protein-ligand binder (Kd ~ 10
-15 M) that nature ever creates. Yet, its prevalence in biological 
sciences never seems to diminish.32,33 Despite nuances among the strategies of its specific 
applications, the four-step general principle remains the same: (a) Tag the target with biotin, 
directly or indirectly, covalently or non-covalently. (b) Conjugate the (strept)avidin to a reporter 
group (for detection) or immobilizing matrix (for isolation), directly or indirectly, covalently or 
non-covalently. (c) Remove irrelevant species by fractionating a reaction mixture of the tagged 
target and its complementary (strept)avidin conjugate. (d) Analyze and recover relevant remnants 
by monitoring and alternating its physicochemical environment, such as photochemical response, 
pH, redox, etc.  
1.2.2.6 Protein digestion 
Bottom-up proteomics focuses on the analysis of proteolytic products of protein mixtures. 
It requires at least one protease to cleave protein analytes into shorter peptides. LC-MS/MS 
analyzes the resulting complex peptide mixture. Among all naturally occurring or engineered 
proteases, trypsin is usually the protease of choice for protein digestion in bottom-up proteomics. 
As a serine protease found in animal small intestines, trypsin is highly specific and only cleaves 




proline. The resulting tryptic peptides carry either a C-terminal arginine or lysine, both of which 
are highly basic and easily carry positive charges, leveraging their ionization efficiency and thus 
detectability by mass spectrometers. Less frequently, alternative proteases such as chymotrypsin, 
LysC, LysN, AspN, GluC, ArgC, etc. are also used in proteomics.34 
1.2.2.7 Offline peptide fractionation 
In proteomics profiling, a complex lysate digest can be prepared into several fractions 
before the LC-MS/MS analysis to improve the overall analytical performance. Similar to two-
dimensional online LC, offline fractionation also utilizes an additional chromatographic 
mechanism that is orthogonal or semi-orthogonal to the online reverse-phase chromatography. 
Popular peptide fractionation methods include strong cation exchange (SCX)35 chromatography, 
hydrophilic interaction chromatography (HILIC)36, and high-pH reversed-phase fractionation 
(HpH)37. These methods have been successfully implemented in large-scale proteomics studies to 
greatly improve the protein sequence coverage and PTM hits. 
1.2.3 Liquid chromatography 
In theory, mass spectrometry is perceived as the central technology that allows 
identification and quantitation of thousands of peptides in a complex proteome digest. Liquid 
chromatography (LC) is recognized as the indispensable tool that provides high-performance real-
time separation of those peptides. HPLC relies on fluidic pumps to pressurize liquid solvents 
(mobile phase) that carry a sample mixture of analytes through a column packed with a solid 
sorbent material (stationary phase). Governed by its physicochemical properties, each analyte in 
the sample interacts differently with the stationary phase as the sample mixture travel through the 
column. The separation of analytes occurs when the retention differences of analytes within the 




depends on several physical parameters. With a given set of these parameters, the separation 
efficiency per unit column length can be described as the reciprocal of theoretical plate height 
which is modeled by the van Deemter equation38. For a specific LC column, the smaller the 
theoretical plate height, the larger the theoretical plate number, and thus the higher the separation 
efficiency. As exemplified in Figure 1.4, the van Deemter equation is a hyperbolic function that 
predicts the plate height from a linear velocity of mobile phase as the variable and three 
contributing terms as constants. This model implies it is possible to maximize the separation 
efficiency for a specific column by just tuning the flow rate of the LC for the optimal linear velocity 
of the mobile phase.  
In practice, LC serves as the last but best step of separation that reduces proteomics sample 
complexity prior to mass spectrometric analysis. Although the LC separation plays a critical role 
in bottom-up proteomics for protein/peptide identification and quantitation, LC methods are 
developed and implemented in a relatively conservative and standardized manner. A typical 
bottom-up proteomics LC setup consists of a nanoflow LC system, a nanoflow reverse-phase 
column (usually packed with C18 stationary phase) coupled to a compatible emitter interfacing the 
ESI inlet, and a binary mobile phase system (usually comprised of 0.1 to 0.2% of formic acid in 
water as the weak solvent and 0.1 to 0.2% of formic acid in acetonitrile as the strong solvent). 
Such nanoflow reverse phase LC setups are empirically known, heavily tested, and experimentally 
justified for the optimal peptide resolution and sensitivity as well as practicability. In addition to 
the simple reverse-phase LC setup, the multidimensional protein identification technology 
(MudPIT) was designed to integrate an SCX column and a reversed-phase column in a biphasic 




multidimensional LC setups gradually become less desired as mass spectrometers become more 
powerful in separating and resolving ions in the gas phase. 
1.2.4 Mass spectrometry instrumentation and implementation in 
proteomics 
The general principle of mass spectrometry (MS) is to generate ions of analytes from 
samples and measure them via an optimal analytical method. Capable of ionizing analytes, 
separating, and detecting ions in the gas phase, all mass spectrometers share the basic setup 
consisting of an ion source where solution-phase molecules are converted to gas-phase ions, mass 
analyzer(s) where gas-phase ions are separated, and detector(s) where signals from the ions are 
measured. The readouts of mass spectrometers are mass-to-charge ratio (m/z) values and their 
abundance-correlated signal intensities over the period of measurement. MS datasets can provide 
two types of extracted data: mass spectra and ion chromatograms. While a plot of intensity vs. m/z 
values at a specific time provides a mass spectrum, the plot of ion intensity (sum of 
intensity/current within a given m/z range) vs. time presents an ion chromatogram. Subsequently, 
mass spectra are generated for compound identification, but chromatograms are derived for analyte 
quantitation. In addition to the basic MS setup, advanced mass spectrometers are also equipped 
with collision cell(s), where deliberate gas-phase fragmentation of target ions can take place. These 
instruments offer multi-stage experimental setups that enable breaking down analyte ions into 
fragments in the gas phase for further analysis. These setups are defined as tandem mass 
spectrometry, MS/MS (MS2), or MSn, where “n” is the number of fragmentation stages. In bottom-
up proteomics, it is the MS/MS that serves as the technical fundamental to sequence peptides and 
identify proteins. 




Mass spectrometry is the study of gas-phase ions and their chemistry. The ion source 
generates these ions. Since the downstream components in a mass spectrometer such as mass 
analyzers and detectors can only handle charged species, ionic forms of analytes in the gas phase 
must be created from analyte molecules in solutions. Although a wide range of ionization methods 
are available, proteomics primarily uses electrospray ionization (ESI) and matrix-assisted laser 
desorption/ionization (MALDI) due to their preferred “softness” for ionizing peptide and protein 
analytes while causing minimal in-source fragmentation of these analyte ions. 
ESI is known as the softest ionization technique for solution-to-gas phase conversion of 
analytes. Due to its ionization softness and universal compatibility to LC systems, ESI is the 
method of choice in analyzing peptides and proteins.40 At the ESI source, the pressurized sample 
solution (either from LC or from a syringe pump) is forced to pass through an electrospray emitter 
(a needle made of either metal or metal-coated glass) at a flow rate ranging from hundreds of 
nanoliters per minute to microliters per minute. The emitter is constantly charged and holds an 
electric potential of 2 to 6 kV relative to the ion inlet. During the ESI process (Figure 1.5), the 
electrically sprayed aerosol, comprised of microscopic droplets, is generated. These droplets, 
which carry electric charge on the surface, gradually shrink and disintegrate due to the evaporation 
of solvent and desorption of ions from the solution. Analyte ions are generated via two 
mechanisms: Coulombic fission and surface evaporation. The former mechanism assumes that the 
increase of charge density of a droplet, due to solvent evaporation, causes the droplet to split into 
multiple smaller ones, which ultimately form individual ions in the gas phase. The latter assumes 
that the increase of charge density of a droplet, resulting from solvent evaporation, escalates 




release of ions from the surface of droplets. This process is usually accelerated by heat and 
countercurrent streams of nitrogen gas at microliter flow rates of sample infusion. 
MALDI ionizes the dried samples mixed with a suitable crystalline matrix such as sinapinic 
acid and ferulic acid on a metal plate via pulsed laser (Figure 1.5). It is known only to generate 
singly charged ions. In proteomics, MALDI-MS is normally used for the fast identification of 
reconstituted protein samples isolated from gel electrophoresis, size exclusion chromatography, 
and ion exchange chromatography.41 Unlike ESI, which interfaces with LC systems at the 
atmospheric pressure, the MALDI source usually requires the prepared sample matrix plate placed 
in a vacuum chamber where the ionization takes place. The potential uneven distribution of 
analytes on the matrix plate makes MALDI a less quantitative ionization method compared to ESI. 
Therefore, the application of MALDI is normally limited to the qualitative protein analysis in the 
top-down proteomics while the ESI is more versatile. 
1.2.4.2 Mass analyzers 
In a mass spectrometer, the mass analyzer separates ions in the gas phase before the 
detector measures the m/z values of these ions. The separation of gas-phase ions can be either 
spatial or temporal, according to the physics of the mass analyzer. The resolving power of a mass 
analyzer describes its ability to separate ions with similar m/z values. The higher the resolving 
power, the smaller the distinguishable differences among m/z values. Quadrupole (Q) and ion trap 
are two types of low-resolving power mass analyzers used in proteomics. Time-Of-Flight (TOF), 
Fourier-transform ion cyclotron resonance (FT-ICR), and Orbitrap are three types of high-
resolving power mass analyzers used in proteomics. Both quadrupole and TOF separate ions in 
space. The ion separation occurs in a quadrupole via its alteration of the electric field that enforces 




is also referred to as a quadrupole mass filter or mass selector. The ion separation occurs in a TOF 
mass analyzer via the amplification of the m/z dependent ion differential flight distances in the 
vacuum after the initial acceleration in the electric field. The TOF mass analyzer features the 
intrinsic compatibility to the MALDI source and a wide measurable m/z range at a high spectrum 
acquisition rate; its use is mostly preferred in top-down proteomics. By trapping ions in an 
alternating electric field in the vacuum, the ion trap, FT-ICR, and Orbitrap separate ions in time. 
Detection of trapped ions in an ion trap requires the selective release of ions with specific m/z 
values and the physical contact of these ions with the detector. However, the detection of trapped 
ions in the FT-ICR and Orbitrap does not require the physical contact of any ion with the detector; 
its detection is achieved via electromagnetic induction. In practice, the FT-ICR is known for its 
highest resolving power but low scan rate, which is only suitable for top-down proteomics analysis. 
Orbitrap is becoming the gold standard for proteomics due to its tunable performance balance 
between the resolving power and scan rate, which can be used in both top-down and bottom-up 
proteomics. 
1.2.4.3 Gas-phase peptide fragmentation and tandem mass spectrometry 
The MS/MS process can be simply perceived as two-stage mass analysis of analyte ions. 
This process thus involves two mass analyses, with the first mass analysis selecting ions within a 
specific m/z window. This m/z value is characteristic of a pre-defined analyte precursor from the 
sample mixture. These precursor ions then pass through a gas-pressurized compartment where they 
are activated and break into fragments that are also known as product ions. The fragmentation can 
be achieved via different mechanisms. Collision-induced dissociation (CID; also known as 
collisional activation dissociation, CAD) and higher-energy collisional dissociation (HCD) are two 




accumulate thermodynamic energy for their dissociation. The resulting product ions are further 
subjected to the second mass analysis, following by ion detection for compiling a structure-specific 
mass spectrum for the precursor.  
Unlike those of proteins and small metabolites, fragmentation patterns of peptides that 
provide the sequence information are well documented and highly predictable. The trait makes the 
bottom-up proteomics results more credible and reproducible than others. The interpretation of a 
peptide MS/MS spectrum involves assignments of six types of fragment ions generated from the 
peptide backbone. When the cleavage of an amide bond on a positively charged peptide occurs, b 
and y ions are produced. The apparent cleavage of a Cα-C bond annotates a and x ions. When the 
cleavage of an N-Cα bond occurs, c and z ions are produced. The a, b, and c ions have a positive 
charge on the N-terminus while the x, y, and z ions have a positive charge on the C-terminus. The 
number of amino acids contained in the fragment ion is noted in a subscript, for instance, b3 as the 
N-terminal ion produced by the cleavage of the 3rd amide bond counting from the N-terminus, and 
y6 as the C-terminal ion produced by the cleavage of the 6
th amide counting from the C-terminus 
(Scheme 1.1). Systematic analysis of mass spectra containing information on these product ions 
forms the technological basics of mass spectrometry-based peptide sequencing.  
In addition to CID and HCD, other fragmentation mechanisms such as electron-transfer 
dissociation (ETD), electron capture dissociation (ECD), and ultraviolet photodissociation 
(UVPD) are also used in proteomics for studies of PTMs, intact proteins, and cross-linked protein 
complexes. ETD and ECD fragmentation mechanisms are known to preserve PTM information 
better than CID and HCD. In comparison to CID and HCD that primarily produce b and y ions 
from peptides, ETD and ECD can produce a predictable, homologous series of c and z ions that 




1.2.4.4 Modes of spectral data acquisition in bottom-up proteomics 
The bottom-up proteomics pipeline begins with proteomics profiling experiments to 
characterize complex proteome samples and discover proteins of interest from identification and 
quantitation of individual protein components. The data-dependent acquisition (DDA, Figure 1.6) 
mode is the classic LC-MS/MS method for measuring protein samples in a proteomic profiling 
experiment.42,43 In the LC-MS/MS profiling experiment, LC column-separated tryptic peptides are 
introduced to the mass spectrometer and converted to protonated gas-phase ions at the ESI source. 
The mass spectrometer loops the measurement of these peptide ions in duty cycles. In each duty 
cycle, the instrument first performs a quick MS1 survey scan for all the detectable ions. Second, 
the instrument identifies “top N” (according to the pre-set “N” value in the instrumental method) 
precursor ions with the highest intensities as targets for gas-phase fragmentation and MS2 
analyses. Third, the instrument performs a series of MS2 scans for all these target ions. During 
each MS2 scan, the instrument isolates, fragments, and measures the product ions of each pre-
selected target ion, generating target-specific MS2 spectra. Moreover, programmable DDA filters 
(such as charge state inclusion/exclusion, dynamic exclusion, and isotope pattern matching) are 
used routinely to maximize the detectability and MS2 analyses of peptide analytes. However, due 
to the stochastic ion sampling, limited scan rates of mass spectrometers and inadequate peak 
capacities of LC44, DDA data usually fails to provide a complete picture of the sample. 
In recent years, data-independent acquisition (DIA) has been gaining popularity45-49, thanks 
to faster computers and sophisticated data mining algorithms50-54. In contrast to DDA, DIA (Figure 
1.6) does not rely on the MS1 survey scans that trigger the selection of detected precursor ions for 
gas-phase fragmentation and subsequent MS2 scans of their product ions. In a DIA mode, the mass 




fragmentation, AIF55; MSE56) or precursor ion isolation window (MSX-DIA57,58, SWATH59) so 
that each duty cycle can cover a broad range of spectral information. However, such information 
is usually not immediately available and requires in-depth post-acquisition processing of resulting 
DIA datasets containing complex spectra of fragment ions.50,60 While the analysis of DIA data can 
be tricky, each dataset provides a more complete and less biased depiction of the sample.61 When 
incorporated with internal standard peptides for retention time normalization, a DIA method was 
shown to outperform a typical DDA method in both the number of consistently identified peptides 
across multiple measurements and quantitation of proteins with various abundance.62 Furthermore, 
archived DIA datasets hold more value than DDA datasets in retrospective analyses60,63 when the 
knowledge of previously-unknown analytes becomes available. However, DIA methods lack the 
ability of generating high-quality precursor-specific MS2 spectra, thus may suffer from poorer 
specificity of identified peptides than that of DDA methods. Because every scan of DIA contains 
multiple groups of fragment ions (corresponding to different peptidyl precursor ions) recorded on 
a single MS2 spectrum in a convoluted manner while DDA scans are designed only to measure 
the fragment ions generated from a single defined precursor ion in principle.  
In the downstream segment of the bottom-up proteomics pipeline, protein targets of interest 
are usually analyzed as tryptic peptides in a target-specific manner that ignores or removes 
everything other than the target analytes from the sample. The targeted proteomics relies on two 
acquisition modes known as selected reaction monitoring (SRM; also known as multiple reaction 
monitoring, MRM) on the triple quadrupole (QqQ) tandem mass spectrometer and parallel reaction 
monitoring (PRM) on the quadrupole-orbitrap (Q-Orbi) tandem mass spectrometer. When a QqQ 
instrument operates in the SRM mode (Figure 1.7), its first mass analyzer (Q1) selectively 




precursor ions are then subject to CID in a collision cell (q2) filled with neutral gas regulated with 
proper instrumental settings. This process produces a variety of fragment ions of the target analyte. 
However, only a few pre-selected fragment ions with high intensity and specificity are, once again, 
selectively transmitted through the second mass analyzer (Q3). The transmitted ions finally reach 
the detector in the mass spectrometer, and detected signals are recorded as an ion chromatogram 
for a precursor-fragment ion pair, which is known as a transition in the SRM MS experiment. 
Transitions are pre-determined during the experiment design stage. Notably, new QqQ mass 
spectrometers are faster and can analyze a larger number of transitions within a duty cycle. The 
duration of a duty cycle is defined as the cycle time, while the time the instrument spends on 
scanning each transition is defined as the dwell time. The cycle time heavily depends on the LC 
gradient profile, which affects the chromatogram peak widths of peptides because a good 
quantitation method usually implements 12 to 20 data points per LC peak and 3 to 5 transitions 
per peptide.64 Moreover, with robust LC instrumentation and known LC retention profiles of target 
peptides, the SRM acquisition can be scheduled for a limited number of expected transitions at 
each specific time window. This scheduled SRM method can greatly leverage the total number of 
transitions per run. Overall, selective ion transmission features SRM MS analysis with excellent 
limits of quantitation (LOQs), high specificity, and a wide dynamic range at a lower cost.  
In contrast to SRM, the PRM mode is the next-generation ion monitoring technique 
exclusive to high-resolving power and high-mass accuracy hybrid tandem mass spectrometers like 
quadrupole-orbitrap.65-68 The principle of PRM MS is comparable to SRM MS (Figure 1.7). 
Briefly, the quadrupole mass analyzer of these tandem instruments selects precursor ions. These 
precursor ions then undergo high-energy collisional dissociation (HCD) in a collision cell. 




global detectability of peptide analytes.69 These fragment ions are transmitted to an orbitrap mass 
analyzer for gas-phase separation and detection at MS2 level with high resolving power and high 
mass accuracy. Unlike the SRM, which records the signal for one fragment ion of the selected 
precursor at a time, the PRM simultaneously detects a full range of fragment ions of one precursor. 
Therefore, the number of fragment ions does not restrict the speed of such a full scan, which is 
instead limited by the orbitrap mass analyzer’s resolving power. The LOQ of analytes in the PRM 
mode can be improved by summing intensities of multiple fragment ions, which makes up the 
sensitivity loss due to compromised transmission of individual fragment ions (compared to SRM). 
Moreover, the full scan of fragment ions can eliminate the need for selecting best precursor-to-
fragment ion pairs before LC-MS/MS measurements. For the PRM data processing, the mass 
accuracy (in ppm) and isotope distribution patterns of each measured fragment ion can be 
incorporated as part of data-refinement algorithms to minimize the background interference and 
false detection. The implementation of PRM-based quantitation methods can be easier than SRM-
based methods due to the fact that targeted proteomics methods are usually built based proteomics 
profiling data, which are mostly acquired on the same Orbitrap-based mass spectrometers used in 
PRM MS experiments due to the growing trend of Orbitrap-based proteomics practice. Overall, in 
addition to its SRM-comparable target quantification capability, the PRM technique offers more 
analyte multiplexity and an easier LC-MS/MS-based assay development workflow.  
1.2.5 Bioinformatics of database search and peptide identification 
The rapid advancement of mass spectrometry-based proteomics has shifted large-scale 
studies of protein sequences from the genomics/transcriptomics-based prediction towards direct 
analysis of complex protein mixtures. The practice of mass spectrometry-based protein 




These software tools identify proteins by referring to and searching sequence databases acquired 
from the genomics sequence infrastructure. In a typical bottom-up proteomics profiling 
experiment, MS/MS spectra are acquired from peptides generated from trypsin digestion of 
complex protein mixtures. These MS/MS spectra are stored as two-dimensional arrays of signal 
intensity (integers) versus m/z (floating point numbers) values. Each of these MS/MS spectral 
datasets is also tagged with its corresponding precursor ion m/z, charge state, and retention time 
on the LC column. In general, a computer program splits the database search process into four 
steps to assign a peptide identity to such a MS/MS spectrum. These four steps are input pre-
processing, in silico protein digestion, peptide mass filtering, and peptide-spectrum 
matching/scoring. (Figure 1.8) 
1.2.5.1 Input pre-processing 
A database search program initiates a new task by reading and extracting information from 
two pieces of input data: the protein sequence database predicted from genomics and raw MS/MS 
data (usually acquired by an HR/AM mass spectrometer in DDA mode). The former is stored in 
FASTA format as a single text-based file compiling all known protein sequences from the 
proteome of a specified organism. For each protein entry, the first line in a FASTA file starts with 
a”>” (greater-than) character that followed by the entry title consisting of the protein name and 
comments parsed by other special characters. The second line is the actual protein sequence itself 
in the standard single letter code for amino acids. The raw LC-MS/MS data are stored in 
proprietary formats (e.g., RAW, and WIFF) that are convertible to open-source formats (e.g., 
mzML, and MGF). The program either directly reads raw data files in their proprietary formats or 
requires third party software for the conversion to an open-source format. After the import of raw 




spectral data reduction with a series of calculations that convert the raw MS/MS spectra to search-
compatible ones. These calculations include centroiding, mass rounding, de-isotoping, and charge 
state reduction. The centroiding refers to calculations that extract apex m/z values of continuously 
sampled data points in the interval recording (profile or continuum) mode of the mass 
spectrometer. The mass rounding refers to calculations that round the m/z values to less precise 
figures according to a pre-defined mass accuracy threshold. The de-isotoping refers to the practice 
that merges multiple m/z peaks and isotope clusters that feature the same fragment ion in different 
charge states on the sample MS/MS spectrum. The charge state reduction is always performed as 
part of the de-isotoping, which preserves only the m/z peaks of singly charged fragment ions on 
processed MS/MS spectra. These pre-search MS/MS spectrum processing measures can greatly 
facilitate down-stream search algorithms by reducing data complexity and increase the overall 
computational efficiency. 
1.2.5.2 in silico protein digestion 
Similar to the process of the actual enzymatic digestion of proteins, the in silico protein 
digestion refers to calculating and indexing theoretical m/z values from protein sequences fetched 
from the database. For each protein, the digestion algorithm predicts a list of peptides according 
to the specified protease and its empirical enzymatic cleavage sites (such as cleavage at the C-
terminal side of lysine or arginine for trypsin) as well as a pre-defined number of missed cleavage 
(usually 1 to 3). Theoretical masses of these peptides are then calculated from their predictable 
elemental compositions based on their amino acid residues, pre-defined chemical modifications, 
PTMs, and secondary fragment ions with neutral losses. Additional constraints such as maximum 




parameters. The resulting theoretical m/z values are compiled as theoretical MS/MS spectra for 
later uses. 
1.2.5.3 Peptide mass filtering 
Before the search program can match an experimental MS/MS spectrum to a theoretical 
one and score it for a peptide hit, the theoretical spectra are filtered at the MS level. For each 
experimental MS/MS spectrum tagged with its precursor mass, the filtering algorithm extracts 
theoretical MS/MS spectra that have identical masses within a pre-defined mass accuracy 
threshold (usually ± 5 to 10 ppm). The search program may perform additional search engine-
specific filtering that dynamically removes low-intensity peaks from an experimental MS/MS 
spectrum to improve its overall spectrum quality. 
1.2.5.4 Peptide-spectrum matching and scoring 
The peptide-spectrum matching (PSM) algorithm is the core algorithm that compares 
candidate sequences to experimental MS/MS spectra with appropriate precursor masses. Different 
spectra may have different maximum numbers of detectable fragment ion masses, numbers of 
peaks with different quality, and signal-to-noise ratios. Therefore, successful identification of an 
observed MS/MS spectrum depends on several factors, including the number of matching peaks, 
mass accuracy, overall spectrum quality, and the uniqueness of the underlying peptide within the 
whole proteome. To report meaningful PSM results, search engines usually adopt mathematical 
and statistical models to score peptide-spectrum matches (PSMs) and systematically describe the 
statistical significance and confidence of these PSMs before they report them in the final result. A 
target-decoy strategy,70 where a decoy database (consisting of either reverse or scrambled protein 
sequences) is generated from the input database and used together for PSM, is implemented to 




step filtering of the final result. Different search engines implement the PSM scoring system 
differently. Table 1.1 summarizes some key features of five popular search engines that are heavily 





1.3 Tools and Strategies in Chemical Proteomics 
The mass spectrometric analysis in most proteomics studies has extended beyond the 
profiling of protein expression. The investigation and utilization of modified proteins and peptides 
have become major topics in proteomics research. A modification can be broadly defined as an 
observable positive delta mass (mass increase) on the protein or peptide. It can be a result of either 
the chemical alteration or biological manipulation of proteins as different modifications are 
introduced to or exist intrinsically within a proteome. Some modifications can be products of 
chemical probes that label a specific number of target proteins. Some can be metabolic labels or 
chemical tags introduced to proteins and peptides during the sample preparation to achieve 
analytical objectives. Others may simply exist naturally as part of cell signaling and regulation 
processes where enzymes and biochemical pathways are activated. Although conducted for diverse 
chemical or biological principles, these modification-specific proteomics studies share similarities 
in multiple analytical perspectives of sample preparation, analyte detection, and data 
interpretation. 
Chemical proteomics or chemoproteomics can be defined as a proteomics-based systematic 
approach to study the interaction between small molecule compounds and proteins in complex 
biological systems. In contrast to the conventional “one-on-one” strategy used in studying small 
molecule-protein interactions such as ligand binding assays, chemical proteomics emphasizes 
multiplexed protein analysis with the inclusion of the biochemical complexity in the experimental 
model, where the small molecule-protein interactions take place. Therefore, compared to 
traditional methods in chemical biology and drug discovery studies, chemical proteomics profiling 
is more suitable for discovering protein targets of small molecule compounds, measuring target 




proteomics relies on chemical probes that introduce detectable chemical modification and/or 
distinguishable analytical traits of proteins that interact with the small molecule of interest. 
Consequently, the preparation of probe-treated protein samples, detection of probe-modified 
peptides, and analysis of probe-reacted protein depends on a dedicated set of chemical tools and 
analytical strategies. 
1.3.1 Compound-centric vs. activity-based probes 
Chemical proteomics studies usually involve one of two probing strategies (Figure 1.8). 
The compound-centric strategy features the use of chemically modified, either tagged71 or 
immobilized,72 compounds of interest as either covalent or non-covalent chemical probes. These 
chemical probes are introduced directly as baits to capture target proteins from a complex 
proteome. In contrast, the activity-based strategy depends on covalent probes. These activity-based 
probes (ABPs) are capable of irreversibly binding, reacting with, and labeling target proteins from 
a complex proteome, which is pre-treated with compounds of interests. The subsequent elucidation 
of target activity relies on the measurement of probe-target adducts in competitive binding assays.  
Presumably, the compound-centric strategy is straightforward for studying the proteome-
wide activity of a known drug molecule. It mandates a boutique probe created by installing a 
reporting group on the drug molecule. However, the construction of a drug-derived probe often 
bears high synthetic costs. The application of such a compound-centric probe also suffers from the 
consequence of chemical modifications; any structural changes made to the drug molecule may 
significantly alter the parent molecule’s potency and selectivity profile.73 The more sophisticated 
strategy is activity-based chemical proteomics, which emphasizes the use of a covalent probe. 
Activity-based competitive chemical proteomics, also technically known as competitive activity-




effectively decipher proteome-wide actions of different underivatized drugs and other reactive 
molecules like environmental toxins and reactive metabolites from the human microbiota.76-79 
Opposing to the design of compound-centric probes, ABPs are designed to show little or no 
specificity to proteins. They capture proteome-wide “snapshots” visualizing drug-protein 
interactions by permanently occupying available active sites post drug treatment on the model 
proteome. As illustrated in Figure 1.8, a competitive ABPP platform depends on its ABP to 
measure the proteome-wide action of an underivatized drug.80,81 Competitive ABPP’s distinctive 
technological advantage is that a single ABP with broad proteome coverage can establish a 
versatile analytical platform capable of evaluating different drugs or drug candidates on different 
subsets of a single proteome. Therefore, ABPs with a broad spectrum of reactivity can fully 
unleash the enormous potential of competitive ABPP technology. 
1.3.2 Chemical tagging on peptides 
The quantitative analysis of in vitro drug dose response is challenging. It demands not only 
identification but also accurate and precise quantitation of biochemically altered proteins from 
proteome samples treated at various drug concentrations. Fortunately, several types of peptide 
derivatization reagents are available for label-based quantitation. These versatile derivatization 
reagents tag multiple protein digest samples that are combined for simultaneous analysis, which 
enhance both the accuracy and sample throughput. These chemical tags can be either stable 
isotope-based or non-isotopic. 
Stable isotope-based peptide tagging involves either isobaric82-84 or mass-difference85-94 
derivatization reagents. These reagents tag peptides and incorporate stable isotope labels 
differentially. In comparison to mass-difference derivatization reagents, isobaric reagents are more 




additional multiplexity: 4-plex iTRAQ,83 6-plex TMT84, 8-plex iTRAQ95, 11-plex TMT96,97, and 
16-plex TMT98. Using tandem mass tag (TMT™) reagents as an example, peptides derivatized 
with isobaric reagents have the same precursor ion masses but produce product ions with 
differentiable masses only after gas-phase fragmentation (Figure 1.10A). Therefore, tandem mass 
tags enable the concurrent measurements of chemical proteomics samples. The LC-MS/MS 
measurements of pooled TMT-labeled samples minimizes unwanted run-to-run variations in target 
quantitation. Because these tandem mass tags multiply the abundance of a peptide precursor ion 
by the number of combined samples. This analyte abundance boost has little effect on the 
spectrometric complexity during the MS precursor ion scan of a DDA profiling experiment. Only 
the reporter ions are measured for peptide quantitation during the MS/MS product ion scan, which 
significantly mitigates chemical interference. Besides, signal intensities of sequence ions from 
different samples are additive. This feature ensures that combining multiple samples for a single 
LC-MS/MS run enhances the detectability of peptide sequence ions and has a minimal negative 
impact on the sample matrix. As illustrated in Figure 1.10B, the 10-plex TMT-based chemical 
proteomics workflow can provide a powerful shortcut to quantify dose responses of small molecule 
compounds of interest within a complex proteome. 
It is also possible to use mass-difference derivatization reagents for incorporating peptides 
with stable isotope labels.86,87,90,92,94 For instance, the reductive methylation of peptidyl amines is 
a commonly practiced method for multiplexed proteomic quantitation.85,88,89,91,93 It features a 
simpler derivatization procedure, lower cost,91 and the potential for automation.88,99 However, it 
can only be applied for labeling up to five different samples. The quantitation of methylated 
peptides is based on fragment ions generated from tagged peptides with different precursor 




Non-isotopic derivatization reagents leverage the analytical performance of a 
chemoproteomics platform in a slightly different way. These reagents are designed to provide a 
cost-effective solution to improve the sample throughput in targeted proteomics quantitation rather 
than analyte multiplexity in untargeted proteomics profiling. This technology is proposed as ultra-
throughput MRM MS, or uMRM MS.100,101 This method re-allocates the scan capacity of fast 
contemporary QqQ instruments from a large number of pre-selected peptides in a single sample102 
to several key peptides of interest from a large number of samples in a single experiment.100,101 As 
demonstrated on Figure 1.11, once integrated with stable isotope by amino acids in cell culture 
(SILAC), the open-source uMRM MS technology can also greatly facilitate the development of 
chemical probes and chemical proteomics by enhancing the quantitation performance in the 
scaling analysis of proteome-wide reactivity of activity-based chemical probes.103 
1.3.3 Metabolic labeling on proteins 
Metabolic labeling methods incorporate stable isotope labels biologically into a model 
proteome during the cell culture (SILAC) or small animal feeding process (stable isotope labeling 
by amino acids in mammals, SILAM).104 These powerful labeling methods are residue-specific 
and rely on the natural metabolism of a living system to produce heavy copies of proteins.105 
Although commonly used in a heavy/light duplex fashion, up to five samples can be pooled for 
concurrent proteomic quantitation.106 Compared to chemical tagging, the most significant 
advantage of metabolic labeling is the potential of introducing the labeled proteins at an earlier 
stage of proteomic sample preparation workflow. Thus, the reduction of sample complexity at the 
protein level can be implemented for high accuracy and precision proteome quantification, with 
little differential protein loss.107 By only supplying heavy amino acid feed to an organism, 




disease mechanisms and identifying biomarkers in human samples.108-112 Similar to the mass-
difference tagging, the use of metabolic labeling suffers from analyte dilution and increased 
sample complexity. Nevertheless, as demonstrated on Figure 1.11, once integrated with the open-
source uMRM MS technology, SILAC the can also greatly facilitate the development of chemical 
probes and chemical proteomics by enhancing the quantitation performance in the scaling analysis 





1.4 Challenges and Opportunities in Chemical Proteomics 
1.4.1 Alternative bio-orthogonal affinity tags and trypsin-resistant 
affinity binders 
In most cases, biotin-(strept)avidin system-based techniques are versatile and fit 
seamlessly in their applicable experimental workflow. However, when being used for affinity 
enrichment of probe-reacted proteins, this pair of binders often delivers poor enrichment efficiency 
due to the mandatory harsh conditions for releasing captured targets, such as prolonged heating 
and use of chaotropic agents at an extremely low pH for analyte elution. While these harsh 
conditions can disturb the strong biotin-(strept)avidin interaction, they may also inflict undesired 
damages on both the solid-matrices and captured analytes, thus increasing the sample’s complexity 
and decreasing the analyte’s recovery. In comparison to biotin (Kd ~ 10
-15 M), the desthiobiotin 
has been developed as a synthetic biotin analog with a deliberately-reduced avidin affinity (Kd ~ 
10-11 M) to afford less chemical disruption for its release.113 The desthiobiotin affinity tag also has 
its unique advantages as a xenobiotic tag, which is chemically unique and bio-orthogonal with a 
biological system. Its mass signature is distinguishable by mass spectrometric analysis. It also is 
not part of any biochemical reactions. On the other hand, biotin-specific antibodies with lower 
affinities (Kd ~ 10
-8 M) have also been developed to serve as an affinity enrichment platform for 
higher analyte recovery.114  
Nevertheless, protein-based macromolecular binders share a significant drawback. That is 
chemical orthogonality. As proteins, these macromolecular binders are prone to biochemical 
manipulations that affect proteins. Trypsin digestion is often implemented in technically distinct 




step within the sample processing workflow according to specific analytical strategies, which 
would provide distinct advantages and drawbacks. Compared to the other two methods, the on-
bead digestion approach provides an uncompromising shortcut to protein-level enrichment. 
Because the captured probe-protein adducts do not leave the solid matrix until the very end, fewer 
steps and less analyte loss are expected. However, in practice, there is always an intangible trade-
off between the trypsin digestion efficiency and contamination from tryptic (strept)avidin peptides. 
Even after meticulous optimization, an on-bead digestion protocol frequently leads to an 
overwhelming number of either miscleaved analyte peptides or (strept)avidin contaminant 
peptides. In some applications, co-existence of the enrichment media and trypsin is required, 
particularly known as the on-surface (on-bead) trypsin digestion strategy115,116. In this case, 
trypsin’s proteolytic activity can also affect the macromolecular binders, which causes inevitable 
contamination and loss of analytes. 
In recent years, the significance of ligand-binding capability of oligonucleotides has 
attracted a tremendous amount of attention. Due to several substantial advantages over antibodies, 
aptamers have gradually gained ground in clinical applications.117 In comparison to antibodies that 
are biologically-produced large-sized (150kDa for IgG made in animals or cell lines) protein 
molecules, aptamers are chemically-synthesized small-sized oligonucleotides (24kDa for 80-NTs 
ssDNA, made on automated chemical synthesizer) that are easy to create, use, and manipulate. 
Therefore, it is possible and will be beneficial to develop alternative affinity-capturing platforms 
consisting of immobilized aptamers and non-biotin affinity tag-based chemical probes. These 
novel affinity capturing systems may provide superior flexibility, robustness, compatibility, and 




1.4.2 Reactivity and selectivity of chemical probes 
In contrast to ideal covalent drugs that react with target proteins selectively and sensitively, 
ideal chemical probes may occupy both ends of the selectivity spectrum. While a successful 
compound-centric probe must recreate the high selectivity of its drug template, a versatile ABP 
would react with a wide range of proteins at their active sites, which are targeted respectively by 
various drugs to be analyzed. Covalent inhibitors and drugs have prolonged selective engagement 
with their targets and improved pharmacodynamic properties, but they react unavoidably with off-
target proteins, leading to toxicity and safety concerns.118 During the drug development, chemical 
proteomics are increasingly used to reveal selective covalent inhibitors early, identify toxicity 
liabilities, and help mitigate the risk of late-stage failures.74,119 
ABPs are also uniquely useful in chemical proteomics for measuring the proteome-wide 
action of all sorts of reactive molecules other than covalent drugs to understand their biological 
consequences.74,79,119,120 These molecules include environmental toxins, natural products, reactive 
metabolites from the human microbiota. At the low end of the selectivity spectrum, broadly 
reactive ABPs77,78,121 are used as measurement probes in ABPP platforms that can be flexibly 
adapted for the (re)activity analysis of underivatized reactive molecules. The platform adaptability 
relies on the reactivity coverage of the measurement probe—the number of proteins and the type 
of amino acid residues with which the probe reacts. The broader the coverage, the higher the 
adaptability. 
It is challenging for a warhead to cover a large fraction of a proteome reactivity’s domain. 
Individual proteins differ in molecular composition and structure. Their reactions with small 
molecules are distinct from site to site, domain to domain, and protein to protein. The diversity of 




proteome. When designed to be broadly reactive, an ABP does not carry a binding/recognizing 
group and depends on its warhead for its reactivity and proteome coverage.122-124 Exemplified by 
iodoacetamide (IA)-alkyne, the IA warhead reactivity represents the proteome coverage of a class 
of broadly reactive probes,76 which react with large numbers of proteins in a proteome, but 
primarily targeting cysteine residues.77,119 On the other hand, warheads that target multiple amino 
acid residues are also available. For instance, ABPs that are developed on the acrylate warhead125 
or sulfonyl fluoride126 warhead are utilized to target nucleophiles, including amino, hydroxyl, and 
thiol groups. Although being useful in some cases, probes based on these warheads may limit their 
applications due to storage, sample compatibility, and experimental reproducibility issues caused 
by their cytotoxicity, background reactions, and instability. The large extent of nonspecific 
background reactions usually compromises competition assay-based proteomics analysis of the 
probe-reacted proteins. Therefore, novel warheads with moderate electrophilicity and reaction 
rates but a high coverage of residue types are still in high demand for developing activity-based 
measurement probes. These probes are expected to lessen background reactions and establish more 




1.4.3 Bioinformatics for modification-specific proteomics 
Chemical proteomics utilizes chemical probes to study biological functions of proteins and 
small molecule-protein interactions within a highly complex biological sample. Direct LC-MS/MS 
analysis of a total protein digest prior to any offline analyte separation is typically futile because 
of the competition between analytes and interfering non-target peptides for ionization and 
stochastic sampling resource in the mass spectrometer. Fortunately, only a fraction of peptides are 
actual analytes that should be selected for LC-MS/MS analysis. The selection/enrichment of these 
analytes is achieved via the affinity tagging approach, where only peptides modified by the 
chemical probe that carry an affinity tag are retained for further analysis. This intrinsic trait has 
shifted the analytical focus from all peptides onto probe-modified peptides, which characterizes 
chemical proteomics as modification-specific proteomics akin to large-scale PTM studies. 
It is challenging to analyze modification-specific proteomics data. Conventional 
proteomics database search engines handle search requests for modified peptides by expanding the 
peptide sequence pool using a list of modification masses. These modification masses are set as 
search parameters before the search workflow initiates. When the numbers and locations of 
specific chemical modification are unknown (known as a variable modification), this approach has 
to enumerate all possible instances of such modification on native peptides. It also appends 
modified peptides to the native ones to create an exponentially larger peptide sequence pool as the 
search space. Problems occur when multiple variable modifications are introduced because the 
inclusion of combinatory modified peptide variants artificially inflates the search space with more 
isobaric peptide masses, resulting in a much larger candidate peptide list. Compared to search 
without modifications, the subsequent iterative peptide-spectrum matching and scoring algorithm 




elevated error rates, and compromised sensitivity. Moreover, some chemically modified peptides 
may undergo secondary chemical reactions during sample preparation or LC-MS/MS analysis. 
Others may simply be unknown or mispredicted during exploration of novel chemical probes and 
biochemical reactions. It is also possible that modified peptides will be less detectable due to their 
erratic gas-phase behaviors such as low ionization efficiency, poor fragmentation, and unusual 
fragmentation patterns. On the other hand, existing software packages are developed ubiquitously 
for analysis of all peptides and proteins. They often offer limited support for post-search processing 
of modification-specific data. These packages usually frustrate end-users by presenting proteomics 
profiling reports adulterated with a large volume of information on native proteins and peptides 
that are irrelevant to the research objectives. Therefore, novel search algorithms and post-search 
data processing tools remain to be developed. Together with novel chemical probes and analytical 
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Figure 1.2 Overview of omics pipeline. 
 
Note: Figure adapted with permission from (Wang, L., McShane, A. J., Castillo, M. J. & Yao, X. in 
Proteomic and Metabolomic Approaches to Biomarker Discovery (Second Edition)   (eds Haleem J. Issaq 

























































Figure 1.11 Ultra-throughput MRM MS for quantitative scaling of proteome-
wide reactivity of activity-based chemical probes. 
 
 
*Note: plot adapted with permission from (Li, S. et al. Scaling Proteome-Wide Reactions of Activity-Based 








Note: (A) general workflow chemical proteomics, (B) in-solution trypsin digestion procedure for peptide-
level target enrichment, (C) in-gel trypsin digestion procedure for protein-level target enrichment, and (D) 
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• Convert observed and theoretical spectra to 
frequency domain by fast Fourier transform 
• Cross-correlation, reporting ratio between 
zero-offset alignment and nearby 
alignments 
X!Tandem130 
Parallel Tandem131 (open 
source), 
Trans-Proteomic 
Pipeline132 (open source) 
• Count matching fragment ions (b and y ions 
only) on the observed spectrum 
• Calculate dot product using ion intensities 
and the number of matching ions 
• Calculate “hypercore” by multiplying with 
factorials of the number of assigned b and y 
ions (hypergeometric distribution)  
• Build a histogram of scores per spectrum 
and report its expectation value 
MOWSE133 Mascot (commercial) 
• Calculate the probability (P) if a PSM occurs 
by chance 
• Report the score as -10log10 (P) 
MS-GF+134 
MS-GF+ (open source), 
ProteoSAFe (web-based) 
• Convert peptide P and spectrum S into 
peptide vector P* and spectral vector S*. 




Andromeda135 MaxQuant136 (freeware) 
• Filter top q peaks per 100 Da mass interval 
on the theoretical spectrum 
• Count matching fragment ions (k) on the 
observed spectrum to all possible 
theoretical ions (n) 
• Score each mass interval as -10log10 of the 
probability of matching at least k out of the n 
theoretical masses by chance (binomial 
distribution) 






Chapter 2 Investigation of Covalent Protein Adducts of 2-
Nitroimidazole-ICG as a Hypoxia-targeting Probe in Mouse 
Tumor 
2-Nitroimidazole is a well-known chemical probe targeting hypoxic environments of solid 
tumors, and its derivatives are widely used as imaging agents to investigate tissue and tumor 
hypoxia. However, the underlying chemistry for the hypoxia-detection capability of 2-
nitroimidazole is still unclear. This chapter reports the deployment of a biotin conjugate of 2-
nitroimidazole-indocyanine green (2-nitro-ICG) for the investigation of in vivo hypoxia-probing 
mechanism of 2-nitro-ICG compounds. Mass spectrometry-based proteomics and exhaustive data 
mining concluded that 2-nitro-ICG and its fragments modified mouse serum albumin as the 
primary protein target, but at two structurally distinct sites, possibly via two different mechanisms. 
The identification of probe-modified peptides not only contributes to the understanding of the in 
vivo metabolism of 2-nitroimidazole compounds but also demonstrates a competent analytical 
workflow that enables the search for peptides with undefined modifications in complex proteome 
digests. 
The Journal of Mass Spectrometry published this study under the title “Treasure hunt for 
peptides with undefined chemical modifications: Proteomics identification of differential albumin 
adducts of 2‐nitroimidazole‐indocyanine green in hypoxic tumor” as a research article.137 The 
reuse of its content in this Chapter 1s permitted by John Wiley and Sons and Copyright Clearance 





2.1.1 Tumor hypoxia and its detection 
Hypoxia is a well-renowned vicious low-oxygen condition that that is a salient feature of 
most tumors. Tumor hypoxia occurs because of a cumulative micro-environmental imbalance 
between diminished oxygen supply and elevated demand in the region of a fast-growing 
tumor.138,139 As a consequence of inefficient local vascular network and hyperactive cellular 
metabolism, tumor hypoxia is often responsible for severe inhibition of immune cells, strict 
exclusion of therapeutic agents, and malignant progression of tumors.140 Thus, detection and 
measurement of tumor hypoxia can provide invaluable clinical information for initialization and 
evaluation of anti-cancer therapy.141-143  
Selectively monitoring an exogenous bio-reducible and traceable marker is one of the 
mainstream methods for hypoxia assessment, where 2-nitroimidazole derivatives are typically 
used as the hypoxia tracer for indirect measurements.144 In contrast to 2-nitroimidazole derivatives 
as established radiotracers for positron emission tomography (PET) to image tumor hypoxia, 
indocyanine green (ICG) conjugates of 2-nitroimidazole are a novel class of near-infrared (NIR) 
fluorescent tumor hypoxia tracers demonstrating superb in vivo detectability and 
biocompatibility.145-150 Built on a fluorophore analogous to the commercial ICG as the scaffold 
structure, this class of compounds has evolved for three generations as ICG conjugates differing 




2.1.2 A brief history of nitroimidazole-ICG probes 
On Scheme 2.1, all of these nitroimidazole-ICG probes were synthesized at Dr. Michael 
Smith’s laboratory at Department of Chemistry, University of Connecticut, referred to as 
Generation I145,146, Generation II147-149, Generation IIIa150, Generation IIIb151, and Generation IIIc 
(to be used this study) dye. Regarding the lower reduction potential and toxicity of some 4-
nitroimidazole derivatives, the initial work focused on the development of 2-nitroimidazole 
derivatives as chemical probes that target tumor hypoxia, based on the scaffold compound, bis-
carboxylic ICG (compound 1).145,148,152-154 In a continuous effort to develop the best probe, the 
first-generation dye conjugate using an ethanolamine linker (compound 1-1)146, and the second-
generation dye conjugate using a piperazine linker (compound 1-2)147-149 were prepared. In both 
cases, previous in vivo studies showed that the dye conjugate was retained in hypoxic tumors, 
allowing imaging by the NIR fluorescence technique.145 For the third-generation dye-conjugates, 
apart from the 2-nitroimidazole-based probes (compound 2-1 and 1-5-1), the unsubstituted 
imidazole derivative (compound 1-3) and the 4-nitroimidazole dye-conjugate (compound 1-4) 
were also reported in a recent study.151 
Despite numerous cases where 2-nitroimidazole derivative-assisted tumor hypoxia 
detection techniques have been successfully established, a comprehensive understanding of 
explicit biochemistry for the hypoxia-detection capability of 2-nitroimidazole is still absent. In the 
early 1980s, Dr. Raleigh and his colleagues demonstrated that misonidazole, a 2-nitroimidazole 
derivative, could undergo oxidoreductase-catalyzed degradation in a cell-free experimental 
system.155 The same research team later illustrated that the 2-nitroimidazole derivative could 
covalently bind to macromolecules after reductive activation by high-energy photoirradiation.156 




compared to nucleic acids and the highest reactivity to thiol groups among any other nucleophiles 
on bovine serum albumin in solution. Over the years, a predominant number of in vitro and in vivo 
studies on mammalian cells have been dedicated to analyzing 2-nitroimidazole’s metabolites.157-
160 According to some recent studies, the hypoxia-detection capability of 2-nitroimidazole-
mediated imaging methods mostly arose from the regional accumulation of specific 2-
nitroimidazole metabolites, such as the glutathione conjugate of 2-aminoimidazole.158,159 
However, macromolecular adducts of 2-nitroimidazole have not been thoroughly examined since 
the initial study in the 1990s.156,161 
2.1.3 MS-based proteomics to identify 2-nitroimidazole targets 
To unleash the full potential of 2-nitroimidazole derivatives and similar compounds for 
targeting tumor hypoxia at a higher efficiency, accuracy, and biocompatibility, it has become 
imperative to re-examine the reactivity of 2-nitroimidazoles from the proteomics perspective. 
Related questions (Scheme 2.2a) are: (1) which proteins 2-nitroimidazole-indocyanine green (2-
nitro-ICG) probes preferentially bind to; (2) how these hypoxia-driven probe-protein reactions 
initialize, progress, and terminate; and (3) to what extent these reactions can perturbate the 
proteome of tumor cells in vivo. Therefore, a biotinylated version of the 2-nitro-ICG probe (biotin 
dye, Scheme 2.2b) was developed and applied to facilitate a modern mass spectrometry-based 
proteomics investigation (Scheme 2.2c) of the chemistry for in vivo hypoxia-probing mechanism.  
Nonetheless, given the large molecular weight of 2-nitro-ICG probes, target analytes 
(proteins modified by 2-nitro-ICG in vivo and digested by trypsin) are potentially labile while their 
affinity enrichment efficiency may be low. Substantial degradation of probe-protein adducts may 
occur during sample preparation. It is usually prudent to project a data utility loss of 80% to ensure 




accomplish an ambitious objective aiming at the identification of modification sites, the 
investigator is likely to experience extraordinary challenges when both the target proteins and their 
measurable modification (regarding the increase in mass of the peptide after its modification by 
the chemical probe) are undefined. Consequently, the data often remains uninterpretable for 
identifying probe-modified peptide via the typical data processing workflow used in a shotgun 
proteomics experiment.162,163 While the direct identification of covalent adducts appears 
unachievable, the “gray area” of the profiling data, where a large volume of valuable information 
on modified peptides deposits as unassigned spectra, can offer a second chance.164 As the task of 
“rescuing” spectra featuring probe-modified peptides is extraordinarily labor-intensive and 
frustrating, methods to alleviate such arduousness for the identification of undefined covalent 
adducts are in immediate demand. 
Herein, this study introduces a front-to-end analytical workflow that dictates the successful 
discovery of a primary protein target and its modification sites for a 2-nitroimidazole-based in vivo 
chemical probe. In this workflow, probe-reacted proteins are detected as target analytes using 
fluorescence imaging and isolated using avidin affinity pull-down in conjunction with multiple 
techniques of gel electrophoresis. These electrophoresis techniques include the sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), isoelectric focusing-polyacrylamide gel 
electrophoresis (IEF-PAGE), and a combination of the two as the two-dimensional gel 
electrophoresis (2-DE). The isolated target analytes are measured as tryptic digests using LC-
MS/MS. The profiling data is processed and interpreted using an approach of product-ion-oriented 
data mining for the identification of the target protein and its modification sites. In general, this 
approach bypasses the search restriction on peptidyl precursor ions at MS level, weights the 




gap between MS and MS/MS data with chromatographic information, reconciles MS data for 
evidence supporting the assignment of peptide identities, thus distinguishes otherwise 
unassignable spectra featuring probe-modified peptides. This work broadens the perspective on 
the hypoxia-probing mechanism of 2-nitroimidazole compounds. More significantly, it conveys a 
practical troubleshooting guideline for similar chemical proteomics studies routinely conducted 
during the research and development of new active pharmaceutical ingredients, where the 







Solvents, reagents, stock buffer solutions, and equipment were purchased from Bio-Rad 
Laboratories Inc (Los Angeles, CA), Fisher Scientific Co LLC (Hanover Park, IL), Life 
Technologies (Grand Island, NY), Sigma-Aldrich Inc (St. Louis, MO), and Thermo Fisher 
Scientific LLC (Asheville, NC). Details of materials, mouse tumor model preparation, and 
fluorescence imaging are included in the supplemental information.  
2.2.2 Tumor lysis and protein extraction 
The excised solid mouse tumors had approximate dimensions of 1 cm x 1.5 cm x 0.2 cm. 
For each tumor sample, the solid excision was homogenized in a 7-mL Dounce tissue homogenizer 
(Bellco Glass, Vineland, NJ) with 1 mL of a working lysis buffer (WLB) on ice until visually 
homogeneous. A 5-mL sterile disposable syringe with a 20-gauge needle (BD, Franklin Lakes, 
NJ) was used to assist the disruption of cellular membranes. The WLB contained 1% of Halt™ 
EDTA-free 100X protease inhibitor cocktail in Pierce™ IP Lysis Buffer. The homogeneous 
suspension was split and transferred to 1.5-mL microcentrifuge tubes. The collection tube of the 
homogenizer was washed with 200 μL of WLB, which was combined with the suspension. For 
maximal extraction of the cellular protein content, the suspension underwent two freeze-thaw 
cycles (frozen at -80 °C and thawed on ice), three rounds of centrifugation and resuspension. In 
each round, the homogeneous tumor suspension was centrifuged for 1 h at 16100 rcf, 4 °C. In total, 
an additional 1 mL of WLB was used to resuspend the pellets. All the supernatants were collected 




were saved for further analyses. Next, the crude lysate was purified with Zeba™ Spin Desalting 
Columns to remove its small-molecule content by following the manufacturer’s instruction. For 
each sample, approximately 2 mL of purified lysate was collected as a protein extract. Each extract 
was quantified via the standard BCA assay protocol and aliquoted into new 1.5-mL 
microcentrifuge tubes, which were stored at -80 °C before further analyses. The final protein 
extracts had a concentration of approximately 7 mg/mL. 
2.2.3 Affinity enrichment of covalent adduct  
For each avidin affinity pull-down experiment, a 100-μL aliquot of protein extract was 
diluted for a protein concentration of 2 mg/mL with freshly-prepared WLB and mixed with an 
equal volume solution of 8 M urea in WLB, resulting in a pre-binding solution (PS) containing 1 
mg/ml proteins and 4 M urea. Afterward, the PS was mixed with either Pierce™ NeutrAvidin™ 
agarose resins or Pierce™ high-capacity streptavidin agarose resins (Thermo Fisher Scientific) 
according to the proper the protein amount vs. binding capacity ratios. After overnight incubation 
at 4 °C with constant agitation on the HulaMixer, appropriate washing steps were performed based 
on the manufacturer’s instruction manual. Briefly, the adduct-bound resins were washed with three 
different washing buffers, which were prepared in situ. Washing buffer 1 (WB1) was prepared as 
4 M urea in Pierce™ IP lysis buffer. Washing buffer 2 (WB2) was prepared as 5% isopropanol in 
PBS (pH 7.4). Washing buffer 3 (WB3) was prepared as a solution of 20 mM of Tris-HCl, 50 mM 
of NaCl, whose pH was adjusted to 8.0. The adduct-bound resins were washed three times of WB1 
and WB2, twice of WB3, with either 20X volume of the settled resins for the high-capacity 
streptavidin-agarose or 10X volume of the settled resins for the NeutrAvidin-agarose. After 
resuspension of resins in the washing buffers via brief vortexing, centrifugation was performed for 




20 °C for checkpoint analyses. For releasing resin-bound adducts, an equal resin-volume of a 
freshly prepared working elution buffer (WEB) was added to each 1.5-mL microcentrifuge tube 
that contained washed adduct-bound resins. The WEB was prepared by mixing 2-mercaptoethanol, 
Laemmli sample loading buffer, and a stock solution of biotin in WB3. The resulting resin 
suspension included 2.5% of 2-mercaptoethanol, 1X Laemmli sample loading buffer, and 4 mM 
of biotin, considering the volume of resins. The microcentrifuge tube was then heated in a hot 
water bath at 95 °C for 15 min and cooled down to room temperature, protected from the light. 
The heated resin suspension (HRS) was either used immediately or temporarily stored at 4 °C for 
either analytical or preparative gel electrophoresis experiments. 
2.2.4 Gel electrophoresis and fluorescence detection 
For the analytical SDS-PAGE, a small portion of each sample (5 to 20 µL of either protein 
extract, washes from affinity pull-down experiments, the supernatant of HRS, or whole HRS) was 
loaded onto a Mini-PROTEAN® TGX™ precast gel (1.0-mm, 10-well, Bio-Rad). For the 
preparative SDS-PAGE, approximately 90 µL of whole HRS was loaded into each well of an in-
house prepared gel (1.5-mm, 5-well). The gel consisted of a top stacking layer and a bottom 
resolving layer with a volume ratio of 2:8. The stacking layer was cast with 4% acrylamide/bis-
acrylamide in a buffer of 0.5 M Tris-HCl and 0.4% SDS, whose pH was adjusted to 6.8. Whereas, 
the resolving layer was cast with 12% acrylamide/bis-acrylamide in a buffer of 0.5 M of Tris-HCl 
and 0.4% SDS, whose pH was adjusted to 8.8. Together with the samples, 5 µL of either SeeBlue™ 
Plus2 pre-stained protein standard (Life Technologies) or Precision Plus Protein™ dual color 
standards (Bio-Rad) was loaded to the gel as molecular weight reference protein standards. The 




setting of 120 V for 40 min and 200 V for 20 min until complete migration of the fronting band to 
the bottom of the gel.  
For the implementation of preparative 2-DE, we adopted a high-compatibility but low-cost 
protocol.166 This protocol seamlessly merged two distinct gel electrophoresis techniques: vertical 
isoelectric focusing-polyacrylamide gel electrophoresis (vIEF-PAGE) and SDS-PAGE, with 
minimal instrumentation requirements. As the first part of this 2-DE procedure, vIEF-PAGE was 
performed according to its manufacturer’s instruction. Briefly, 20 µL of protein extract was mixed 
with 20 µL of provided IEF sample buffer at room temperature. The resulting 40 µL sample 
solution was loaded to a provided precast IEF gel in a cassette assembly accommodated in the 
electrophoresis cell. The three-step electrophoresis was operated at 50 V for 60 min, 200 V for 60 
min, and 500 V for 30 min. Afterward, the IEF gel was incubated in 20% TCA for visualization 
of white bands via protein precipitation and sliced into strips along the edge of each well, parallel 
to the well-dividers, with a piece of thin glass on a clean glass surface. The gel strips were 
dehydrated in acetonitrile until turning opaquely white and rehydrated in a solution of 2.5% 2-
mercaptoethanol in the stacking gel buffer. As the second part of this 2-DE procedure, the prepared 
strip was loaded onto an in-house-cast gel (1.5-mm, single-well, 10% polyacrylamide). The 
following SDS-PAGE was performed in the same manner as previously described.  
After electrophoresis, the protein bands were fixed with a solution of 10% acetic acid and 
50% methanol in water. The gels were imaged with an LI-COR Odyssey imaging system (LI-
COR, Inc. Lincoln, NE) with setting as a dual channel (700 nm and 800 nm; the 700-nm channel 
was monitored for visualizing the reference protein ladder), 0.75 mm focus offset, 7.0 intensity, 
and highest quality. After successful detection of the fluorescent protein band, the gels were 




and imaged with a document scanner. Finally, the target protein band or spot was excised and 
diced into 1 mm x 1 mm cubes with a sterile scalpel on a clean glass surface. Gel cubes were 
transferred to clean 1.5-mL microcentrifuge tubes either for immediate preparation for in-gel 
digestion or temporary storage at 4 °C. 
2.2.5 In-gel trypsin digestion  
The excised gel bands or spots were washed with acetonitrile for destaining, treated with 
DTE for reduction, IAA for alkylation, and incubated overnight with trypsin for digestion. Refer 
to Text S6 for details. Afterward, peptides were extracted with an appropriate amount of 
acetonitrile from the post-digestion gel dices, concentrated in SpeedVac, and acidified with formic 
acid (to pH ≤ 3) for desalting with the solid-phase extraction (SPE) technique. For desalting peptide 
samples, Pierce™ C18 StageTips (Thermo Fisher Scientific) were used. The SPE procedure was 
performed according to the manufacturer’s instructions. The desalted tryptic digests were 
concentrated in the SpeedVac, lyophilized, and reconstituted to 10 µL. 
2.2.6 LC-MS/MS analysis 
The in-gel tryptic digests were analyzed on a Q Exactive HF mass spectrometer equipped 
with the nanospray ionization (NSI) source coupled with an UltiMate 3000 UHPLC system 
(Thermo Fisher Scientific).  
For the LC part, a nanoEase M/Z Peptide BEH C18 column (25 cm length, 75 μm diameter, 
1.7 μm particle size, and 130Å pore size) was used for peptide separation. The autosampler 
temperature was 4.0 °C. Column oven temperature was 50.0 °C. Sample injection volume was 1.0 
µL. Mobile phase flow rate was set as 300 nL/min. Solvent A was 0.1 % formic acid in water, and 




10-min sample-loading period, a 50-min mobile phase linear gradient period, and a 30-min post-
gradient column flushing and equilibration period. Specifically, the method profile (% for Solvent 
B at runtime) was 4% at 0 to 10 min, 30% at 50 min, 90% at 60 to 70 min, and 4% at 72 to 90 min.  
For the mass spectrometer part, Xcalibur v2.8 software controlled the instrument. The mass 
spectrometer operated in DDA mode for monitoring positive ions at a spray voltage of 1500 V. 
For MS1, the mass range was from 300 to 1800 m/z. The Orbitrap mass analyzer was set with a 
resolution of 60,000, an AGC target of 1e6, and a maximum ion time of 60 ms. For data dependent 
MS2, the quadrupole was set with an isolation window of 2.0 m/z. The Orbitrap was set with a 
resolution of 15,000, an AGC target of 1e5, and a maximum ion time of 40 ms. This DDA method 
allowed up to 20 MS/MS scans per duty cycle, and a stepped normalized collision energy (NCE) 
of 27. Precursors that triggered MS/MS scans were dynamically excluded from repetitive MS/MS 
scans for 40 s. Charge state exclusion was enabled to reject precursor ions with charge states 
beyond the range of +2 to +8. Peptide match option was set at preferred. MS/MS spectra were 
collected as the centroid data type. 
2.2.7 LC-MS/MS data processing 
For peptide and protein identification, the mass spectral data were searched against a mouse 
reference proteome database (Swiss-Prot, Mus musculus, UP000000589, last modified on October 
22, 2018) containing 16,997 mouse proteins. Database searches were performed with both 
MaxQuant (version 1.6.1.0) and MODa (version 1.60).  
For MaxQuant-based searches, essential parameters were set as follows: 1% peptide-level 
false discovery rate (FDR), 1% protein-level FDR, 1% modification site FDR, a minimum peptide 
length of 5, a minimum score of 0 for unmodified peptides, a minimum score of 10 for modified 




MS/MS mass error tolerance of 20 ppm, a peptide length range of 8 to 25 for unspecific search, a 
maximum missed peptide cleavage of 3, a maximum peptide mass of 8000 Da, and a revert decoy 
mode. For the setting of modification inclusion list, oxidation on methionine, acetylation on 
protein N-terminus were set as variable modification. Besides, carbamidomethylation, biotinyl 
piperazine-2-nitroimidazole-ICG (original form, +1284.5250 Da), biotinyl piperazine-2-
aminoimidazole-ICG (reduced form 1, +1254.5519 Da), or biotinyl piperazine-2-aminoimidazole-
ICG (reduced form 2, + 1239.5410 Da) on cysteine was set as a variable modification. Up to 5 
variable modifications per peptide were allowed. 
MODa-based searches were performed in single-blind mode (maximum one modification 
per peptide). Key parameters are two enzymatic termini, no missed cleavage, a modification mass 
range of 150 to 1500, no fixed modification, a fragment ion tolerance of 0.01 Da, no precursor ion 
auto-correction, and a precursor mass tolerance of 2 Da. FDR of 1% was enforced for separate 
searches against the database appended with reverted decoy protein sequences. Additional data 
processing was performed with the assistance of ProteoWizard Toolkit167 for conversion of data 
format, visualization, and extraction of ion chromatograms and spectral binary datasets from the 
raw data files. 
2.2.8 Mouse serum albumin modeling and molecular docking 
The sequence of mouse serum albumin (AlbM, P07724) was obtained from UniProt protein 
data repository in FASTA format.168 The AlbM structural model was built using the SWISS-
MODEL (https://swissmodel.expasy.org), based on target-template sequence alignment and 
homology.169 After the template database query with the sequence of AlbM as the input, all 42 
available templates were sorted by their global model quality estimation (GMQE) scores. With a 




crystal structure of rabbit serum albumin (PDB accession: 3V09)170 was selected as the template 
to generate the three-dimensional (3D) structure of AlbM in PDB format.  
The virtual probe-protein binding (docking) study was performed using AutoDock Vina171 
and AutoDock Tools version 1.5.6172. For docking model preparation, the 3D structure of AlbM, 
water molecules were removed, and polar hydrogen atoms were added. The 3D structure of biotin 
dye was constructed in two-dimensional MOL format using ChemDraw Prime 16.0.1.4 and 
converted to three-dimensional MOL2 format using Avogadro173. The following 3D structure of 
biotin dye was prepared for docking by assigning torsional bonds. For peptide 
LPCVEDYLSAILNR, the grid box with a size of 60 × 30 × 36 Å was allocated at the center of the 
binding cavity with x, y, and z coordinates of 30, 15, and 12. For peptide DTCFSTEGPNLVTR, 
the grid box with a size of 30 × 30 × 30 Å was centered on the cysteine residue with x, y, and z 
coordinates of 32, 60, and 20. Other parameters were set as default values. The docked models 
with the highest affinity (-8.5 kcal/mol for LPCVEDYLSAILNR and -6.1 kcal/mol for 
DTCFSTEGPNLVTR) were selected result to demonstrate the probe-protein interaction before 





2.3 Results and Discussion 
2.3.1 The biotinyl 2-nitroimidazole-ICG 
By conjugating a biotin moiety to the previously reported 2-nitro-ICG chemical 
probe,148,150 we designed biotinyl 2-nitroimidazole-ICG (referred to as the biotin dye, Scheme 
2.2b) as a “dual-functional” chemical probe. In comparison, most chemical probes used in 
proteomics contain one of two groups for detection: a fluorescence reporter group or biotin 
“affinity handle.174 Ideally, the “dual-functional” design of the biotin dye would offer multiple 
analytical advantages including flexible and confident detection, leveraged sensitivity, and surface 
chemistry-compatibility.  
With its exceptional affinity to avidin (Kd ~ 10
-15 M), the biotin moiety is routinely used as 
a propagable “affinity handle” on the chemical probe for flexible detection and enrichment of 
probe-reacted proteins. The downstream sample preparation is supported by a broad range of 
commercially available products for avidin-based immunoprecipitation and detection.175 By 
design, biotin dye allows solid-phase affinity pull-down of probe-reacted proteins from complex 
tumor tissues.  Besides, the biotin moiety on the adducts can be detected by Western Blot analysis 
(Figure 2.1), offering a complementary detection approach to the fluorescence based on the ICG 
fluorophore of the probe-modified proteins.  
The optical absorption and emission peaks, as well as the extinction coefficient of the biotin 
dye, were measured (Table 2.1) by the Zhu group at Department of Biomedical Engineering, 
University of Connecticut. The absorption and fluorescence emission peaks were similar to those 




“fully-loaded” 2-nitro-ICG probe and two-thirds of that of the “half-loaded” 2-nitro-ICG probe, in 
agreement with the reduced conjugation system in the biotin dye. 
2.3.2 Selective protein modification by biotinyl 2-nitroimidazole-ICG in 
hypoxic mouse tumor 
In vivo fluorescence intensity for tumor peaked between minute 5 to 15 post-injection and 
declined rapidly afterward (Figure 2.2a). The average tumor fluorescence intensity in a range of 
1 to 60 minutes for the biotin dye was the lowest compared with other ICG probes (Figure 2.3). 
This observation was likely due to the optical property of the probe and its diffusion physics in 
solution and intercellular translocation within the tumor tissue.176 After 60 minutes, the 
fluorescence signal intensity from the biotin dye converged towards that of the “half-loaded” 2-
nitro-ICG probe, yet remained weaker than that of the “fully-loaded” 2-nitro-ICG probe (Figure 
2.3 and Figure 2.4), which might be explained by the halved stoichiometry of the hypoxia targeting 
2-nitroimidazole functional group.  
The biotin dye remained highly fluorescent in either the free molecule or adduct forms at 
all three analytical levels (Figure 2.2). At the in vivo level, fluorescence images of the probe-
injected mouse indicated that the dye molecules circulated throughout the cardiovascular system 
of the mouse after a short period upon the injection. At the ex vivo level, only the tumor, kidneys, 
and liver exhibited fluorescence in the specified optical condition 48 hours post-injection. As 
expected, the majority of dye molecules underwent fast excretion via the renal route while a 
smaller population of them sustained delayed elimination and probable enzymatic degradation 
through the biliary and hepatic routes.154,177 It is known that 2-nitroimidazole derivatives are 
reactive and predominantly retainable under hypoxic conditions in cells,144 which is consistent 




imaging profile of in vivo and ex vivo fluorescence akin to those previously reported for original 
2-nitro-ICG probes.148,150  
At the tumor lysate level, proteins separated by SDS-PAGE were analyzed for fluorescence 
emission at 800 nm. Notably, there was only a single protein band with a molecular weight of 
about 70 kDa (left, Figure 2.2b) showing intense fluorescence signal, despite the high complexity 
of its sample matrix as a whole lysate of the tumor (right, Figure 2.2b). Furthermore, this band 
remained intense upon Coomassie Blue staining, compared to intensities of other bands in the 
entire lane (right, Figure 2.2b). These observations suggested that (1) the biotin dye was attached 
to one protein as the primary target, or less likely a few co-migrating proteins, (2) the probe-protein 
adducts were covalent because the denaturing condition of SDS-PAGE did not dissociate the 
adducts, and (3) the protein target would probably be of high abundance. 
2.3.3 Identification of protein targets for modification by biotinyl 2-
nitroimidazole-ICG  
To identify the probe-modified protein, we performed proteomics profiling for two 
preparations of tumor lysates upon treatment with the biotin dye. One sample (Sample 1) was from 
the lysate of fluorescent tumor tissue. The lysate was enriched using immobilized avidin and then 
resolved by SDS-PAGE. The other sample (Sample 2) was from 2-DE-resolved proteins without 
the affinity enrichment. LC-MS/MS profiling data of peptides from in-gel digestion of both 
samples were searched against the mouse proteome database (Swiss-Prot, Mus musculus, 
UP000000589, last modified on October 22, 2018), using Andromeda of MaxQuant.163 The top 
hit for both samples was AlbM with 47 peptides identified for the Sample 1 and 55 for Sample 2, 
among which 34 peptides were shared for both samples (Table 2.2). Co-migrating proteins were 




Sample 1 and 377 peptides corresponding to 155 proteins for Sample 2. Among these identified 
proteins, only 29 proteins (Table 2.3) were shared by both samples. No oxidoreductase was on the 
identified list of proteins. Oxidoreductases play an indispensable role as the bio-reductive activator 
in the metabolic pathway of 2-nitroimidazole, a prerequisite for the detection of hypoxia.155,178 
This observation was not surprising. The sample preparation workflow of this study targeted 
proteins with detectable fluorescence, and the number of fluorescence adducts of reduced forms 
of the probe and oxidoreductases could be too low to call for proteomics profiling. 
The inclusion of the theoretical masses of both biotin dye and its anticipated reduced form 
(biotinyl 2-aminoimidazole-ICG)156 as variable modifications on cysteine for the database search 
did not identify peptides with either modification (Scheme 2.3). Presumably, the reducing 
environment of hypoxic tumor favors the reduction of 2-nitroimidazole to 2-aminoimidazole that 
has increased electrophilicity for forming covalent adducts with nucleophiles on the protein.156 
Since Andromeda of MaxQuant is a commonly used restrictive search engine for proteomics 
profiling,163 MaxQuant requires an input of specified searching constraints for expected 
modifications to be either fixed or variable. 
2.3.4 A general data analysis workflow for identifying peptides with 
defined and mutable modifications  
To identify probe-carrying peptides, we performed an alternative database search using 
MODa179 (Scheme 2.3). MODa is an unrestrictive or “blind” search algorithm that is based on the 
alignment of peptide sequence tags. It was developed for discovering unknown protein post-
translational modifications (PTMs) without any prerequisite knowledge on modification targets or 
modification-induced peptide mass shifts.179 Briefly, MODa first performs in silico digestion, 




calculates theoretical m/z values for b and y ions of each peptide to construct two theoretical 
MS/MS spectra, respectively. In contrast, restricted database search engines, like the Andromeda 
of MaxQuant, enumerate all possible fragment ions and combine their m/z values altogether to 
generate complex theoretical MS/MS spectra for in-depth statistical analyses and comparisons to 
experimental MS/MS spectra.163 Second, MODa creates short sequence tags of 3 to 4 amino acid 
residues in length, using consecutive theoretical b or y ions, for all the in silico peptides. Third, 
MODa compares the resulting short tags with ion patterns in observed MS/MS spectra. Based on 
the Needleman–Wunsch algorithm,180 MODa scores peptide-spectrum matches (PSMs) according 
to numbers of sequence-tag matches, mismatches, and gaps, and assigns up to five candidate 
peptides with highest scores to each experimental MS/MS spectrum. The precursor mass value of 
the spectrum is then compared with calculated masses for the candidate peptides to examine for 
any possible mass shift that is potentially attributed to a peptide modification, followed by further 
verification based on sequence-tag gaps in the previous analysis. When there is no mass shift, the 
peptide is assigned as a native one. Finally, to improve the specificity of the peptide identification, 
a pre-set FDR threshold is ready to be implemented if decoy protein sequences are appended to 
the input proteome database. For the FDR-based filtering, MODa examines the statistical 
distributions of sequence tag-matching scores assigned to co-identified decoy peptides and actual 
peptides, respectively, adjusts the score cut-off for the peptide candidate output according to their 
score distributions, and eliminates a large number of low-quality peptide candidates. In contrast to 
the original candidate pool, the FDR-filtered candidate pool is less inflated and delivers the 
identification result with higher confidence at the cost of sensitivity.181 
MODa identified 25 peptides corresponding to 15 proteins for Sample 1 at 1% FDR and 




while Sample 2 contained 16 peptides (Table 2.4). In comparison, MODa and MaxQanut results 
shared 10 proteins for Sample 1 and 44 proteins for Sample 2 (Table 2.5 and Figure 2.5). 
However, Samples 1 and 2 only shared 3 identified proteins by both searches: serum albumin 
(AlbM, P07724), hemoglobin subunit beta-1 (P02088), and heat shock protein HSP 90-beta 
(P11499). 
Notably, the capability of MODa for aligning short sequence tags assigned the candidacy 
to an AlbM peptide (LPCVEDYLSAILNR) carrying the modification by the biotin dye without 
FDR-filtering. Corresponding MS/MS spectra of the probe-modified peptide were further verified 
manually. This modified peptide was observed as [M + 3H]4+ ions at 723 m/z (Figure 2.6a). In-
source fragmentation of the attached probe was also observed; a cluster of quadruply charged ions, 
captured within the 706-732 m/z window at the same retention time, shared a significant number 
of y ions (Figure 2.7). ICG molecule is prone to gas-phase fragmentation.182 However, due to the 
stochastic sampling of precursor ions for MS/MS in profiling experiments, some intense in-source 
fragments of the modified peptide were missed for sequencing. Additional forms of the same 
peptide carrying the intact probe were also observed (Figure 2.6b to 2.6d): [singly-oxidized M + 
3H]4+ at 727 m/z, [M + 2H + Na]4+ at 729 m/z, and [doubly-oxidized M + 3H]4+ at 731 m/z.  
Importantly, all these forms of modified peptide shared a series of y ions (Figure 2.8). 
Following the same analytical workflow (Scheme 2.3), another modified AlbM peptide 
with a sequence of DTCFSTEGPNLVTR was also discovered (Figure 2.9 and Figure 2.10). 
Initially, this modified peptide was observed as triply charged ions at m/z 927 (Figure 2.9). 
However, the mass increase of this modified peptide matched only a reduced form (loss of the 2-
nitro group) of the probe, a known reduction product of 2-nitroimidazole in hypoxic 




the presence of several other modified forms of the same peptide (Figure 2.11). Their mass 
increases over the native peptide were all smaller than that of the reduced probe (Figure 2.10 vs. 
Figure 2.9). Unlike peptide LPCVEDYLSAILNR, those modified forms of peptide 
DTCFSTEGPNLVTR had different elution times and thus were not in-source fragments.  
Mutable modifications of peptide DTCFSTEGPNLVTR were less likely attributed to the 
degradation of the ICG moiety as part of the reduced probe carried by the peptide. Although ICG 
was prone to degradation during sample preparations,176 similar modifications as partial probes 
were not observed on peptide LPCVEDYLSAILNR. Rather, adducts as partial probes on peptide 
DTCFSTEGPNLVTR were produced in vivo, likely as a result of enzyme-catalyzed degradation 
of the probe moiety on protein adducts177 or catabolic processes of the probe in hypoxic tumor 
preceding or succeeding its conjugation with the protein. Additional ambiguity (Figure 2.10) 
existed for assigning partial probe attachment to the peptide. Mass increases for the peptide 
overlapped the mass increase for peptide AADKDTCFSTEGPNLVTR, which had a miscleaved 
site compared to the fully digested peptide DTCFSTEGPNLVTR. 
For a few reasons, modification sites for both peptides were assigned to a cysteine residue 
near the N-terminus, C472 and C591, respectively. First, MS/MS spectra for the modified peptides 
encompassed y ions up to the C-side residue of cysteine. The sequential y ions denoted both 
peptides as unique hits against the entire mouse proteome. Second, the cysteinyl thiol (C472) was 
the only nucleophile in the N-terminal region of peptide LPCVEDYLSAILNR and the most 
nucleophilic one (C591) in the N-terminal region of peptide DTCFSTEGPNLVTR. Third, no b 
ion was observed, in agreement with the cysteine modification in the N-terminal region. 
Additionally, numbers of fragment ions remained unassigned (Figure 2.8 and Figure 2.9), which 




Additional experiments can further validate identified peptides and identify additional probe-
modified peptides and their precursor proteins. These experiments include targeted proteomics 
analysis using selected reaction monitoring-tandem mass spectrometry and the all-ion-
fragmentation (AIF) for an unbiased measurement of any product ion.185 DDA spectra and AIF 
spectra can be explored simultaneously to identify rare protein targets with improved efficiency 
and confidence. Incorporation of alternative techniques for sample preparation, for instance, on-
resin trypsin diegstion186 and affinity pull-down of probe-modified peptides,174 is also worth 
pursuing. 
2.3.5 Albumin microenvironment steering pathways for the formation of 
differential adducts with biotinyl 2-nitroimidazole-ICG 
To analyze the probe-protein interaction and visualize the structural significance of peptide 
LPCVEDYLSAILNR and DTCFSTEGPNLVTR within the folded AlbM, we conducted a 
computational docking experiment for the biotin dye and AlbM. Although the X-ray 
crystallographic data of AlbM was not available, the 3D structure was effectively modeled using 
SWISS-MODEL.169 SWISS-MODEL is a web-based package for protein structure homology 
modeling that builds protein models at different levels of complexity. In this study, as the 
automated mode for modeling was selected, SWISS-MODEL searched for suitable templates 
against the database of proteins with known 3D structures and identified a list of top hits based on 
the protein sequence homology. By ranking the identified templates according to the GMQE score, 
the top hit, rabbit serum albumin (3V09), was selected. The GMQE score described the estimated 
template-target sequence alignment quality of a specific template and reflected the expected 
accuracy of its resulting target model and the target’s sequence coverage. Afterward, the 3D model 




bonds in the biotin dye model except those forming ring and planar structures were defined as 
flexible bonds. Finally, the prepared AlbM and biotin dye models were used together with a 
defined search space at either the center or the peripheral subdomain of the protein model as the 
docking input for AutoDock Vina.171 Subsequently, AutoDock Vina computed the free energy of 
various ligand-bound protein models and searched for the best docking mode with its relative free 
energy at the local minimum. By placing the ligand at various locations on the protein, an affinity 
value regarding binding energy was calculated for each docked model. AutoDock Vina reported 
nine docked modes with the ligand affinity ranging from -8.0 to -8.5 kcal/mol for peptide 
LPCVEDYLSAILNR and -5.4 to -6.1 kcal/mol for peptide DTCFSTEGPNLVTR. Such energy 
differences were equivalent to 20- to 100-fold differences in the dissociation constant (Kd). The 
structure and location profiles of the docked ligand were saved as the output (Figure 2.12). 
Intriguingly, locations of peptide LPCVEDYLSAILNR containing C472 and 
DTCFSTEGPNLVTR containing C591 were significantly distinct on the 3D model of AlbM. 
Peptide LPCVEDYLSAILNR (with C472 in red, Figure 2.12) was located in a deep pocket, where 
the biotin dye was docked with a higher binding affinity. In contrast, peptide 
DTCFSTEGPNLVTR (with C591 in yellow, Figure 2.12) was located on the surface of the 
protein, where the biotin dye was docked with a lower binding affinity. The homology analysis 
(Table 2.6) of these sequence regions validated their relevant template-deduced conformational 
features of the AlbM model. Hence, different locations of the two cysteine residues could explain 
the differential formation of probe adducts: the intact biotin dye molecule modified the inner 
peptide while a reduced probe or probe fragments modified the surface peptide (Scheme 2.4).  
Upon intravenous administration, the biotin dye could exist in two hypothetical forms as 




AlbM peripheral subdomain-bound form and (2) AlbM core pocket-buried form.187,188 The AlbM 
might carry the probe in both forms through the mouse circulatory system to the tumor site. The 
high affinity of the probe to the pocket increases the effective molarity189 of the probe, thus 
amplifying its apparent electrophilicity, i.e., making the otherwise inert 2-nitroimidazole ring 
reactive towards the reduced cysteine residue (C472) that is made available by the compromised 
redox homeostasis190 at the hypoxic tumor site. 
On the other hand, the peripheral subdomain-interacting or surface-adsorbed 2-
nitroimidazole probe was exposed to the solvent environment, prone to dynamic dissociation and 
re-association, accessible to oxidoreductases for enzymatic reduction. When nucleophilic thiol 
groups become available from impaired disulfide bridges of AlbM at the hypoxic tumor site, the 
thiol group on cysteine (C591) reacts with the activated imidazole ring on the reduced probe and 
metabolic fragments via the nucleophilic addition or substitution mechanism,156,188 leading to 
observed modifications of different mass increases on peptide DTCFSTEGPNLVTR (Figure 2.9 
and Figure 2.10). Modifications of this peptide exemplify a general pathway for 2-nitroimidazole 
modification of proteins in the hypoxic tumor (Scheme 2.4).  
Besides the hypoxic condition, the biodistribution of albumin could play another 
significant role in the fluorescence detection of solid tumors in this study. While 49% of the total 
albumin population is located within the plasma as intravascular albumin or “serum” albumin after 
being synthesized and excreted by hepatocytes, a substantial 51% of it is found as extravascular 
albumin at discrete levels of local abundance.191 Importantly, the tumor cell line 4T1-Luc used in 
this study is a breast cancer cell line, which originates from malignant neoplasms of the mouse 
mammary gland. With lactation as its unique function, the mammary gland can not only capture 




albumin on its own193. In comparison to its scare intracellular abundance of most somatic cells, 
albumin occupies 19% of cytosolic protein contents in breast cancer cells.194 In fact, the level of 
this intracellular albumin has been utilized as a prognostic factor to evaluate the effect of adjuvant 
tamoxifen (whose active metabolites can block estrogen receptors that sustain the growth of breast 
cancer cells) treatment for ER+ (estrogen receptor-positive) breast cancer.195 Therefore, it is 
conceivable that the malignant breast tumor behaves as a “hypoxic reservoir” of albumin, which 
provides an exclusive extra- and intracellular environment where the low abundance of oxygen 
and high abundance of albumin coexist. It is this unique pathophysiological environment that 
enables the hypoxia-targeting capability of 2-nitro-ICG probes.  
The probe molecule would likely to be transiently engaged by a protein carrier, such as 
AlbM, transported through the cardiovascular system to various destinations, activated locally by 
an oxidoreductase, and eventually bond to the protein carrier forming covalent adducts under 
hypoxic condition. Overall, the discovery of two biotin dye-modified AlbM peptides did bestow 
some valuable insights on the hypoxia-detection mechanism of 2-nitroimidazole derivatives 






With the biotinyl 2-nitroimidazole-ICG probe, we have opened a proteomics gate to 
explore the metabolic chemistry of 2-nitroimidazole and its hypoxia-targeting mechanism in the 
hypoxic cellular condition. By applying our product-ion-oriented data-mining methodology, we 
have successfully interpreted otherwise convoluted and indecisive data of proteomics profiling. 
Accordingly, the biotinyl 2-nitroimidazole-ICG probe and its reduced forms modify the mouse 
serum albumin as the primary protein target at two cysteine residues, C472 and C591, located in a 
deep pocket and on the surface, respectively. At the hypoxic tumor site of the probe-injected mouse 
subject, the chemical probe covalently links to these peptides probably via dissimilar mechanisms 
(Scheme 2.4). On top of this constructive interpretation to the global insight on the hypoxia-
probing mechanism of 2-nitroimidazole compounds, our investigation illustrates a distinguished 
analytical workflow that depicts a practical guideline for some foreseeable challenging cases in 
the mass spectrometry-based chemical proteomics, especially during in vivo evaluation of drug 
candidates, where the detectable chemical modifications on target and off-target proteins are 




2.5 Chapter 2 Figures 
Figure 2.1 Western Blot images. 
 
Note: a) WB result for SDS-PAGE gel of unenriched probe-treated sample as Lane 1 and immobilized 
avidin-enriched probe-treated sample as Lane 2. b) WB result for 2-DE gel of unenriched probe-treated 
sample. The protein spot of interest is marked in the green ellipse. The WB experiments involve anti-biotin 





Figure 2.2 Fluorescence imaging results. 
 
Note: a) in vivo (top), ex vivo (bottom) fluorescence images of tumor sample labeled by the biotin dye. b) 
Fluorescence (left) and Coomassie Blue G250-stained (right) gel images of SDS-PAGE-resolved tumor 
lysate samples (lane “-” is control and lane “+” is biotin dye-labeled tumor sample). Refer to Figure 2.10 





Figure 2.3 Quantitative comparison of in vivo tumor fluorescence peak values 






Figure 2.4 in vivo and ex vivo Fluorescence kinetics of individual mice before 
dye injection and at different time points after dye injection. 
 
Note: Each group of mice is injected with one of four dyes: (a) and (e) Bis-carboxylic ICG, (b) and (f) 
Half-loaded ICG, (c) and (g) Pip-2nitroimidazole-ICG and (d) and (h) Biotin dye, with 100 µl at 25 µM 
concentration solved in 9.25% sucrose solution. For each mouse, the tumor is located on top of the right 




Figure 2.5 Venn diagram showing relations among the identification results. 
 
Note: This Venn diagram shows relations among the identification results of both SDS-PAGE-resolved 
avidin-enriched probe-treated sample (Sample 1) and 2-DE-resolved unenriched probe-treated sample 
(Sample 2) by both MODa and MaxQuant. Refer to Table 2.5 for specific protein identities labeled with 4-





Figure 2.6 Example MS spectrum associated with the peptide 
LPCVEDYLSAILNR modified by intact biotin dye. 
 
Note: This example MS spectrum shows a cluster of quadruply-charged molecular ions (labeled) and their 
in-source fragmented forms (unlabeled) associated with the peptide LPCVEDYLSAILNR modified by 
intact biotin dye. a) The peak at m/z of 723 matching the probe-carrying peptide. b) The peak at m/z of 727 
matching the oxidized (plus one oxygen atom) form of a probe-carrying peptide. c) The peak at m/z of 729 
matching the one sodium adduct form (replacing one proton with one sodium) of a probe-carrying peptide. 






Figure 2.7 Alignment of extracted ion chromatograms for the MS ion cluster 
associated with peptide LPCVEDYLSAILNR modified by the intact probe. 
 
Note: The 706-732 m/z ion isolation window of interest is binned into smaller windows of 2 m/z. The 
overlap of ion current peaks implies multiple ions share the same retention profile, suggesting the lability 





Figure 2.8 Annotated MS/MS spectra featuring the peptide 
LPCVEDYLSAILNR modified by intact biotin dye. 
 
Note: a) The spectrum matching the probe-carrying peptide. b) The spectrum matching the oxidized (plus 
one oxygen atom) form of the probe-carrying peptide. c) The spectrum matching the one sodium adduct 
form (replacing one proton with one sodium) of the probe-carrying peptide. d) The spectrum matching the 
doubly oxidized (plus two oxygen atoms) form of the probe-carrying peptide. Oxidation of probe-carrying 




Figure 2.9 Annotated MS/MS spectrum featuring the peptide 
DTCFSTEGPNLVTR modified by a reduced form of the biotin dye. 
 
Note: This triply charged precursor with an m/z ratio of 927 matches a proposed modified peptide carrying 
a reduced probe with a loss of 2-nitro group on its imidazole ring. This peptide eluted at 40.3 min as shown 
on the total ion chromatogram (TIC). Refer to Scheme 2.4 for the complete structural scheme of the 





Figure 2.10 Annotated MS/MS spectrum featuring the probe-modified 
peptide DTCFSTEGPNLVTR or its mis-cleaved form. 
 
Note: This annotated MS/MS spectrum features either the probe-modified peptide DTCFSTEGPNLVTR 
or its mis-cleaved form AADKDTCFSTEGPNLVTR. This triply charged precursor has a m/z ratio of 903. 











Note: a) Aligned y-ion XICs of peptide LPCVEDYLSAILNR. b) Aligned y-ion XICs of 
(AADK)DTCFSTEGPNLVTR. The alignment shows both individual (y1 to y11) and stacked (showing as 
summed y-ion current for MS/MS scans with at least five concurrent y ions) ion chromatograms. Y-axis 
was zoomed for a better illustration with a scale of 1 x 107. On the stack chromatograms, one peak cluster 
indicates either a single molecular ion or multiple molecular ions with similar precursor masses 
(exemplifying in-source fragmentation) occurring at a specific retention window at 63 min, referring to 
Figure 2.7. The dispersion of multiple peak clusters over the retention time (43 min, 48 min, 50 min, 55 






Figure 2.12 Biotin dye docking results visualizing the pre-modification probe-
protein interactions. 
 
Note: The structure of AlbM was modeled using a template X-ray structure (rabbit serum albumin PDB 
accession 3V09). a) Cartoon presentation of AlbM binding the biotin dye molecule in two distinct manners. 
The cysteine residue is highlighted in yellow for the superficial peptide DTCFSTEGPNLVTR and red for 
the conserved peptide LPCVEDYLSAILNR. b) Protein-surface presentation with docked biotin dye 
molecules at both the surface and cavity of AlbM. c) A regional view of the biotin dye-protein interaction 
on the binding surface. d) A regional view of the biotin dye-protein interaction in the binding pocket. The 










Note: a) Visible bands in vIEF-PAGE gel after TCA-induced protein precipitation. Lane 1: denatured 
control sample, Lane 2: denatured probe-treated sample, Lane 3: native control sample, and Lane 4: native 
probe-treated sample. b) Fluorescence image of a. c) 2-DE fluorescence image of a denatured probe-treated 
sample. d) 2-DE fluorescence image of a denatured control sample. e) Coomassie Blue-stained 2-DE gel 
of denatured probe-treated sample. f) Coomassie Blue-stained 2-DE gel of denatured control sample. g) 





2.6 Chapter 2 Schemes 
Scheme 2.1 Evolution of nitroimidazole-indocyanine green derivatives as 






Scheme 2.2 Overview of this investigation. 
 
Note: a) Brief scheme showing proposed general reaction pathways of 2-nitroimidazole probes. Both small-
molecule metabolites and macromolecule adducts are anticipated as in vivo products. b) Structure of biotin 
dye showing the reactive hypoxia-targeting 2-nitroimidazole group in red, ICG fluorophore in green, and 
biotin affinity handle in blue. c) Experimental workflow of this study. Note the biotin dye is dual-functional 
thus allows for flexible and orthogonal detection of target analytes at various stages (color-coded to indicate 




Scheme 2.3 Recommended data-mining workflow for the identification of 
protein targets and their modification sites in chemical proteomics profiling 
studies. 
 
Note: The mass spectra acquired in data-dependent acquisition mode should be analyzed with 
complementary tactics in parallel, regarding the identifiability of modified peptides. Using this study as an 
example, the output corresponding to each step of data processing has been verified (✓). The dashed arrow 
represents the prevalent restrictive search strategy relying on an input of defined modifications to assign 
spectra featuring modified peptides, which has been proven inapplicable to this study. Traceable surrogate 
probe fragment ions remain to be determined *(TBD), which requires a dedicated MS/MS study of the 





Scheme 2.4 Proposed AlbM-biotin dye in vivo reaction mechanism. 
 
Note: The AlbM carries the biotin dye in two hypothetical forms (regardless of stoichiometry), the 
peripheral subdomain-bound (surface-adsorbed) and core pocket-buried, to the hypoxic tumor site through 
the circulatory system of the mouse subject. These two forms of the protein-probe complex theoretically 
have a 20- to 100-fold difference in equilibrium constants for the probe binding (K1 vs. K2). Under hypoxic 
condition, as the compromised redox homeostasis impairs proximate disulfide bridges of AlbM cysteine 
residues, both forms of the probe can covalently modify AlbM. Note the high affinity of the probe to the 




which provides additional reactivity of the probe to the adjacent thiol in the binding pocket, leading to direct 
addition of the intact probe to the cysteine residue (center a and b). In contrast, the surface-adsorbed probe 
is only reactive to the adjacent thiol after the bio-reductive activation (top, b). Furthermore, post-covalent-
binding bio-reductive reactions reduce 2-aminoimidazole (top, c) to imidazole (top, d) or other unknown 





2.7 Chapter 2 Tables 
Table 2.1 Optical properties of the biotin dye in comparison with the previous 
ICG-based fluorescence imaging probes. 




























C55H65N12NaO14S2 753 790 230 
Biotin dye 
 




Note: Optical properties of the biotin dye are compared with the previous ICG-based fluorescence imaging 
probes.148,150 For the measurement of optical properties, 9.25% of sucrose was used as the solvent in 
consistence with published results. The fluorescence signal was more stable in this solvent. The 





Table 2.2 AlbM peptides identified by MaxQuant. 
Identified Sample1 (SDS-PAGE) 
Peptide Sequence 










































































Note: The identified peptides shared in both SDS-PAGE-resolved avidin-enriched sample (Sample 1) and 
















P01027 Complement C3 (HSE-MSF) [Cleaved into: Complement C3 beta 
chain; C3-beta-c (C3bc); Complement C3 alpha chain; C3a 
anaphylatoxin; Acylation stimulating protein (ASP) (C3adesArg); 
Complement C3b alpha' chain; Complement C3c alpha' chain 
fragment 1; Complement C3dg fragment; Complement C3g 
fragment; Complement C3d fragment; Complement C3f fragment; 
Complement C3c alpha' chain fragment 2] 
C3 186,484 
P01942 Hemoglobin subunit alpha (Alpha-globin) (Hemoglobin alpha chain) Hba Hba-
a1 
15,085 
P02088 Hemoglobin subunit beta-1 (Beta-1-globin) (Hemoglobin beta-1 
chain) (Hemoglobin beta-major chain) 
Hbb-b1 15,840 
P05213 Tubulin alpha-1B chain (Alpha-tubulin 2) (Alpha-tubulin isotype M-
alpha-2) (Tubulin alpha-2 chain) [Cleaved into: Detyrosinated 




P07724 Serum albumin Alb Alb-1 
Alb1 
68,693 




P07901 Heat shock protein HSP 90-alpha (Heat shock 86 kDa) (HSP 86) 






P11499 Heat shock protein HSP 90-beta (Heat shock 84 kDa) (HSP 84) 






P14824 Annexin A6 (67 kDa calelectrin) (Annexin VI) (Annexin-6) 
(Calphobindin-II) (CPB-II) (Chromobindin-20) (Lipocortin VI) 




P20029 Endoplasmic reticulum chaperone BiP (EC 3.6.4.10) (78 kDa 
glucose-regulated protein) (GRP-78) (Binding-immunoglobulin 
protein) (BiP) (Heat shock protein 70 family protein 5) (HSP70 
family protein 5) (Heat shock protein family A member 5) 




P23953 Carboxylesterase 1C (EC 3.1.1.1) (Liver carboxylesterase N) (Lung 




P40142 Transketolase (TK) (EC 2.2.1.1) (P68) Tkt 67,630 
P50446 Keratin, type II cytoskeletal 6A (Cytokeratin-6A) (CK-6A) (Keratin-
















P60710 Actin, cytoplasmic 1 (Beta-actin) [Cleaved into: Actin, cytoplasmic 
1, N-terminally processed] 
Actb 41,737 
P62737 Actin, aortic smooth muscle (Alpha-actin-2) [Cleaved into: Actin, 









P63260 Actin, cytoplasmic 2 (Gamma-actin) [Cleaved into: Actin, 




P63268 Actin, gamma-enteric smooth muscle (Alpha-actin-3) (Gamma-2-
actin) (Smooth muscle gamma-actin) [Cleaved into: Actin, gamma-





P68033 Actin, alpha cardiac muscle 1 (Alpha-cardiac actin) [Cleaved into: 




P68369 Tubulin alpha-1A chain (Alpha-tubulin 1) (Alpha-tubulin isotype M-
alpha-1) (Tubulin alpha-1 chain) [Cleaved into: Detyrosinated 




P68373 Tubulin alpha-1C chain (Alpha-tubulin 6) (Alpha-tubulin isotype M-
alpha-6) (Tubulin alpha-6 chain) [Cleaved into: Detyrosinated 






Keratin, type II cytoskeletal 73 (Cytokeratin-73) (CK-73) (Keratin-





Q8BFZ3 Beta-actin-like protein 2 (Kappa-actin) Actbl2 42,004 
Q8BGZ
7 
Keratin, type II cytoskeletal 75 (Cytokeratin-75) (CK-75) (Keratin-6 
hair follicle) (mK6hf) (Keratin-75) (K75) (Type II keratin-K6hf) 






Keratin, type II cytoskeletal 79 (Cytokeratin-79) (CK-79) (Keratin-




Q91X72 Hemopexin Hpx Hpxn 51,318 
Q922U2 Keratin, type II cytoskeletal 5 (Cytokeratin-5) (CK-5) (Keratin-5) 




Q9Z331 Keratin, type II cytoskeletal 6B (Cytokeratin-6B) (CK-6B) (Keratin-





Note: 29 proteins were identified in both samples (SDS-PAGE-resolved avidin-enriched sample and 2-DE-





Table 2.4 Peptides and their corresponding proteins identified by MODa. 
Identified Peptides from Sample 1 Correspondi
ng Sample 
1 Proteins 
Identified Peptides from Sample 
2 
Correspondi
ng Sample 2 
Proteins 
DVFLGTFLYEYSR P07724 DVFLGTFLYEYSR P07724 
ENPTTFMGHYLHEVAR P07724 ENPTTFMGHYLHEVAR P07724 
GLVLIAFSQYLQK P07724 GLVLIAFSQYLQK P07724 
LGEYGFQNAILVR P07724 LGEYGFQNAILVR P07724 
QTALAELVK P07724 QTALAELVK P07724 
FLEQQNQVLQTK Q6IFZ6 FLEQQNQVLQTK Q6IFZ6 
VNSDEVGGEALGR P02088 APQVSTPTLVEAAR P07724 
DLVVLLFETALLSSGFSLEDPQTHS
NR 
P11499 CCSGSLVER P07724 
GTGASGSFK Q07133 DTCFSTEGPNLVTR P07724 
GFSSGSAVVSGGSR Q3TTY5 HPDYSVSLLLR P07724 
SADELENLILQQN Q6DIB4 LPCVEDYLSAILNR P07724 
SGSEGPVLLLLHGGGHSALSWAVF
TAAIISR 
Q8BVQ5 LSQTFPNADFAEITK P07724 
SSAFDGLLPQQN Q8VBT3 LVQEVTDFAK P07724 
GVTHNIPLLR Q91ZA3 PCFSALTVDETYVPK P07724 
HIEIQVLGDK Q91ZA3 SLHTLFGDK P07724 
LVTYGSDR Q91ZA3 TPVSEHVTK P07724 
SFGLPSIGR Q91ZA3 YNDLGEQHFK P07724 
VVEEAPSIFLDPETR Q91ZA3 DIPVDSPELK O08677 
YSSAGTVEFLVDSQK Q91ZA3 ALLNVVDSAR O35405 
LYLGHNYVTAIR Q921I1 IGGHGAEYGAEALER P01942 
SDIVIAVTYNR Q99MR8 VITAFNDGLNHLDSLK P02088 
VFFSEGAQANR Q99MR8 YFDSFGDLSSASAIMGNAK P02088 
LGLALNFSVFYYEILNSPEK Q9CQV8 LHVDPENFR P02089 
SLQSVAEER Q9CZM2 VVAGVATALAHK P02089 
























































































































































































































Note: AlbM peptides are highlighted in yellow. Shared peptides and their corresponding proteins (shown 
as UniProt accession numbers), are labeled in red. Sample 1 is the SDS-PAGE-resolved avidin-enriched 





Table 2.5 Venn data table showing relations among the identification results. 
(0001) (0010) (0100) (0101) (1000) (1010) (1011) (1100) (1110) (1111) 








Q6DIB4 P16627 E9Q286 Q8BVQ
5 



































O88491 P17156   P62737 Q91X7
2 
  
    P08071   O89110 P22599   P63017     
    P0C6F1   P04104 P32261   P63260     
    P10126   P04441 P42932   P63268     
    P12382   P05214 P49182   P68033     
    P14148   P08003 P51885   P68369     
    P15864   P0CG49 P57780   P68373     
    P26041   P0CG50 P63038   Q6NXH
9 
    
    P35700   P10077 P82198   Q8BFZ
3 
    
    P35980   P10711 Q01853   Q8BGZ
7 
    
    P43274   P16045 Q02819   Q8VED
5 
    
    P43276   P16301 Q06770   Q922U
2 
    
    P43277   P17182 Q3TW9
6 
  Q9Z331     
    P46662   P18529 Q60963         
    P47857   P20152 Q61233         
    P47911   P20918 Q61247         
    P47915   P21614 Q61503         
    P47962   P24527 Q76MZ
3 
        
    P49962   P27005 Q7TMM
9 
        
    P53026   P29699 Q8R317         
    P54310   P42859 Q8VBW
6 
        
    P62631   P48036 Q99K51         
    P62806   P59240 Q9CWJ
9 




    P62849   P61979 Q9DBB
9 
        
    P62855   P62983 Q9JHU
9 
        
    P62918   P62984 Q9QUR
6 
        
    P63101   P68134 Q9QXC
1 
        
    P68433   P68368           
    P84228   P68372           
    P84244   P80316           
    P86048   P83626           
    Q05920   P97386           
    Q3USH
1 
  P97504           
    Q3UV17   P99024           
    Q5DTX
6 
  Q00896           
    Q5SWU
9 
  Q00897           
    Q61881   Q00PI9           
    Q6ZWV
3 
  Q01514           
    Q8BMK
4 
  Q03526           
    Q8BQM
9 
  Q3TLH4           




          
    Q8BTI8   Q3UTQ
7 
          
    Q8C341   Q3UXZ6           
    Q8VEK
3 
  Q4VA45           
    Q91YQ
5 
  Q569L8           
    Q9CR5
7 
  Q60674           
    Q9CTN
5 
  Q61316           
    Q9CXB
8 
  Q61329           
    Q9CY62   Q61576           
    Q9D8E6   Q61702           
    Q9DBN
5 
  Q62255           
    Q9DCV
7 
  Q64438           
    Q9QYB
2 
  Q684R7           




        Q6P8J2           
        Q6P9J9           
        Q7TNG
5 
          
        Q7TNP2           
        Q7TPR4           
        Q80TK0           
        Q80X19           
        Q80YV3           
        Q811F1           
        Q8BGA
8 
          
        Q8BGC
4 
          
        Q8BKI2           
        Q8BND
5 
          
        Q8BTF7           
        Q8BTY8           
        Q8BVK9           
        Q8C145           
        Q8C166           
        Q8C551           
        Q8C5W
4 
          
        Q8K0D2           
        Q8K3V4           
        Q8R0W
0 
          
        Q8R2S9           
        Q8VCT9           
        Q8VDC
1 
          
        Q8VDW
0 
          
        Q8VIM9           
        Q91WB
4 
          
        Q91WG
0 
          
        Q99J45           
        Q99K95           
        Q99KC8           
        Q99KD5           
        Q99KW
3 
          
        Q9CQB
5 




        Q9CQW
3 
          
        Q9CWF
2 
          
        Q9CXV9           
        Q9D0F9           
        Q9D281           
        Q9D3R6           
        Q9D4B1           
        Q9D554           
        Q9D6F9           
        Q9DC60           
        Q9EP96           
        Q9ERC
8 
          
        Q9ERD
7 
          
        Q9JJN2           
        Q9JKF1           
        Q9JLC8           
        Q9JMA1           
        Q9JMH6           
        Q9R0H5           
        Q9WU7
9 
          
        Q9WUP
0 
          
        Q9WVE
8 
          
        Q9Z0G7           
        Q9Z1N5           
        Q9Z1X4           
        Q9Z247           
Note: This Venn data table shows detailed identification results of both SDS-PAGE-resolved avidin-
enriched sample (Sample 1) and 2-DE-resolved unenriched sample (Sample 2) by both MODa and 













Sequence region 1 
(showing the inner peptide) 
Omitted 
region (…) 
Sequence region 2 




SALSA Q03156 … 459 CCKDEPGHFVLPCAEEKLTDAIDATCDDYDPSSINPHIAHCCNQSYSMRR 508 … 580 KCCAAEDQAACFTEEAPKLVSESAELVKV-- 608 
SALSA P21848 … 459 CCKDEQGHFVLPCAEEKLTDAIDATCDDYDPSSINPHIAHCCNQSYSMRR 508 … 580 KCCAAEDQAACFTEEAPKLVSESAELVKV-- 608 
CHICK P19121 … 465 CCQ-LGEDRRMACSEGYLSIVIHDTCRKQETTPINDNVSQCCSQLYANRR 513 … 585 KCCKQSDINTCFGEEGANLIVQSRATLGIGA 615 
MERUN O35090 … 462 CCA-LPEKKRLPCVEDYLSAILNRVCLLHEKTPVSEQVTKCCSGSLVERR 510 … 580 KCCKQEDKEACFSTEGPKLVAESQKALA--- 609 
MESAU A6YF56 … 461 CCV-LPEAQRLPCVEDYISAILNRVCVLHEKTPVSEQVTKCCTGSVVERR 509 … 581 KCCKAEDKEACFSEDGPKLVASSQAALA--- 608 
MOUSE P07724 … 461 CCT-LPEDQRLPCVEDYLSAILNRVCLLHEKTPVSEHVTKCCSGSLVERR 509 … 581 TCCKAADKDTCFSTEGPNLVTRCKDALA--- 608 
RAT P02770 … 461 CCT-LPEAQRLPCVEDYLSAILNRLCVLHEKTPVSEKVTKCCSGSLVERR 509 … 581 KCCKAADKDNCFATEGPNLVARSKEALA--- 608 
RABIT P49065 … 461 CCK-HPEAERLPCVEDYLSVVLNRLCVLHEKTPVSEKVTKCCSESLVDRR 509 … 581 KCCSAEDKEACFAVEGPKLVESSKATLG--- 608 
PIG P08835 … 460 CCK-RPEEERLSCAEDYLSLVLNRLCVLHEKTPVSEKVTKCCTESLVNRR 508 … 580 KCCAAPDHEACFAVEGPKFVIEIRGILA--- 607 
BOVIN P02769 … 460 CCT-KPESERMPCTEDYLSLILNRLCVLHEKTPVSEKVTKCCTESLVNRR 508 … 580 KCCAADDKEACFAVEGPKLVVSTQTALA--- 607 
SHEEP P14639 … 460 CCA-KPESERMPCTEDYLSLILNRLCVLHEKTPVSEKVTKCCTESLVNRR 508 … 580 KCCAADDKEGCFVLEGPKLVASTQAALA--- 607 
EQUAS Q5XLE4 … 460 CCK-LPESERLPCSENHLALALNRLCVLHEKTPVSEKITKCCTDSLAERR 508 … 580 KCCGAEDKEACFAEEGPKLVASSQLALA--- 607 
HORSE P35747 … 460 CCK-LPESERLPCSENHLALALNRLCVLHEKTPVSEKITKCCTDSLAERR 508 … 580 KCCGREDKEACFAEEGPKLVASSQLALA--- 607 
MACFA A2V9Z4 … 461 CCK-LPEAKRMPCAEDYLSVVLNRLCVLHEKTPVSEKVTKCCTESLVNRR 509 … 581 KCCKADDKEACFAEEGPKFVAASQAALA--- 608 
MACMU Q28522 … 453 CCK-LPEAKRMPCAEDYLSVVLNRLCVLHEKTPVSEKVTKCCTESLVNRR 501 … 573 KCCKADDKEACFAEEGPKFVAASQAALA--- 600 
HUMAN P02768 … 461 CCK-HPEAKRMPCAEDYLSVVLNQLCVLHEKTPVSDRVTKCCTESLVNRR 509 … 581 KCCKADDKETCFAEEGKKLVAASQAALGL-- 609 
PONAB Q5NVH5 … 461 CCK-HPEPKRMPCAEDYLSVVLNQLCVLHEKTPVSERVTKCCTESLVNRR 509 … 581 KCCKADDKETCFAEEGKKLVAASQAALGL-- 609 
FELCA P49064 … 461 CCT-HPEAERLSCAEDYLSVVLNRLCVLHEKTPVSERVTKCCTESLVNRR 509 … 581 KCCAAEDKEACFAEEGPKLVAAAQAALA--- 608 
CANLF P49822 … 461 CCK-KPESERMSCAEDFLSVVLNRLCVLHEKTPVSERVTKCCSESLVNRR 509 … 581 KCCAAENKEGCFSEEGPKLVAAAQAALV--- 608 
BOMMX Q3T478 … 460 CCA-LPNTQKMPCAEGGLSLIIGEFCEMEKTHPINEHVKNCCWKSYSNRR 508 … 580 KCCAAEDHQACFNAEEPILIEHCKQLAA--- 607 
XENLA P14872 … 460 CCA-VPENQRMPCAEGDLTILIGKMCERQKKTFINNHVAHCCTDSYSGMR 508 … 580 KCCTADEHQPCFDTEKPVLIEHCQKLHP--- 607 
XENLA P08759 … 459 CCA-VPENQRMPCAEGDLTILIGKMCERQKKTFINNHVAHCCTDSYSGMR 507 … 579 KCCTADEHQPCFDTEKPVLIEHCQKLHP--- 606 
Output **        : * *  ::  :   *   .   :. .: :**       *  .**   :   **  :   ::  
                                                             
Legend. 
Alignment output symbol Indication 
* Fully conserved residue positions 
: Strongly conserved residue positions (shared by groups of amino acids with similar chemical properties) 
. Weakly conserved residue positions (shared by groups of amino acids with slightly distinct chemical properties)  
 
Note: The in silico tryptic peptides are highlighted. Note the intact-probe-modified peptide in the deep pocket (yellow) contains more conserved 
residues than reduced-probe-modified peptide on the AlbM surface (turquoise). The cysteine residues (in red and orange) of both peptides are fully 





Chapter 3 Measuring Proteome-wide Live-cell Actions of 
Small Molecules Using α-Methylene-β-lactone and Mass 
Spectrometry 
This chapter reports novel utilities of the α-methylene-β-lactone (MeLac) moiety as a 
chemical probe warhead of multiple electrophilic sites. This study demonstrates that MeLac-
alkyne is a competent covalent probe and reacts with diverse proteins in live cells. Proteomics 
analysis of affinity-enriched samples identified probe-reacted proteins, resolved their modified 
peptides/residues, and thus characterized probe-protein reactions. Unique methods have been 
developed to evaluate confidence in identification of the reacted proteins and modified peptides. 
Tandem mass spectra of the peptides have uncovered that MeLac reacts with nucleophilic cysteine, 
serine, lysine, threonine, and tyrosine residues, through either Michael addition or acyl addition. 
As a broad-spectrum measurement probe, MeLac-alkyne has successfully analyzed orlistat and 
parthenolide selectivity in live HT-29 cells within a unique peptide-centric proteomics platform. 
As a scaffold, MeLac-alkyne has created a selective β-lactone probe with glutathione via 
proteome-assisted probe-ligand assembly in biological matrices. The MeLac-alkyne-empowered  
chemical proteomics platform is widely adaptable for measuring the live-cell action of reactive 
molecules. The assembly of MeLac-alkyne glutathione adduct exemplifies a scalable route to 
develop selective probes. It also provides an unprecedented opportunity to probe the glutathione 
S-transferase P1 (GSTP1) responsible for multi-drug resistance in cancer patients. Overall, MeLac 
is a versatile warhead bearing enormous potential in expediting the development of chemical 
probes and targeted covalent inhibitors. MeLac-based probes are novel chemical tools making 
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3.1.1 Significance of chemical proteomics in drug development 
Bioactive small molecules have always been the focus of interest for developing diagnostic 
and therapeutic agents to elucidate and alter biochemical pathways. Drug discovery pipelines 
typically involve two approaches for screening bioactive small molecules: target-based screening, 
where compounds are developed to target a disease-causing enzyme, and phenotypic screening, 
where libraries of small molecules are screened against model organisms to revert a disease-related 
phenotype.198,199 In general, the target-based approach, which operates at a lower level, is target-
specific, thus reliable and low-risk. However, the implementation of target-based screening is 
usually restricted by the progress of biological understanding of the disease and throttled by the 
unforeseeable ADME-Tox (Absorption, Distribution, Metabolism, Excretion, and Toxicity) 
profile. On the other hand, phenotypic screening, which operates at a higher level and factors in 
drug delivery and toxicity, rarely provides opportunities to discover and validate the mode of 
action of a drug candidate.200 Although expeditable and scalable, phenotypic screening is always 
riskier to perform due to the fact that chemically distinct drug candidates may function on different 
modes of action in different contexts or organisms beyond the experimental expectation. 
Fortunately, the fast-advancing field of chemical proteomics provides a suitable middle-ground 
between target-based and phenotypic screening approaches for unbiased exploration of drug-
target-phenotype relationships.201 
Chemical proteomics is a progressive subfield of chemical biology. Chemical proteomics 
tactically integrates synthetic chemistry to generate investigational small molecules to study and 




bioanalytical platforms. These platforms investigate modes of action for bioactive small molecules 
and functions of proteins.74 Chemical proteomics analysis of drug-protein reactions expedites the 
development of new drugs by revealing selective inhibitors early, identifying toxicity liabilities, 
and mitigating the risk of late-stage failures.74 In a typical chemical proteomics workflow, direct 
chemical perturbation is usually introduced as a measure of treatment to a model proteome at a 
specific level of biological relevance, such as cell lysates, living cells, tissues, and animal 
specimens. Afterward, latent measurements of biochemical changes are performed. Offering 
multiplexed analyses on, these chemical proteomics platforms often facilitate quantitative studies 
of target engagement, off-target effect, and cytotoxicity for a compound of interest 
simultaneously.202-204  
3.1.2 Chemical probes and chemical proteomics methodologies 
The measurement of post-treatment biochemical changes of a proteome relies on an 
elaborate set of analytical and chemical tools. The analytical tools can be either optics-based or 
mass spectrometry-based. The chemical probes are either covalent or non-covalent. Although 
affinity capture approaches for target protein profiling are used with both types of chemical probes, 
each type of chemical probes denotes a distinguishable analytical and biochemical methodology 
of the underlying chemical proteomics experiments. Compound-centric approaches feature 
chemically modified, either tagged71 or immobilized72, compounds of interest as either covalent or 
non-covalent chemical probes. Also known as boutique probes, these chemical probes are 
introduced directly as baits to capture target proteins from a complex proteome. In contrast, 
activity-based approaches depend on meticulously designed covalent chemical probes. These 
activity-based probes are capable of irreversibly binding, reacting with, and labeling target proteins 




elucidation of target activity relies on the indirect measurement of probe-target adducts as 
competitive binding assays.  
Presumably, compound-centric chemical proteomics is the most straightforward strategy 
for studying the proteome-wide activity of a known drug molecule. It mandates a boutique probe 
created by installing a reporting group on the drug molecule. However, the construction of a drug-
derived probe often bears high synthetic costs. The application of such a boutique probe also 
suffers from the consequence of chemical modifications. Because any structural changes made to 
the drug molecule may significantly alter the parent molecule’s potency and selectivity profile.73 
The more sophisticated strategy is activity-based chemical proteomics, which emphasizes the use 
of a broad-spectrum covalent probe. Activity-based chemical proteomics, technically referring to 
competitive ABPP, offers a nearly universal bioanalytical platform.74,75 Such a platform can 
effectively decipher the proteome-wide action of underivatized drugs, as well as other reactive 
molecules like environmental toxins and reactive metabolites from the human microbiota.76-79  
In contrast to boutique probes, ABPs are designed to carry less specificity to their protein 
targets or are not specific at all. They capture proteome-wide “snapshots” visualizing drug-protein 
interactions by permanently occupying available active sites post drug treatment on the model 
proteome. As illustrated in Scheme 3.1, a competitive ABPP platform depends on its ABP to 
measure the proteome-wide action of an underivatized drug.80,81 The distinctive technological 
advantage of competitive ABPP is that a single ABP with broad proteome coverage can establish 
a versatile analytical platform capable of evaluating multiple drugs or drug candidates on different 
subsets of a single proteome. Therefore, ABPs with a broad spectrum of reactivity can fully 




An ABP normally consists of three chemical components: a reactive group that is 
commonly known as the “warhead,” a recognizing group that is commonly established as a 
chemically inert binding moiety, and a reporting group that is commonly devised as an 
affinity/fluorophore tag. (top, Scheme 3.1) An ABP’s warhead dictates the probe’s reactivity while 
the recognizing group mainly determines the probe’s specificity towards a subset of proteins within 
a proteome. In principle, when a broad reactivity spectrum is desired, an ABP should incorporate 
(1) no recognizing group that may direct pre-reaction probe-protein complexation and (2) a 
warhead of broad reactivity spectrum. While fluorophosphonate-based probes provide a successful 
example of exploiting the first option of this principle,205 the second option is rarely explored due 
to the limited availability of broad-reactivity warhead. It has always been a challenge to design a 
warhead that covers the diverse reactivity space of a proteome. Individual proteins differ in 
molecular composition and structure. Their reactions with small molecules are distinct from site 
to site, domain to domain, and protein to protein. The diversity of these reactions rapidly multiplies 
due to the large number and abundance range of proteins in a proteome.  
3.1.3 The emerging need for novel warheads of broad reactivity   
Existing warheads are far from ideal for universal platforms of competitive ABPP. To date, 
a diverse collection of reactivity of warheads has been implemented on ABPs, including Michael 
addition, non-Michael nucleophilic addition, addition-elimination, nucleophilic substitution, and 
oxidation.124,206,207 Unfortunately, these conventional warheads typically react with only one 
functional group on amino acid residues: cysteine,119,208,209 serine,205,210,211  threonine, tyrosine,212 
lysine,79,212,213 and histidine,212 resulting in limited proteome coverage. Their reactivity depends 
on either a specific reaction mechanism or a single electrophilic site.79,122-124,214-216 After all, a 




warhead of broad reactivity. To broaden the reactivity spectrum further, ABPs should adopt a 
warhead with multiple electrophilic sites, which can extend the coverage of diverse functional 
groups on amino acid residues. Nonetheless, due to the lack of warheads consisting of multiple 
electrophiles, such an ideal broad-spectrum ABP is still absent. 
This study employed α-methylene-β-lactone (MeLac) as a novel warhead with broad 
reactivity and live-cell compatibility. Small and rigid, MeLac couples the Michael acceptor 
functionality of acrylate217,218 with β-lactone reactivity.219-221 MeLac was proposed to be 
susceptible to nucleophilic attacks at three distinct sites, as shown on Scheme 3.2, which would 
result in a broad reactivity spectrum covering multiple nucleophilic side chains on different amino 
acid residues. Therefore, this hypothesis was tested as follows: when used on a chemical probe as 
the warhead for proteomics profiling, MeLac would react with different nucleophilic groups on 
proteins via different mechanisms. This new warhead is prone to reactions with nucleophilic thiol 
(Cys), hydroxyl (Ser, Thr, and Tyr), and amino (Lys) groups on the protein. Also, MeLac can 
provide separate sites for regioselective reactions with spatially arranged protein nucleophiles. 
Thus, the reactivity of the small and rigid MeLac is projected to be broad. A MeLac-equipped 
chemical probe would make a competent measurement probe for building a widely adaptable 
platform of competitive ABPP.  
Using a MeLac-alkyne as a probe without recognizing group, the probe-protein reactions 
in live cells were examined and characterized using both gel-based and mass spectrometry-based 
proteomics profiling. New methods for the confident identification of protein adducts were 
developed. A peptide-centric live cell compatible platform of competitive ABPP was built using 
MeLac-alkyne. This platform was used for analyzing the selectivity profiles of protein reactions 




which were used as model inhibitors with the β-lactone, Michael acceptor, and MeLac reactivity, 
respectively. 
3.1.4 The versatility of a chemical scaffold 
On the other hand, MeLac was also introduced as a useful scaffold in developing selective 
probes. MeLac offers separate electrophilic sites allowing not only regioselective reactions with 
spatially arranged protein nucleophiles but also scalable development of selective probes to protein 
targets of interest. Derivatization of one electrophilic site on the MeLac scaffold with an affinity 
ligand can introduce a recognizing group in-situ for its pre-reaction complexation with the active 
site on a protein. In this study, the in-cell conjugation of reduced glutathione (GSH) to MeLac was 
also discovered. This surprising intracellular process produced a highly selective β-lactone 
boutique probe for GSH. Overall, this study demonstrates utilities of the MeLac scaffold in 
developing (1) broad-reactivity ABPs for measuring proteome-wide actions of underivatized small 







To investigate the intriguing broad reactivity aspect of MeLac, the 4-(but-3-ynyl)-3-
methyleneoxetan-2-one (MeLac-alkyne probe, Scheme 3.3)222,223 was studied for its protein target 
and labeling site-specific profile. After reactivity and target characterization of MeLac-alkyne, it 
was then implemented as a competitive ABP for analyzing proteome-wide reactions of three 
compounds in live HT-29 cells. These three compounds were 4-decyl-4-methyleneoxetan-2-one 
(alkyl MeLac inhibitor), orlistat, and parthenolide. (Scheme 3.3) Both MeLac-alkyne and alkyl 
MeLac inhibitor were synthesized and characterized at Howell group at Department of Chemistry. 
Orlistat and parthenolide were purchased commercially. MeLac-alkyne probe-protein reactions 
were initially evaluated using gel-based ABPP. Next, as illustrated in Scheme 3.4, probe-reacted 
proteins were conjugated to azide-(desthio)biotin tags and enriched with immobilized avidin. This 
affinity enrichment allowed the selective release of probe-reacted proteins and probe-modified 
peptides for the following MS-based probe reactivity characterization, target profiling, structural 
elucidation of probe-modified peptides, and dose-dependent target site-specific profiling of 
benchmark inhibitors using MeLac-alkyne in competitive ABPP.  
3.2.2 HT-29 cell culture 
HT-29 cells were cultured to a confluency of 90-95%, as shown on Figure 3.1 in either 
T75 or T175 cell culture flasks (CELLTREAT Scientific; about 8 million cells/ T75 flask or 23 
million cells/T175 flask) with appropriate amount of growth medium (GM). The GM was prepared 




bovine serum (FBS, Gibco) and 1% (v/v) Pen/Strep antibiotics (FBS, Gibco). Sterile disposable 
filter units (with a pore size of 0.22 μm or 0.45 μm) were used to sterilize the GM before its use 
for cell culture. The incubation of cell culture flasks was performed in a humidified incubator at 
5% of CO2 and 37 °C. 
To initiate the culturing of HT-29 cells, a vial of cryogenically preserved cells (seeds) was 
thawed and washed with GM at 37 °C. The washed cells were then transferred to a proper cell 
culture flask at a proper seeding density, as suggested in Table 3.1. GM change (replacing old GM 
with fresh GM) was performed three to four times per week, depending on the cell growth and 
viability. To maintain a healthy HT-29 cell line, cells were routinely passed at a confluency of 
above 75%. For each passage, cells were detached from the supporting surface of the vessel by 
trypsin/EDTA solution (Gibco). The detached culture suspension was then split at a ratio of 1:3 or 
1:4 into new vessels of the same size. Cell viability (the number of living cells divided by the 
number of total cells) was checked on a small aliquot of the culture suspension treated with trypan 
blue on a hemocytometer under a microscope. 
3.2.3 In vitro probe-proteome reaction for competitive ABPP using 
MeLac-alkyne probe and HT-29 cells 
Before reaction, cells were washed twice with 10 mL (for cells in each T75 flask) or 20 
mL (for cells in each T175 flask) of phosphate-buffered saline (PBS, 1X, pre-heated at 37 °C, 
Gibco).  
For inhibitor-free probe treatment of the cells, either 10 or 20 µL of a pre-aliquoted stock 
solution of MeLac-alkyne probe (dissolved in dimethylacetamide, DMAC, Sigma-Aldrich) or its 
diluate in situ was added to each flask containing pre-washed cells and 10 or 20 mL of PBS, 




cells, the flasks were placed on a rocking platform at 37 °C for 30 minutes. After the reaction, 10 
or 20 mL of ice-cold tris-buffered saline (TBS, 1X, pre-heated at 37 °C, Pierce) was added to each 
flask to quench the reaction. Cells in each flask were then gently scraped off the flask surface. The 
subsequent suspension was transferred to either a 15-mL or 50-mL conical tube, centrifuged at 
500 xg, 4 °C for 3 min to pellet the cells. Cells in each conical tube were washed with 10 or 20 mL 
of PBS. Cell pellets were either used immediately or stored at -80 °C.  
For the competitive activity-based proteomics profiling, the inhibitor (orlistat, 
parthenolide, or alkyl MeLac) treatment of the cells was performed before the MeLac-alkyne probe 
treatment at a working probe concentration of 20 μM. Briefly, a pre-aliquoted storage stock 
solution of 20 mM, 50 mM, or 100 mM inhibitor (dissolved in DMSO, stored as aliquots at -80 
°C) was diluted with DMSO to suitable concentrations to prepare working stock solutions if 
necessary. At each inhibitor concentration, an appropriate volume of each inhibitor working stock 
solution was then added to each prepared cell culture flask for each biological replicate (10 µL per 
T75 flask with 10 mL of PBS or 20 µL per T175 flask with 20 mL of PBS). Various inhibitor 
concentrations were investigated (1 μM vs. 10 μM for orlistat and parthenolide; 10 μM vs. 100 μM 
for alkyl MeLac). The inhibitor-treated cells were subject to similar quenching and washing steps, 
as described above. 
3.2.4 Cell lysis and protein extraction 
An appropriate volume of ice-cold PBS lysis buffer (6 to 10X of pellet volume) containing 
1X EDTA-free protease inhibitor cocktail (Thermo Scientific) and phosphatase inhibitor cocktails 
(Thermo Scientific) was added to each cell pellet. The subsequent cell suspension was 
homogenized using an ultrasonic cell disruptor (VCX 130, Vibra-Cell) at 40% power on ice for 




to multiple 2-mL microcentrifuge tubes for centrifugation at 16,000 g for 30 min at 4 °C. The 
lysate supernatants in microcentrifuge tubes were recombined for each original lysate sample, 
followed by BCA (Pierce) assay quantitation for total protein content. Finally, the cleared cell 
lysates were diluted with PBS lysis buffer to give a final protein concentration of 1.5 mg/mL for 
copper-catalyzed azide-alkyne cycloaddition (CuAAC) click reactions. 
3.2.5 CuAAC click conjugation of probe-reacted proteins with azide 
tags 
A click reagent cocktail was prepared in situ by mixing tris(benzyltriazolylmethyl)amine 
(TBTA, TCI) with a final concentration of 100 μM, copper(II) sulfate (Sigma-Aldrich, at a final 
concentration of 1 mM), TCEP (tris(2-carboxyethyl)phosphine, Pierce, at a final concentration of 
1 mM), and the azide fluorescence or affinity tag of choice [at a final concentration of 25 μM; 
tetramethylrhodamine biotin azide (TAMRA), desthiobiotin azide (Des, Scheme 3.5), Dde biotin 
picolyl azide (Dde, Scheme 3.6), or diazo biotin azide (Dia, Scheme 3.7) from Click Chemistry 
Tools], in a tri-solvent system consisting of DMSO (Sigma-Aldrich), tert-butanol (Fisher 
Scientific), and water (MS-grade, Fisher Scientific). The click reagent cocktail was added to each 
sample of diluted probe-reacted lysate containing 1.5 mg/mL of protein. The reaction mixtures 
were incubated at room temperature for 1 hour with constant agitation. After the reaction, proteins 
were precipitated using cold acetone at -20 °C overnight. The resulting protein precipitate was 
pelleted by centrifugation, resuspended once in cold methanol using ultrasonic cell disruptor, re-
pelleted, and washed with cold methanol two more times without sonication. The slightly air-dried 
pellet was then re-dissolved in 500 μL to 1mL of a reconstitution buffer (pH 8.0) containing 50 
mM Tris-HCl (Fisher Scientific), 8 M urea (Pierce), and 10 mM 2-mercaptoethanol (Bio-Rad). 




at room temperature for 45 minutes, followed by 18.8 mM iodoacetamide (G-Biosciences) at room 
temperature in the dark for 30 minutes. Finally, sodium dodecyl sulfate (SDS, Fisher Scientific) 
was added to each protein sample to a final concentration of 2%. Samples were directly used for 
either SDS-PAGE or affinity enrichment or stored at -80 °C. 
3.2.6 Trypsin digestion of probe-reacted proteins and affinity enrichment 
of probe-modified analytes  
For each probe-treated sample, affinity enrichment was performed at either the protein 
level (for the enrichment of probe-reacted proteins before trypsin digestion, performed for all three 
affinity tags) or peptide level (for the enrichment of probe-modified tryptic peptides after trypsin 
digestion, only performed for Des). 
3.2.6.1 Affinity enrichment at the protein level 
500 μL (containing about 0.75 mg of total protein) of each sample was transferred to a 
centrifuge column and diluted with 12 mL of 100 mM Tris-HCl buffer (diluting SDS to less than 
0.1%, urea to less than 0.3 M). Next, 200 μL of pre-washed 50% NeutrAvidin-agarose resin 
(Pierce) slurry was added to each centrifuge column and incubated with constant agitation at 4 °C 
overnight. For each sample, the protein-bound resins were washed twice with 10 mL of washing 
buffer A (100 mM Tris-HCl, 0.1% SDS), three times with 10 mL of washing buffer B (100 mM 
Tris-HCl), and twice with 10 mL of LC-MS-grade water. Afterward, the probe-reacted proteins 
were eluted with one of three corresponding elution buffers prepared fresh. The Des elution buffer 
consisted of 0.1% SDS (or 4 M urea), 5 mM biotin (Sigma-Aldrich), and 20 mM TEAB; the Dia 
elution buffer consisted of 4 M urea, 37.5 mM sodium dithionite, and 20 mM TEAB; the Dde 




(TEAB, Sigma-Aldrich). The subsequent eluates were concentrated by a vacuum concentrator, 
extracted and digested using a tip-based solid-phase extraction/trypsin digestion protocol. 
3.2.6.2 In-tip trypsin digestion of affinity enriched proteins 
Solid-phase extraction/trypsin digestion (SxTd) tips were prepared in-house. To prepare 
each SxTd tip, two lays of Empore C18 material (two pre-stacked 3M Empore C18 Extraction 
Disks), and ten lays of glass fiber material (packed twice of five pre-stacked Whatman glass 
microfiber filters) into a 300 μL pipette tip (Fisherbrand, SureOne, Micropoint Pipette Tips, 
Universal Fit, Non-Filtered). After packing the SxTd tip, the sorbent was pre-wet twice with 200 
μL of 0.1% trifluoroacetic acid in 80% acetonitrile, spun at 1000 xg, RT, for 2 min. The sorbent 
was then conditioned twice with 200 μL of freshly prepared 0.1M TEAB in 90% methanol, spun 
at 1000 xg, RT, for 2 min. The maximal loading capacity of each SxTd tip was 50 μL (containing 
up to 20 μg of total protein) affinity enrichment eluate sample.  
For all protein samples with 5 to 20 μg of total protein in each, the total amount of needed 
trypsin was determined on the theoretical NeutrAvidin-agarose resin binding capacity (8 mg 
biotinylated protein per 1 mL of settled resin) and a trypsin:protein ratio (w/w) of 1:30. Fresh 
precipitation buffer (PrecB) was prepared by mixing methanol and 1 M TEAB at a ratio (v/v) of 
9:1. Trypsin suspension was prepared by mixing 1.0 μg/μL trypsin stock with ice-cold PrecB at a 
volume ratio of 1:850. After brief vortexing, 280 μL of trypsin suspension was mixed with each 
50 μL protein sample. Each suspension was then loaded to an SxTd tip, spun at 1000 xg for 3 min. 
The loaded SxTd tips were washed with 200 μL of ice-cold PrecB for three times, 200 μL of dry 
ice-cold acetone twice, and 200 μL of ice-cold PrecB once; all steps were followed by 
centrifugation at 1000 xg for 3 min. Afterward, 20 μL of freshly prepared ice-cold trypsin in 20 




the sorbent fully (no air bubble). Finally, the loaded SxTd tips were placed in an appropriate pipette 
tip box with deionized water at the bottom (pipette tip not touching the water), sealed in a clean 
plastic bag, and incubated in a cell culture incubator at 37°C for 16 hrs. On the second day, each 
SxTd tip was quenched with 200 μL of 0.1% trifluoroacetic acid twice. The digest was eluted with 
60 μL of 50% acetonitrile, spun at 1000 xg for 5 min, concentrated in SpeedVac (Thermo), 
lyophilized on a FreeZone Freeze Dry System (Labconco), and reconstituted in a solvent 
containing 0.1% formic acid (Fisher Scientific), 2.5% acetonitrile in LC-MS grade water for LC-
MS/MS analyses. 
3.2.6.3 Affinity enrichment at the peptide level 
Buffer exchange was performed using Zeba spin desalting columns (7K MWCO, Pierce) 
according to the manufacture’s instruction manual. After buffer exchange, the eluates (containing 
50 mM ammonium bicarbonate, 2 M urea, and 1 mM calcium chloride, Sigma-Aldrich) from the 
spin columns were diluted to a resulting urea concentration of 0.8 M. The protein samples were 
then digested at a trypsin (sequencing grade, Pierce, or TPCK-treated, bioWORLD)-to-protein 
ratio of 1:50 or 1:25 and incubated at 37 °C for 16 hours. Next, pre-washed 50% NeutrAvidin-
agarose resin slurry (100 μL per 0.75 mg of protein) was mixed with each digested sample, 
followed by 1-hour incubation at room temperature with constant agitation. The resins were then 
washed three times with 500 μL of Pierce IP Lysis Buffer, four times with 500 μL of PBS, and 
four times with 500μL of LC-MS-grade water. The captured peptides were eluted by the elution 
solvent (1.5X volume of the resin slurry, 50% acetonitrile, 0.1% trifluoroacetic acid, Fisher 
Scientific) with 3-minute incubation for three times. The subsequent eluate fractions were pooled 




containing 0.1% formic acid (Fisher Scientific), 2.5% acetonitrile in LC-MS grade water for LC-
MS/MS analyses. 
3.2.7 Sodium dodecyl sulfate-polyacrylamide gel electrophoresis and 
Western Blot 
The gel-based analysis was performed on all the probe-reacted and avidin-enriched protein 
samples. A small portion of each sample (10 µL) was loaded onto a Mini-PROTEAN® TGX™ 
precast gel (1.0-mm, 10-well, Bio-Rad). Together with the samples, 5 µL of either SeeBlue™ 
Plus2 pre-stained protein standard (Life Technologies) or Precision Plus Protein™ dual color 
protein standards (Bio-Rad) was loaded to the gel as molecular weight references. The gels were 
prepared in duplicates for performing analytical electrophoresis and Western Blot in parallel. The 
subsequent electrophoresis was performed using Tris/Glycine/SDS premixed electrophoresis 
buffer (Bio-Rad) either at constant 120 V for 90 min until complete migration of the fronting dye 
band to the bottom of the gel. After electrophoresis, the protein bands were fixed with a solution 
of 10% acetic acid and 50% methanol in water. For the analytical electrophoresis, gels were stained 
with QC Colloidal Coomassie Stain (Bio-Rad), placed in a clear resealable plastic pouch, and 
imaged with a document scanner. For the Western Blot, the gel was removed from the 
electrophoresis cassette immediately after electrophoresis, rinsed with water, and accommodated 
in a sandwich assembly of pre-wet fiber pads, filter paper, PVDF membrane (Life Technologies; 
pre-soaked in methanol), and gel holder cassette. The sandwich assembly was then placed together 
with a pre-frozen cooling pack and a magnetic stirrer in the buffer tank containing freshly prepared 
transfer buffer (10% methanol in Tris/Glycine/SDS premixed electrophoresis buffer). The transfer 
was performed at constant 30V overnight. After completion of the transfer, the PVDF membrane 




WesternBreeze kit (Invitrogen). Solutions for chromogenic immunodetection were prepared 
according to the WesternBreeze instruction manual. Briefly, the membrane was incubated on an 
orbital shaker (Thermo Fisher Scientific) at 1 rev/s with: 1) 20 mL of water for 5 min; 2) 10 mL 
of blocking solution for 30 min; 3) 20 mL of water for 5 min (twice); 4) 10 mL of primary antibody 
(diluted to 1 mg/mL from original 8.17 mg/mL solution, mouse monoclonal anti-biotin IgG, 
Fitzgerald) solution (0.05 μg/mL, 1:20000) for 1 h; 5) 20 mL of antibody wash solution for 5 min 
(4 times); 6) 10 mL of secondary antibody- alkaline phosphatase conjugate (anti-mouse IgG, Life 
Technologies) for 30 min; 7) 20 mL of antibody wash solution for 5 min (4 times); 8) 20 mL of 
water for 2 min (3 times); 9) 5 mL of chromogenic substrate solution for 1 h; and 10) 20 mL of 
water for 2 min (3 times). Finally, the blotted PVDF membrane was dried in air and scanned with 
a document scanner. 
3.2.8 Liquid chromatography-tandem mass spectrometry methods 
For each sample, enriched and reconstituted tryptic digests were analyzed on a Q Exactive 
Plus mass spectrometer equipped with the nanospray ionization (EASY-Spray nano) source 
coupled with an EASY-nLC 1200 system (Thermo Fisher Scientific). For the LC part, peptides 
were separated on a fused silica capillary (30 cm x 100 um I.D) packed with Halo C18 (2.7 um 
particle size, 90 nm pore size, Michrom Bioresources). The autosampler temperature was 4.0 °C. 
Column oven temperature was 50.0 °C. Sample injection volume was 2.0 µL. Mobile phase flow 
rate was set as 300 nL/min. Solvent A was 0.1 % formic acid in water, and solvent B was 0.1 % 
formic acid in acetonitrile. A gradient of 0 to 40% solvent B over 180 min was applied. For the 
mass spectrometer part, the Xcalibur v2.8 software was used to control the instrument. The mass 
spectrometer operated in DDA mode for monitoring positive ions at a spray voltage of 2200 V. 




resolution of 70,000, an AGC target of 1E6, and a maximum ion time of 100 ms. For data 
dependent MS2, the quadrupole was set with an isolation window of 2.0 m/z. The Orbitrap was set 
with a resolution of 17,500, an AGC target of 1E5, and a maximum ion time of 50 ms. This DDA 
method allowed up to 10 MS/MS scans per duty cycle, and a stepped normalized collision energy 
(NCE) of 27. Precursors that triggered MS/MS scans were dynamically excluded from repetitive 
MS/MS scans for 40 s. Charge state exclusion was enabled to reject precursor ions with charge 
states outside the range of +2 to +4. The peptide match option was set as preferred. MS/MS spectra 
were collected as the profile data type. 
3.2.9 Mass spectrometry data qualification and analysis  
For peptide and protein identification, the data was initially searched against a canonical 
human reference proteome database (a FASTA file, Swiss-Prot, Homo Sapiens, UP000005640, 
last modified on January 26th, 2019) containing 20,425 protein sequences. DDA raw files were 
analyzed with both FragPipe224 (Version 12.2, with MSFragger Version 2.3) for unrestricted 
database search (open-search) and MaxQuant225 (Version 1.6.5.0) for restricted database search 
with distinct settings. For more comprehensive identification and quantitation of probe 
modification site-specific peptides, the same MaxQuant database search was also performed with 
an extended proteome database (a FASTA file, UniProt, Homo Sapiens, UP000005640, last 
modified on May 7th, 2020) containing 210,599 protein sequences compiled of both canonical and 
isoform protein entries. 
3.2.9.1 Unrestricted database search for a global illustration of MeLac and MeLac-related 
chemical modifications 
The open search of processed data was performed on all the samples using MSFragger. 




ProteoWizard167. To perform the search, a set of default open-search parameters was then used 
except for the items as follows: a precursor m/z tolerance (DeltaMass) window of 0 to 1000 Da, a 
peptide length range of 5 to 50 residues, a peptide mass range of 500 to 5000, a maximum missed 
peptide cleavage of 1. Both variable and fixed modification inclusion lists were disabled. Finally, 
mass shifts (of precursor ions, caused by chemical modifications in samples) in the open-search 
results were visualized using the DeltaMass226 software tool. 
3.2.9.2 Restricted database search for identification of MeLac-reacted proteins 
For the identification of target proteins for MeLac-alkyne probe 1, the MaxQuant search 
was performed on probe-treated samples that underwent the protein-level enrichment procedure. 
The corresponding search parameters were less than 1% peptide-level false discovery rate (FDR), 
less than 1% protein-level FDR, less than 1% modification site FDR, a minimum peptide length 
of 5, a minimum score of 0 for unmodified peptides, a minimum score of 40 for modif ied peptides, 
a minimum unique peptide number of 2, a minimum razor (+ unique) peptide number of 2, a 
minimum peptide number of 2, an MS/MS mass error tolerance of 20 ppm, a peptide length range 
of 8 to 25 for unspecific search, a maximum missed peptide cleavage of 1, a maximum peptide 
mass of 4600 Da, and a revert decoy mode. A basic modification inclusion list (variable oxidation 
on methionine, variable acetylation on protein N-terminus, and fixed carbamidomethylation on 
cysteine) was used with up to 3 modifications per peptide.  
3.2.9.3 Restricted database search for identification of MeLac-modified peptides 
For the identification of MeLac-alkyne probe-modified peptides and their modification 
sites, the MaxQuant search was performed on probe-treated samples that underwent peptide-level 
enrichment procedure. To limit the search space, a separate search was performed on each dataset 




or tyrosine, respectively). Apart from the common settings reported above, the distinct search 
parameters were a minimum unique peptide number of 0, a minimum razor (+ unique) peptide 
number of 1, a minimum peptide number of 1. The modification inclusion list was set according 
to the expected residue to be modified. For cysteine-specific search, a customized modification 
inclusion list covering variable oxidation on methionine, variable acetylation on protein N-
terminus, variable carbamidomethylation on cysteine, variable original Des-MeLac (+550.3115) 
on cysteine, and variable hydrolyzed Des-MeLac (+568.3221) on cysteine was used with up to 5 
modifications per peptide. For non-cysteine-specific search, a customized modification inclusion 
list was used with up to 5 modifications per peptide, covering variable oxidation on methionine, 
variable acetylation on protein N-terminus, fixed carbamidomethylation on cysteine, variable 
original Des-MeLac (+550.3115 on either lysine, serine, threonine, or tyrosine), and variable 2-
mercaptoethanol-quenched Des-MeLac (+628.3254 on either lysine, serine, threonine, or 
tyrosine). Two reported desthiobiotin-PEG3-specific fragment ions were set as diagnostic peaks 
(197.1285 Da and 240.1707 Da).227,228 Example spectra were visualized and modified for formal 
presentation using IPSA.229 
3.2.9.4 Identification of glutathione Des-MeLac-modified peptides 
For the identification of glutathione Des-MeLac-modified peptides and their modification 
sites, the MaxQuant search was performed on probe-treated samples that underwent peptide-level 
enrichment procedure. A separate custom human proteome database (a FASTA file, Swiss-Prot, 
Homo Sapiens, UP000005640, last modified on April 9th, 2020, appended with GSTP1-I105 → 
V105) containing 20,351 protein sequence entries was used (before the switching to the extended 
UniProt database) as the reference proteome for covering the isoform-specific peptide 




search results. Reactive amino acid residues: cysteine, lysine, serine, threonine, and tyrosine were 
included. Other settings were a minimum unique peptide number of 0, a minimum razor (+ unique) 
peptide number of 1, a minimum peptide number of 1. For the customized modification inclusion 
list covering variable oxidation on methionine, variable acetylation on protein N-terminus, variable 
carbamidomethylation on cysteine, and variable glutathione Des-MeLac (+857.3953) on cysteine 
with up to 5 modifications per peptide. Two reported desthiobiotin-PEG3-specific fragment ions 
were set as diagnostic peaks (197.1285 Da and 240.1707 Da).227,228 
3.2.9.5 Label-free quantitation of probe-modified peptides and visualization of orlistat, 
parthenolide and alkyl MeLac competitive ABPP data  
The relative abundance of each identified/sequenced tryptic peptide was quantified and 
calculated as the extracted chromatogram peak area of its corresponding precursor at the MS1 level 
as part of the MaxQuant database search workflow. The MaxQuant search output was then 
processed and summarized as tables of fold change vs. p-value by the in-house developed R 
package maxabpp. The data was finally visualized as volcano plots. 
3.2.10 Quantum mechanical modeling 
All computational studies were performed using Gaussian 09 (Revision D.01). All the input 
model structures were built with GaussView 5.0.9. 
3.2.10.1 MeLac reaction paths 
MeLac reaction paths were modeled with three different protein nucleophiles: thiol, 
hydroxyl, and amino groups. Simplified model structures, methyl MeLac, methanethiol, methanol, 
and methylamine, as well as their corresponding six transition states (TS) and six products, were 
built for either Michael addition or acyl addition reaction path. Geometric optimization of these 




correlation-consistent Dunning basis set aug-cc-pVTZ for effective modeling of Michael addition 
reaction path for the thiol.230 The Self-Consistent Reaction Field (SCRF) used Polarizable 
Continuum Model (PCM) as an implicit method to account for the polarizable solvent effect of 
water on reactions. Afterward, intrinsic reaction coordinate scan (IRC) computation was 
performed on each TS structure to ensure its energy saddle point location on the reaction path. 
Finally, vibrational frequency computation was performed on all optimized structures to determine 
thermal corrections to their Gibbs free energy. 
3.2.10.2 Des signature ions 
The geometry minimization of Des signature ions was performed with a basic DFT 
functional B3LYP, employing a Pople basis set 6-311+g(d, p) of moderate size. The output 
structures of the lowest total energy (f1 and f2) were consistent with the previously reported 
fragments.228 
3.2.11 Computational protein-ligand modeling 
The computational protein-ligand modeling (molecular docking) experiment was 
performed using Schrödinger Suite (2020-1 Release). 
3.2.11.1 Ligand and protein preparation 
Four GSH-Lac β-lactone stereoisomers, 3R,4R-, 3R,4S-, 3S,4R-, and 3S,4S- were generated 
on ChemDraw (version 19.0) as two-dimensional (2D) structures with specified chirality on both 
the β-lactone and the GSH moieties. Their corresponding SDF files were imported to the Maestro 
(version 12.3) workspace as ligands. Next, three-dimensional (3D) coordinates of all ligands were 
generated by the LigPrep module with protonation states dominant within a pH range of 7.0 ± 2.0, 





The crystal structure of a human glutathione S-transferase P dimer (GSTP1) complexing 
two hydrolyzed piperlongumine ligands (PDB ID: 5J41)231 obtained from Protein Data Bank 
(PDB) was subjected to several preparation steps on the Protein Preparation Wizard in Maestro 
before used as protein model for docking: removal of surface water molecules, assignment of bond 
orders, and addition of missing hydrogen atoms. Next, the orientation of amide (Asn and Gln), 
hydroxyl (Ser, Thr, and Tyr), and thiol groups (Cys) and the protonation and tautomeric state of 
His residues on the protein model were also optimized. In the final preparation step, restrained 
minimization of the protein model was applied using 0.3 Å RMSD constraint and OPLS3e force 
field. The Protein Preparation Wizard output then served as the starting protein geometry for 
receptor grid generation. 
3.2.11.2 Receptor grid generation 
For the starting protein geometry, a ligand-enclosing box was centered on one of the 
piperlongumine ligands so that the ligand to be docked (GSH-Lac) would be confined to the 
enclosing box.  The size of the enclosing box was set to be dependent on the piperlongumine 
ligand. 
3.2.11.3 Ligand docking 
Docking calculations involved Glide Extra Precision (XP) with default sampling, pre-
processing, and postprocessing. The preprocessing refers to the restrained minimization of the 
model GSTP1-piperlongumine complex in the OPLS3e force field, which is part of the protein 
preparation process. Postprocessing refers to post docking minimization of the GSTP1-GSH-Lac 
complex. Glide was set to write the 5 best poses per ligand. 




3.3.1 Broad reactivity of MeLac delivering wide proteome coverage 
The broad reactivity of MeLac was characterized at four levels of resolution according to 
the resolving power of each specific analytical method and scope of data interpretation applicable 
throughout the workflow of this study. These resolution levels were the gel-based proteome 
resolution, MS-based protein resolution, MS-based peptide resolution, and MS-based amino acid 
residue resolution. First, the fluorescent TAMRA tag provided a gel-based shortcut to reveal the 
in-proteome reactivity of MeLac. Upon CuAAC conjugation to MeLac-alkyne probe-reacted 
proteins, the TAMRA fluorophore enabled direct detection of those proteins after gel 
electrophoresis. As a result, the fluorescence gel image of in vitro probe-treated cellular proteome 
(Figure 3.2A) displayed multiple fluorescent protein bands throughout gel lanes. This gel image 
suggested the successful labeling of various proteins by the MeLac-alkyne probe. The labeled 
proteins had a wide range of molecular weight from 250 kDa to 10 kDa, implying a wide proteome 
coverage of the MeLac-alkyne probe and broad reactivity of the MeLac warhead. Full lanes of 
protein bands were observed for proteome samples treated by the MeLac-alkyne probe at a probe 
concentration as low as 0.5 µM, indicating the in-cell applicability of the probe. The extent of 
background probe-protein reactions, where the probe labeled surface residues instead of ligand -
binding/active site residues on proteins, was unclear. However, by comparing the rate of darkness 
diminishing of individual protein bands over the decline of probe concentration, the probe did 
potentially offer some selectivity towards certain proteins with molecular weight around 50 kDa. 
3.3.2 Interpreting MS-based profiling data: probe-protein reactions 
characterized at multiple levels of resolution 
Over the gel-based analysis, MS-based proteomics profiling provides more details of 




analyzed as tryptic digests via the bottom-up approach by HR/AM mass spectrometers. As part of 
the affinity capture methodology and sample processing workflow, biotin-avidin-based affinity 
enrichment techniques are indispensable. These affinity enrichment techniques can significantly 
improve the detectability of low-abundance analytes. In practice, the enrichment of analytes can 
be performed either before the trypsin digestion of protein samples (at the protein level) or after 
trypsin digestion of those samples (at the peptide level). If captured at the protein level, the 
enriched analytes are mapped to a comprehensive picture of the whole target protein candidate 
pool of the chemical probe. For each target candidate in the pool, multiple tryptic peptides are 
measured both qualitatively and quantitatively. According to the sequence coverage and number 
of detected unique peptides, indistinguishable proteins (usually isoforms or homologous proteins 
within the same family) are aggregated as a single identification hit. Once defined by the 
proteomics database search engine, these aggregated identification hits are usually treated as 
indivisible protein groups for downstream qualitative and quantitative analyses. Therefore, the 
identification of individual proteins is more straightforward and less proteins are grouped if the 
sequence coverage is high and number of sequenced unique peptides is large for each protein. On 
the flip side, the protein-level enrichment process almost always produces less-than-ideal 
preparations adulterated with non-probe target background proteins. The double aggravated 
sample complexity, by both tryptic peptides from background proteins and unmodified peptides 
from probe-reacted proteins, usually fails the detection of probe-modified peptides. In contrast to 
protein-level enrichment, the peptide-level enrichment process concentrates probe-modified 





For this study, the MS-based characterization of protein reactions with the MeLac-alkyne 
probe is defined at three levels of resolution according to the assignability of  reaction sites on 
specific proteins, residues, or peptides. Complete characterization of a protein reaction with a 
covalent chemical probe ultimately requires localizing the probe modification on a specific amino 
acid residue of a protein (residue resolution). Both the protein-level and peptide-level affinity 
enrichment were performed on MeLac-alkyne treated samples. When the affinity enrichment was 
performed at the protein level, few probe-modified peptides were detected. Consequently, the 
assignment of probe-protein reactions could solely depend on the identification of reacted proteins 
(protein resolution) in enriched samples. There are two reasons. Some probe-reacted proteins may 
not produce probe-modified peptides that are suitable for bottom-up proteomics, the method-of-
choice for chemical proteomics. Not all precursor ions of suitable peptides are sampled for MS/MS 
analysis in proteomics profiling. When the affinity enrichment was extended to the peptide level, 
for a few target proteins, it remained challenging to localize their probe modification sites because 
of several issues. A probe-modified peptide, in comparison to its native counterpart, does not 
always produce adequate sequence ions during its gas-phase fragmentation within the mass 
spectrometer. For each peptide precursor ion acquired for gas-phase fragmentation and MS/MS 
scans, the whole set of these sequence ions is essential evidence to localizing the probe reaction 
site at a specific residue. When the observable set of sequence ions is truncated as the probe 
modification perturbs the gas-phase fragmentation behavior232 of probe-modified peptide, the site 
localization can be ambiguous. In this case, it is plausible to only assign the probe reaction site to 
the modified peptide (or its fragment) instead of a specific residue on the corresponding protein. 
Consequently, the corresponding protein reaction is characterized at a moderately reduced 




Depending on chemical properties of the chemical probe and affinity enrichment method 
of choice in various chemical proteomics studies, not all probe-protein reactions can be 
characterized based on probe-modified peptides. In some cases, probe-protein reactions can only 
be characterized at a heavily reduced resolution of the protein level. For instance, when a labile 
covalent probe is used in compound-centric chemical proteomics, target proteins are universally 
characterized at the resolution of the protein level. With decreasing resolution from the residue to 
protein level, tightened constraints must be set to determine confidence in reporting reactivity of 
the probe, which demands new analytical methods to evaluate confidence in the identification of 
the probe-reacted proteins. 
3.3.3 Affinity tagging triplication differentiating target candidates at the 
protein level 
To confront the analytical challenge in identifying and reporting probe-reacted proteins at 
the protein-level resolution, a novel method named affinity tagging triplication was developed to 
differentiate MeLac-alkyne probe-reacted proteins with discrete analytical confidence, even 
without detection of any probe-modified peptide. In each of three separate preparations (step 3, 
Scheme 3.4), a different (desthio)biotin tag was used for avidin-based affinity enrichment of 
probe-reacted proteins from one lysate sample of MeLac-alkyne probe-treated HT-29 cells. The 
rationale was that the tagged proteins underwent different releasing conditions to recover MeLac-
alkyne probe-reacted proteins. Consequently, the resulting sample matrices and background 
proteins in the preparations obtained would be significantly different. When a protein was 
identified in more than one enrichment preparation, the confidence of it being a true MeLac-alkyne 
probe-reacted protein was increased. Specifically, the MeLac-alkyne probe-reacted proteins were 




picolyl azide (Dde, Scheme 3.6) azide or diazo biotin azide (Dia, Scheme 3.7). Tagged proteins 
were captured by NeutrAvidin-agarose resins and then released using different elution conditions 
for preparing trypsin digests. 
Subsequently, a unique three-tier system was set based on the number of reproduced 
identifications of a particular protein in the differentially tagged preparations f rom a common 
lysate sample. The lysate was prepared from HT-29 cells upon in-live-cell reactions with MeLac-
alkyne. In total, a protein target candidate pool of 1,505 canonical proteins (distinguished by gene 
names)—related to 2,074 protein groups (distinguished by aggregated UniProt accession 
numbers)—was identified by proteomics profiling and MaxQuant225 database search (Table ia, ib, 
and ic, Appendix) at a threshold of 1% maximal peptide/protein FDR and two minimal unique 
peptides. The identified proteins were categorized in Tier I, II, or III (Figure 3.2B and 3.2C) with 
decreasing confidence in being true probe-reacted proteins, accordingly. Proteins in Tier I were 
identified in all the three tagged samples; Tier II in two; Tier III for only one. Analogous to the 
minimum requirement of two unique peptides for identifying a precursor protein within a 
proteome, Tier I and II proteins are reported as confident identifications; Tier III proteins need 
further investigation. Notably, the three-tier categorization of identified proteins was performed 
with either gene names or protein groups of aggregated UniProt accession numbers. When 
categorized with gene names which did not annotate protein isoforms (Figure 3.2B), 17.5% 
proteins (264 out of 1,505) were identified as Tier I proteins, 25.1% proteins (378 out of 1,505) 
were identified as Tier II proteins, and 57.3% proteins (863 out of 1,505) were identified as Tier 
III proteins. When categorized with UniProt protein accession numbers, which annotated protein 
isoforms (Figure 3.2C), isoform-specific proteins in each protein group were compared  across 




series of characters and compared for exact matches, the maxabpp matching algorithm treats 
aggregated protein IDs as a group of individual entries. When comparing two protein groups, if 
maxabpp detects the existence of one or more shared individual protein(s), it will mark these two 
protein groups as related. Consequently, if unequal numbers of aggregated protein isoforms are 
identified in all three differentially tagged samples of unique sample matrices, these related protein 
isoforms will be categorized as Tier I proteins. With the implementation of this matching 
algorithm, higher numbers of intersecting proteins were observed as identified isoforms and 
homologous sequences. 34.3% proteins (711 out of 2,074) were identified as Tier I proteins, 31.5% 
proteins (653 out of 2,074) were identified as Tier II proteins, and 34.2% proteins (710 out of 
2,074) were identified as Tier III proteins (Figure 3.2C and Table ii, Appendix). Overall, 
proteomics profiling of enriched MeLac-alkyne probe-reacted proteins supported the broad 
reactivity of the MeLac warhead with proteins in the proteome, as observed in gel-based ABPP 
(Figure 3.2A), but offered limited information for understanding protein reactions with MeLac. 
3.3.4 Reactivity investigation to deepen at peptide the level 
Proteomics profiling of enriched MeLac-alkyne probe-modified peptides confirmed the 
broad reactivity of MeLac. A total of 751 MeLac-alkyne probe-modified peptides with 1,430 
modification sites were identified by MaxQuant225, resulting in the identification of 562 canonical 
proteins (Figure 3.2D and 3.2E; Table iii, Appendix). The Andromeda233 peptide-spectrum 
match (PSM) scoring algorithm of MaxQuant was set to filter PSM hits with a minimum score 
cutoff of 40 and 1% false discovery rate threshold for both peptide and protein identification. 
Consequently, for most peptides, alternative PSM assignments with lower scores were discarded. 
Among all 1,430 MeLac modification sites, a fraction of sites had ambiguity in localization on 




Approximately 1,000 peptides had localized modification sites. Moreover, MeLac-alkyne probe-
modified peptides originated from functionally diverse proteins, covering enzymatic reactions of 
all seven general types; these proteins were modified at either catalytic or non-catalytic residues 
(Figure 3.3, Figure 3.4, and Table 3.2). Interestingly, in comparison with 1,505 gene name-
annotated canonical proteins identified in samples from protein-level enrichment experiments, a 
significant number (292 out of 1,505) of proteins were identified only from samples of enriched 
MeLac-alkyne probe-modified peptides. Apart from the existence of background peptides, this 
observation implied that the detection of low-abundance peptides, upon probe modification, 
required further concentration at the peptide level. The affinity pull-down of these peptides 
successfully reduced sample complexity and achieved higher identification rate of probe-modified 
peptides. 
Identification of MeLac-alkyne probe-modified peptides had its own challenge in 
confidence, differing from the confidence challenge for enriched samples of MeLac-alkyne probe-
reacted proteins. The identification of the modified peptides depended only on a single amino acid 
sequence. Higher-energy collisional dissociation (HCD) of peptide ions used in the mass 
spectrometer of this work generated incomplete sequence ions, preventing de novo sequencing of 
the peptides. Therefore, additional constraints should be imposed for verifying MS/MS spectra 
and identifying MeLac-alkyne probe-modified peptides. These constraints were particularly 
important because a relatively low PSM score of 40 was set for the database search and 
identification of modified peptides. The verification of a spectral match would require the presence 
of two signature ions from Des as the modification-specific fragment ions (labeled on spectra as 
f1 and f2, Figure 3.2F and Scheme 3.8). Specificity of these two fragment ions was high (Table 




introduced to the modified peptide as a xenobiotic moiety via CuAAC attachment of the Des tag 
for enriching modified peptides. However, not all identified spectra of probe-modified peptides 
had a lower mass cutoff to detect the signature ions, due to the dynamic mass range setup during 
MS analysis (white vs. red areas in Figure 3.2E). The gene name-annotated canonical proteins 
identified based on probe-modified peptides (red slides in Figure 3.2D) were compared to the 
identified ones from protein-level enrichment samples (Figure 3.2B). A decreasing trend on the 
percentage of identifiable probe-reacted proteins from Tier I to III (30.6% to 21.4% to 12.5%, 
respectively) supported the effectiveness of the affinity tagging triplication strategy for identifying 
true MeLac targets. Although the Tier III proteins should be treated with lower confidence, 
observing probe-modified peptides provided a means to separate the protein targets from the 
remaining pool of proteins, which had the largest fraction of background proteins. Proteomics 
profiling of enriched peptide samples also identified significant numbers of proteins in each tier 
(orange slides, Figure 3.2D) based on peptides, which did not carry MeLac modifications in the 
samples; 36.4% for Tier I, 21.2% for Tier II and 18.4% for Tier III, respectively. The decreasing 
percentages were consistent with the declining confidence levels of Tier I, II, and III proteins being 
true MeLac targets. Overlapping sequences between probe-modified and non-probe-carrying 
peptides indicated a possible loss of the MeLac modification during sample preparation. For 
instance, acyl addition by nucleophilic thiol produces labile thioesters.220 Non-specific peptides 
carried through the peptide enrichment preparation could also contribute to the observed non-
probe-carrying peptides. However, the fact that more than one third (inner orange slide, Figure 
3.2D) of the Tier I proteins were also identifiable based on the non-probe-carrying peptides 




MS/MS spectra of MeLac-alkyne probe-modified peptides provided direct and detailed 
information for characterizing probe-protein reactions. MS/MS spectra with unambiguously 
localized sites for modification were used to explain the MeLac chemistry. Modification of 
peptides by MeLac-alkyne was attributable to both Michael addition and acyl addition of MeLac 
by Cys, Ser, Thr, Tyr, and Lys (Scheme 3.9 and Appendix). Despite being uncommon and 
thermodynamically unfavorable based on computation results (Figure 3.5), Michael addition 
modifications of Lys and Thr have been reported for proteins.234,235  Possible nucleophilic 
substitutions of the lactone ring of MeLac (mechanism 2b on Scheme 3.2), whose reaction 
products would have degenerate masses as those from acyl addition, were not considered in this 
work. Upon chemical modification by MeLac-alkyne and downstream CuAAC tagging with Des, 
the modified peptides had three distinct mass shift values. A global view of MeLac modifications 
on peptides was apparent on a DeltaMass plot based on unrestricted MSFragger search226 (Figure 
3.6A). Upon CuAAC attachment of the Des tag, the modification of a residue by MeLac-alkyne 
led to a total mass shift of 550.3115 Da (Des MeLac, top of Figure 3.6B). Depending on the 
reaction site on MeLac, further modifications by Des MeLac on reacted peptides occurred during 
sample preparation: hydrolysis of the lactone ring causing an additional increase of 18.0106 Da 
(568.3221 Da in total, bottom of Figure 3.6B) and quenching of the Michael receptor with 2-
mercaptoethanol adding a further increase of 78.0139 Da (628.3254 Da in total) as in Figure 3.6C. 
Modified peptides with a mass increase of 550.3115 Da were attributed to the products of Michael 
addition (Scheme 3.9), but not acyl addition; an excessive amount of 2-mercaptoethanol was used 
for quenching the Michael acceptor and the thioester bond formed via acyl addition of the β-lactone 
ring is labile.220 Indeed, few modified peptides could be assigned as quenched adducts from the 




3.3.5 Advantages of MeLac-alkyne in probing reactive cysteine 
Cys residues had the largest number of MeLac modification sites (Figure 3.2E). The 
cysteinome provides many important targets for covalent drugs.119 The majority of MeLac-alkyne 
probe-modified peptides carried a localized site of Cys modification. This observation was not a 
surprising fact considering the large numbers of reactive cysteines under physiological conditions. 
The profiling results of MeLac-alkyne were compared with those of iodoacetamide (IA)-alkyne, a 
routinely used broad-spectrum cysteine-reactive probe in chemical proteomics. Localized IA 
reaction sites on 6143 cysteinyl peptides had been reported, among which 758 sites were 
ligandable.77 Although sharing 128 ligandable peptides with the IA-alkyne pool, 224 out of the 
653 peptides with probe modification, either catalytic or non-catalytic cysteines, were unique to 
MeLac (Figure 3.7). It is important to note that besides the chemical difference between MeLac 
and IA, MDA-MB-231 and Ramos cells were used in the IA study. Although known as highly 
cytotoxic and incompatible with live cells, the IA-alkyne probe was used at a concentration of 100 
µM to treat live cells.77 In comparison, HT-29 cells were treated with MeLac-alkyne at 
concentrations up to 50 µM for gel-based analysis and 20 µM for MS-based analysis in this work.  
A significant advantage of MeLac over IA probes comes from differences in cytotoxicity. 
IA has high cytotoxicity,236 limiting the application of IA probes mainly to lysates.237 In contrast, 
MeLac compounds were used with live cells at concentrations up to 100 µM for MeLac-alkyne 
and 300 µM for alkyl MeLac inhibitor in this work. Cells remained adhered to culture flask surface 
under these concentrations for incubation times up to 1 hour. Two important analytical advantages 
from the live-cell application of a measurement probe are (1) decreased background reactions and 




MeLac-based competitive ABPP for analyzing the action of non-covalent inhibitors in live cells is 
a unique potential.  
3.3.6 Establishing a versatile competitive ABPP platform using MeLac-
alkyne probe and peptide-centric quantitation approach 
This study then proceeded to test the major designed utility of MeLac probes in competitive 
ABPP platforms for analyzing proteome-wide reactions of reactive molecules. Three inhibitors: 
orlistat, parthenolide, and alkyl MeLac inhibitor, were analyzed the competitive ABPP platform 
using the MeLac-alkyne probe. The orlistat and parthenolide were selected  as model covalent 
inhibitors, while the alkyl MeLac was introduced as a MeLac parent compound or putative MeLac-
based inhibitor for studying the chemoselectivity of the MeLac warhead.  
Orlistat is a β-lactone compound capable of forming covalent adducts with nucleophilic 
hydroxyl and thiol groups on proteins. It is an FDA-approved drug that targets lipases for weight 
management. Extensive chemical proteomics analysis has revealed many off-target proteins,73,220, 
which are linked to anti-tumor activities238 and organ toxicity239 for this over-the-counter drug. 
Most of the covalent orlistat-protein adducts are formed via a labile thioester bond.220 Confident 
identification of off-target proteins of orlistat, especially orlistat-modified peptide, is extremely 
challenging due to the fact that the thioester or ester bond is not stable during sample preparation 
for proteomics analysis. This is a common problem for β-lactone based probes. Live-cell 
competitive ABPP using MeLac-alkyne as the measurement probe provides a valuable solution to 
this analytical challenge.  
Parthenolide is an α-methylene-γ-lactone natural product with anti-inflammation and anti-
tumor activity.240-243 Parthenolide has a Michael acceptor subject to nucleophilic addition as well; 




ring-opening reactions, γ-lactone is significantly more stable and inert.244 Although a systematic 
chemistry study comparing the reactivity of the Michael acceptor and γ-lactone of parthenolide is 
unavailable, the existing cysteine-dominant parthenolide reactivity profile240 suggests that 
parthenolide would only react with protein nucleophiles as a Michael acceptor for nucleophilic 
addition reactions. 
Proteome-wide inhibitor selectivity and protein dose responses were first explored with 
gel-based competitive ABPP at various inhibitor concentrations over a wide concentration 
window. Subsequently, two reasonable concentrations were selected based on the gel-based ABPP 
results (Figure 3.8) for MS-based quantitative experiments for each inhibitor. Orlistat, 
parthenolide (1 vs. 10 µM), or alkyl MeLac (10 vs. 100 µM) treatment, live HT-29 cells were 
incubated with MeLac-alkyne at 20 µM. The probe-modified peptides were then enriched for MS-
based profiling. In total, 395 probe-modified peptides from 316 proteins were quantified for 
samples from the orlistat competition experiment (Figure 3.9A); 320 probe-modified peptides 
from 276 proteins were quantified for parthenolide (Figure 3.9B); 44 probe-modified peptides 
from 41 proteins were quantified for alkyl MeLac (Figure 3.9C). Pairwise quantitative comparison 
of enriched probe-modified peptide samples from cells pre-treated with either orlistat, parthenolide 
at 10 μM vs. 1 μM, or alkyl MeLac at 100 μM vs. 10 μM was performed using a method of label-
free quantitation (LFQ). For each quantified probe-modified peptide, the relative amount was 
determined as the mean of normalized areas of MS1 chromatographic peaks of precursor ions for 
the peptide in six replicates (two biological replicates with three analytical replicates each). The 
normalization was performed against the total ion intensity of all quantified ions of probe-modified 
peptides to correct run-to-run variations. In addition, if a longer miscleaved sequence was observed 




calculated as the sum of the miscleaved and fully cleaved. Volcano plots of Log10 p-value vs. Log2 
FC were based on quantified probe-modified peptides (Figure 3.9). An FC cutoff threshed was 
not set for selecting protein targets of orlistat, parthenolide, or alkyl MeLac due to two reasons. 
The quantitative comparison was only performed within a tentative dose window, 10 μM vs. 1 
μM, or 100 μM vs. 10 μM, which could be at any location on a dose-response curve for the 
inhibitory potency of the two inhibitor molecules. LFQ is less precise than isotope-labeling based 
quantitation by design. At the 5% statistical level of significance (p-value ≤ 0.05), 40 
peptides/proteins responded to the increased orlistat concentration, and 16 peptides/proteins 
responded to the increased parthenolide concentration. Intriguingly, the parthenolide target 
candidate pool highlighted six previously reported protein targets, DCTN4, RPL4, RPL14, RPL18, 
RPS2, and PRKDC, (high-lighted in red, Figure 3.9B) from a label-based competitive ABPP 
experiment using a different human cell line and IA-alkyne probe.240 Remarkably, the DNA-
dependent protein kinase catalytic subunit (PRKDC) was reported as one of three major kinase 
targets showing high dose response (with a log2 FC value of -5) to parthenolide.  
In contrast to orlistat and parthenolide, the alkyl MeLac competition experiment had the 
smallest number of quantified proteins. This could be explained with: (1) Cells were treated with 
alkyl MeLac at concentrations 10-fold higher than the other two inhibitors, resulting in a less 
informative dose window capturing the region of dose saturation on the dose response curve; (2) 
alkyl MeLac shared the same reactivity with MeLac-alkyne, thus completely labeled and occupied 
all possible sites on protein targets of MeLac-alkyne at a higher concentration, resulting in 
detection of few MeLac-alkyne probe-modified peptides. In addition, probe-modified peptides 
were not detected for a group of proteins at the higher inhibitor concentration, particularly for alkyl 




proteins formed an off-chart list of protein targets of the inhibitor used in the competition 
experiment. It was highly likely that these proteins were the best targets for the corresponding 
inhibitor. However, this statement would require further experimental verification considering the 
stochastic sampling of peptide ions during MS analysis. Notably, the selectivity profiles for 
orlistat, parthenolide, and alkyl MeLac differed significantly, exemplifying that the broadly 
reactive MeLac-alkyne probe assembles a versatile peptide-centric platform of competitive ABPP 
capable of analyzing reactive molecules with different chemical properties. The capability of 
MeLac reacting with multiple nucleophilic residues and measuring enzymes of all classes (colored 
dots in Figure 3.9) endorsed its foreseeable versatility. 
3.3.7 MeLac warhead recruiting glutathione in live cells to assemble a 
selective β-lactone probe 
Intriguingly, multiple electrophilic sites on the MeLac scaffold made it possible for MeLac-
alkyne to conjugate a reactive affinity ligand on one site and use another site to react with protein 
nucleophiles. Considering the diversity of intracellular reactive metabolites, the unrestricted 
database search was initially used to screen for unknown protein modifications. Surprisingly, the 
MeLac-alkyne probe recruited endogenous glutathione to form a β-lactone probe that had much 
increased selectivity as the DeltaMass plot highlighted an unexpected modification with an 
unusual mass shift of 857 Da (Figure 3.10A). The high mass region of the DeltaMass plot also 
showed several other mass shifts with noticeable peptide spectra matching densities. The mass 
shift of 857 Da, being the most significant one, was attributed to the direct addition of GSH 
presumably at the Michael acceptor on MeLac to form a new β-lactone probe, namely GSH-Lac 
in live cells (Scheme 3.10). A dedicated MaxQuant search (with 857 Da as the input modification 




as MeLac-alkyne probe-modified peptides (Figure 3.11; Table iv and v, Appendix). The search 
results also revealed a modification site preference shift. As shown in Figure 3.12, compared to 
MeLac-alkyne that modified proteins mostly on cysteine (more than 50% of modifications sites 
were cysteine), GSH-Lac modified proteins mostly on non-cysteine residues (less than 20% of 
modifications sites were cysteine). This discovery confirmed the proposed reaction routes of 
MeLac with amino acids, as MeLac and GSH-Lac differed significantly in the reaction route 
preference (the Michael addition reaction path for thiol with MeLac vs. acyl addition reaction path 
for amino and hydroxyl groups with GSH-Lac). 
Modified peptides observed for glutathione S-transferase P1 (UniProt ID P09211, GSTP1) 
provided evidence for processes of in-cell assembly of GSH-Lac as well as its reactions with 
proteins (Figure 3.10; Scheme 3.10). Peptide YISLIYTNYEAGK together with its miscleaved  
counterpart YISLIYTNYEAGKDDYVK was observed with both MeLac-alkyne and GSH-Lac 
modifications at Y108; a natural variant245 with 104I → V was also identified to carry the same 
modifications. Because the GSH-Lac modification initially appeared to be a mass shift of 843 Da 
on the 104I → V variant peptide from the unrestricted database search using only the canonical 
proteome sequence database (Figure 3.10A). The peptide ASCLYGQLPK, located in a narrow 
cavity (green, Figure 3.10B), was modified at C47 only by MeLac-alkyne. The N-terminal tryptic 
peptide PPYTVVYFPVR was only modified at Y7 by GSH-Lac. Y7 (red, Figure 3.10B) and Y108 
(blue, Figure 3.10B) are located in a wide-open cavity. During the GSTP1 detoxification activity 
of xenobiotics, Y108 and Y7 are involved as electrophilic participants in the addition of GSH to 
exogenous molecules.246 This catalytic mechanism is related to multidrug resistance in cancer 




Therefore, a selective probe targeting GSTP1 has a direct impact in developing drugs regulating 
the protein activity. 
The formation of observed GSTP1 adducts with MeLac-alkyne and GSH-Lac could be 
explained by different routes, as shown on Scheme 3.11. The first route initiated from MeLac-
alkyne reacting with GSH-bound GSTP1 to form the MeLac-alkyne GSTP adduct at Y108 (and 
C47) through steps A and B; additional probe modifications on nearby residues were also observed 
(Figure 3.12). Further attachment of GSH to the Y108 adduct formed the same product as the 
directed reaction product with GSH-Lac (step D and E, Scheme 3.11). Consequently, the Y108 
peptides were detected with both MeLac-alkyne and GSH-Lac modifications. The formation of 
GSH-Lac or in-live-cell installation of GSH to MeLac-alkyne was likely to be catalyzed by 
GSTP1. When GSH-Lac reacted locally with GSTP1, both Y108 and Y7 were modified (steps E 
and F, Scheme 3.11). It was also plausible that newly formed GSH-Lac could diffuse away from 
GSTP1 and react with other intracellular proteins (step G and H, Scheme 3.11), resulting in the 
detection of 48 modified peptides unique to GSH-Lac. In contrast to the reactions between MeLac-
alkyne and its protein targets corresponding to the identified 640 unique peptides, the reaction 
between GSH-Lac and its protein targets had substantial selectivity, which was indicated by it 
smaller target pool of proteins corresponding to only 48 unique modified peptides. (Figure 3.11; 
also see Table v on Appendix for more details of these peptides) 
GSH-Lac, not MeLac-alkyne modified Y7. The accessibility of Y7 and Y108 to the β-
lactone C2 (acyl) carbon on GSH-Lac was evaluated via computational protein-ligand docking 
using Schrödinger Suite. Up to five energetically favorable protein-ligand interacting models were 
calculated for all four possible β-lactone stereoisomers of GSH-Lac. The GSH-Lac docked protein 




docking energy (Glide energy) and closer distances to the oxygen atoms of both Y7 and Y108 
compared to the other two stereoisomers. These docking results implied possible stereoselectivity 
on GSH-Lac by the GSTP1 catalytic cavity featuring Y7 and Y108 (Figure 3.14). Comparing 
(3S,4S) and (3S,4R), the latter was docked with the shortest distances to both Y7 and Y108 (red 
projection dots highlighted in the green ellipse, Figure 3.14A), while the former had slightly 
longer distances to Y108 (blue projection dots highlighted in the yellow ellipse, Figure 3.14A) 
but the lowest Glide energy. This observation suggested Y7 favored the reaction with (3S,4S), but 
Y108 was closed to (3S,4R). Nevertheless, validation of the GSTP1 stereoselectivity on GSH-Lac 






MeLac is a novel chemical probe warhead that couples a Michael acceptor with a β-lactone 
moiety. This small, rigid warhead’s broad reactivity allows it to react with different protein 
nucleophiles through distinct mechanisms. Multiple reactive sites on MeLac extend the scope of 
these reactions and provide a potential means of conjugating recognizing moieties for ligand -
directed chemistry250 in live cells. With its broad reactivity, the MeLac warhead also offers a 
unique possibility to convert non-covalent inhibitors to measurement probes targeting different 
enzymes,251 as well as to broaden druggable targets by identifying new binding sites.77,78 MeLac 
probes, being useful for live-cell applications, potentially have an immense impact on drug 
discovery and further expand the analysis of the reactions with proteins that can deactivate during 
cell lysis. MeLac-based competitive ABPP platforms are highly adaptable and are appropriate for 





3.5 Chapter 3 Figures 
Figure 3.1 HT-29 cells under microscope. 
 





Figure 3.2 Multi-level characterization of protein reactions with α-methylene-






Note: (A) Gel-based activity-based protein profiling showing broad reactivity of the MeLac-alkyne probe. 
(B) Triplicated selective enrichment (Affinity Tagging Triplication) of probe-reacted proteins resulting in 
discrete identification confidence (Tier I > Tier II > Tier III) of probe-reacted proteins annotated with gene 
names. (C) Three-tier identification confidence ranking of isoform-specific proteins annotated with UniProt 
accession numbers. (D) Comparison of identification numbers of protein-level vs. peptide-level enrichment. 
(E) MeLac modification sites on nucleophilic amino acid residues identified at a residue-level resolution 
from peptide-level enrichment workflow. (F) Signature ion-based reduction of data complexity and 
validation of identification of probe-modified peptide; insert comparing total ion chromatogram of peptide 
fragment ions and extracted ion chromatograms for highly specific fragment ions of desthiobiotin-PEG3 (f1 




Figure 3.3 Example protein models showing probe-modified catalytical 
residues. 
 
Note: The identified/sequenced probe-modified peptides are highlighted in orange. The probe-modified 
residues are highlighted in red. (A) Aldehyde dehydrogenase, mitochondrial (ALDH2, PDB ID: 1o04).252 
(B) Methylated-DNA-protein-cysteine methyltransferase (MGMT, PDB ID: 1eh6).253 (C) Caspase-8 




Figure 3.4 Example protein models showing probe-modified non-catalytic 
residues. 
 
Note: The identified/sequenced probe-modified peptides are highlighted in orange (or cyan). The probe-
modified residues are highlighted in red. The reported catalytical residues are highlighted in blue. (A) 
Calpain-2 catalytic subunit (CAN2, PDB ID: 1kfu).255 (B) Ribonuclease inhibitor (RINI, PDB ID: 1a4y).256 










Figure 3.6 Global and residue-specific illustration of MeLac modifications on 
peptides.  
 
Note: (A) A DeltaMass plot showing identified global modification of peptides with mass shifts 
accountable to the conjugation with MeLac. (B) Representative MeLac modifications on peptides at Cys 




Figure 3.7 Venn diagram comparison of MeLac vs. IA alkyne77 probe-













Figure 3.8 Competitive activity-based protein profiling displaying broad 




Note: HT-29 Cells were first incubated with the alkyl MeLac inhibitor or orlistat at the corresponding 
concentration for 30 minutes. Cells were then incubated for 30 minutes with the MeLac-alkyne probe at 5 
µM for 1 hour. Cells were washed and lysed. The subsequent lysate underwent CuAAC with TAMRA 
biotin azide as the fluorescent reporting tag or Des as the affinity tag. (See Experimental 3.2.5 for detailed 
procedure) Approximately 100 µg of total protein was loaded to each well without affinity enrichment. Gel 
images were acquired to show fluorescent protein bands (probe-reacted proteins) and Coomassie Blue-




Figure 3.9 MeLac-alkyne quantitively probing protein selectivity/reactivity 










Note: The volcano plots show that (A) orlistat, (B) parthenolide, and (C) alkyl MeLac selectively reacted 
with different proteins. These reactions were detectable by changing the inhibitor concentrations, 10 vs. 1 
µM for orlistat and parthenolide, 100 vs. 10 µM for alkyl MeLac, using the MeLac-alkyne as the 
measurement probe. Inert tables showing proteins of quantified probe-modified peptides at the lower 
inhibitor concentration with p-value ≤ 0.05, but not detected at the higher inhibitor concentration (zero 




Figure 3.10 Identification of GSH-Lac adducts. 
 
Note: (A) The DeltaMass plot showing identified global modification of peptides with mass shifts 
accountable to the conjugation with GSH-Lac. (B) GSH-bound GSTP1 dimmer (PDB ID: 5j41)231 with 
three reactive residues labeled: Y7 in red, Y108 in blue, and C47 in green. MS/MS spectra for a GSTP1 
peptide with modifications of MeLac-alkyne uniquely at C47 (C), GSH-Lac uniquely at Y7(D), and 
peptides with modifications of both MeLac-alkyne and GSH-Lac detected at Y108 (E and F). Spectra for 
peptides of a mutant GSTP1 isoform carrying modifications of both MeLac-alkyne and GSH-Lac detected 









































Figure 3.13 Additional MS/MS spectra observed different MeLac 
modification sites on peptide YISLIYTNYEAGKDDYVK of glutathione S-
transferase P. 
 
Note: sw = Des MeLac warhead modification (+ 550.3115 Da), sh = Des MeLac hydrolyzed modification 






Figure 3.14 MeLac-alkyne recruiting endogenous glutathione to assemble a 
selective β-lactone probe. 
 
Note: (A) Selectivity comparison, ID numbers of probe-modified peptides, GSH-Lac vs. MeLac-alkyne 
(B) Minimized docking pose of GSH-Lac probe in GSTP1 for selective reaction with Y108 with possible 
general acid catalysis by Y7. (C) Docking energy comparison indicating differentiation of GSH-Lac 





3.6 Chapter 3 Schemes 
Scheme 3.1 Illustration of the “3-R” anatomy of an activity-based probe and 






Scheme 3.2 Proposed reactivity of MeLac towards different protein 






Scheme 3.3 Structures of MeLac-alkyne probe, alkyl MeLac inhibitor, 






Scheme 3.4 Overview of the experimental workflow featuring affinity tagging 
















































3.7 Chapter 3 Tables 










of cells in 
millions) 





     
35mm 8.8 0.3 1.2 1 2 
60mm 21.5 0.8 3.2 3 5 
100mm 56.7 2.2 8.8 5 12 
150mm 145 5.0 20.0 10 30 
Well 
plates 
     
6-well 9.6 0.3 1.2 1 1 to 3 
12-well 3.5 0.1 0.5 0.4 to 1 1 to 2 
24-well 1.9 0.05 0.24 0.2 to 0.3 0.5 to 1.0 
48-well 1.1 0.03 0.12 0.1 to 0.2 0.2 to 0.4 
96-well 0.32 0.01 0.04 0.05 to 0.1 0.1 to 0.2 
Flasks 
     
T-25 25 0.7 2.8 3 3–5 
T-75 75 2.1 8.4 5 8–15 
T-175 175 4.9 23.3 17 35–53 
T-225 225 6.3 30 22 45–68 
Note: Table adapted from Ryan, John A. (2005). Growing more cells: A simple guide to small volume 






























































LLC(1)GGGIAADR 550.3115 + 
18.0106 
Cys 































































































































GNPVPILIPC(1)HR 550.3115 + 
18.0106 
Cys 
65.842 GNPVPILIPC(1)HR 550.3115 Cys 
51.495 
VVC(1)SSGAVGN

























































































Note: *Catalytical residue information was obtained from Mechanism and Catalytic Site Atlas (M-CSA)257 
data repository. According to M-CSA, a total of 667 human proteins were reported to have catalytical 
residues with their side chains involved. As shown above, among these 667 proteins, 8 proteins were 
identified as MeLac-modified ones. Among these 8 proteins, 3 proteins had MeLac modification on 






Table 3.3 Specificity of Des signature ions. 
f1 
Molecular formula Monoisotopic mass Unsaturation Error (ppm) 
C10H17N2O2+ 197.1284542 3.5 -0.2323 
C8H15N5O+ 197.1271115 4 -7.0434 
 
f2 
Molecular formula Monoisotopic mass Unsaturation Error (ppm) 
C12H22N3O2+ 240.1706534 3.5 -0.1941 
C14H24O3+ 240.1719961 3 5.3964 
C17H22N+ 240.1746761 7.5 16.5552 
Note:  
Element composition range: C0-30, H0-60, N0-5, O0-10, S0-5.  
Error range (ppm): 20.  
Formula calculation used software from 
http://www.cheminfo.org/Spectra/Mass/MF_from_monoisotopic_mass_and_PubChem/index.html. 





Table 3.4 Geometry optimization results of Des signature ions. 























Note: The geometry minimization of Des signature ions was performed using Gaussian 09 (Revision D.01) 
at b3lyp/6-311+g(d,p) level of theory. Input ion structures were built with GaussView 5.0.9. The minimized 






Chapter 4 maxabpp as an R Package for Augmented 
Visualization of Peptide-centric Competitive Activity-based 
Protein Profiling Data from MaxQuant 
4.1 Introduction 
ABPP platforms are powerful chemoproteomics tools for analyzing proteome-wide 
perturbation introduced to living systems by foreign small molecules.74,75 ABPP platforms are used 
routinely to measure the proteome-wide action of underivatized covalent drugs, environmental 
toxins, and reactive metabolites from the human microbiota.76-79 When conducted for analyzing 
selectivity, target engagement, and off-target effects of a small molecule, an ABPP experiment  
usually uses competition strategy for indirect measurements of small molecule pre-occupied 
protein sites by comparing the probe modification difference of small molecule pre-treated sample 
and the control. The mass spectrometry readout of these samples can be tandem mass spectra of 
either probe-modified plus unmodified peptides from proteolysis of probe-labeled proteins or 
probe-modified peptides only. 
MaxQuant is the most appreciated free software suite for analyzing MS-based proteomics 
profiling data163. The MaxQuant suite offers an easy-to-use graphic user interface (GUI), a robust 
peptide-spectrum matching and scoring algorithm named Andromeda,135 and various user-
configurable search parameters for tunable sensitivity and accuracy. The output of a MaxQuant 
run is a “txt” folder consisting of several tab-delimited tables, formatting the processed data 
according to different aspects of downstream analysis. These tables are intended to be read by 
MaxQuant and its sister software package Perseus258 for browsing, manual validation, processing, 




In a conventional proteomics profiling experiment, such as comparing two sets of 
proteomes from two different biological conditions for their qualitative and quantitative 
differences in expression of individual proteins, the “MaxQuant plus Perseus” workflow is usually 
an excellent choice for deriving the statistical inference and biological interpretation from the data. 
Unfortunately, this workflow does not meet some special demands in analyzing the data from 
various competitive ABPP experiments.197 Without additional software support for processing 
ABPP data, most MaxQuant users are often forced to explore the “txt” folder manually using 
Microsoft Excel. These users eventually find themselves overwhelmed and frustrated by these 
error-prone manual steps of data manipulation. 
Herein, we introduce the maxabpp package that provides a practical software tool for 
comprehensive downstream analysis of MaxQuant output in the R environment259. It is built for 
practicability, simplicity, flexibility, and transparency. The maxabpp package is open-source and 
actively maintained at https://github.com/devradiumking/maxabpp. It does not depend on any 
bioinformatics package, which ensures its compatibility with most user’s R environments. With 
maxabpp and minimal efforts, novice users can perform highly reproducible and scalable data 
analysis that summarizes and visualizes ABPP results ready for biological interpretation. All the 
essential data analysis only requires a few files from the MaxQuant “txt” folder as the input, a 
user-created metadata.txt, and a few lines of code following the tutorial as the instruction. On the 
other hand, experienced R programmers can customize most functions in maxabpp to generate 
personalized reports. Biostatisticians and bioinformaticians can also test and implement more 
sophisticated statistical models on existing functions in the maxabpp package. 




The maxabpp package contains two modules: a qualitative analysis module for cross-
sample comparisons of identified proteins and a quantitative analysis module for label-free 
quantitation (LFQ) of probe-modified peptides.  
As shown in Figure 4.1A, the qualitative module begins with reading the proteinGroups.txt 
files generated from multiple separate MaxQuant runs on the MS raw data files from samples 
processed in different conditions. Proteins labeled by different covalent probes or tagged by 
different affinity handles can be compared within and across sample groups. The proteinGroups.txt 
files are renamed and placed in a user-specified folder under the R working directory. Reverse 
sequences automatically are rejected. Proteins can be compared according to the specified column 
of either Protein IDs, Majority protein IDs, Protein names or Gene names on the proteinGroups.txt 
files as a function argument: 
#read .txt files as datasets, for instance, condition1.txt, condition2.txt, and condition3.txt, 
from a folder named #“proteinGroups” under the R working directory 
datasets <- read_proteinGroups(folderName = "proteinGroups") 
#extract the Protein IDs column from each file and combine as setList  
setList <- make_custom_setList(datasets, “Protein IDs”) 
The maxabpp package naturally supports the conventional approach that visualizes the 
intersections of identified protein sets on a Venn Diagram. In addition to the Venn Diagram, 
maxabpp plots the Target Diagram as a novel alternative for visualizing the intersecting protein 
sets: 
#generate a Venn object by calling Max_Venn function on the setList 
Venn_object <- Max_Venn(setList, IndividualAnalysis = FALSE) 





As shown on Figure 4.1B, the quantitative module begins with reading the 
ModificationSpecificPeptides.txt file generated from a single MaxQuant run on multiple MS raw 
data files from samples treated with inhibitor(s) at various inhibitor concentrations. A user-created 
metadata.txt file listing all the raw data files and their corresponding experimental conditions is 
also required: 
#read the .txt file as a dataset 
dataset <- read_tsv("ModificationSpecificPeptides.txt") 
#read the metadata.txt file 
metadata <- read_tsv(“metadata.txt”) 
#call pairwise_LFQ function to generate a LFQ table 
LFQ_table <- pairwise_LFQ( 
  raw = dataset, 
  metadata = metadata, 
  name_probe_mod = c("Mod"), 
  max_each_mod = 1, 
  max_total_mods = 1, 
  quantitation_level = "peptide", 
  background_check = FALSE, 
  normalize_to = "sum_all") 
#append additional information to the LFQ table 
LFQ_table <- append_ec_sites(LFQ_table, quantitation_level = "peptide") 




plot_volcano(LFQ_table, "InhibitorConcentration1 _vs_ InhibitorConcentration2 
_log2fold_change" , " InhibitorConcentration1 _vs_ InhibitorConcentration2 _-log10p-value", 
xlim = c(-5.5, 2), ylim = c(0, 4), "Gene Names", pCutoff = 1.3, FCcutoff = 0, 
"InhibitorConcentration1 _vs_ InhibitorConcentration2/Probe Name") 
Notably, the pairwise_LFQ function is highly versatile and flexible. Users can toggle 
parameters such as “quantitation_level”, “background_check” and “normalize_to” to perform 
additional analysis on the same set of data. For instance, when quantitation_level = “protein” is 
set, the pairwise_LFQ will perform quantitation at the protein level by aggregating/summarizing 
the intensity of all the probe-modified peptides belonging to individual protein groups. When the 
background_check = “TRUE” is set, the pairwise_LFQ will perform quantitation on background 
peptides (peptides without any probe modification) so that the user can assess the run-to-run 






4.1.2 maxabpp Enables specialized MaxQuant data analysis for 
competitive ABPP platforms. 
Occasionally, the cross-sample comparison of identified proteins can be a frustrating task. 
As part of the search algorithm, MaxQuant aggregates indistinguishable sequences, usually protein 
isoforms and homologous sequences, into protein groups. The aggregation of these proteins results 
in concatenated protein IDs, delimited by a semicolon. For example, the 5-AMP-activated protein 
kinase subunit gamma-1 is identified as a protein group of five isoforms/homologous sequences, 
“F8VYY9; A0A024R125; P54619-2; P54619; P54619-3; F8VPF5”. When comparing multiple 
sets of protein IDs for intersections, the conventional approach simply treats each protein group as 
a sequence of characters (string). Consequently, when related by slightly different protein groups 
(scrambled or missing protein ID components) from different sets are compared, the st ring-
matching algorithm would return FALSE, which reports these protein groups are totally different, 
for instance, “F8VYY9; A0A024R125; P54619-2; P54619; P54619-3; F8VPF5” vs. “P54619; 
A0A024R125; P54619-2; P54619-3; F8VPF5; F8VYY9” (scrambled components) vs. “F8VYY9; 
P54619-2; P54619; P54619-3; F8VPF5” (missing component A0A024R125) vs. “P54619-3” 
(single isoform). Alternatively, users often use gene names or protein names for protein IDs 
comparison, which drops the isoform-specific protein IDs and treats protein groups as a single 
canonical protein or a smaller group of homologous canonical proteins. This simplification is not 
ideal for processing ABPP data because protein isoform selectivity of both chemical probes and 
inhibitors is also considered valuable information and should be preserved. In the case of peptide-
centric and site-specific analysis, distinguishable protein isoforms should be treated as individual 
entities rather than part of protein groups.  
Therefore, a protein group-compatible alternative to Venn Diagram is needed to illustrate 




distinct sample processing methods. The qualitative module of maxabpp features the Target 
Diagram as a novel alternative for visualizing the intersecting protein sets. For instance, during the 
development of a new chemical probe, multiple distinct affinity tags may be used to explore its 
reactivity within a model proteome. After the CuAAC and affinity pulldown, probe-labeled 
proteins are enriched from each sample within a unique sample matrix. Each pulldown sample 
produces a unique LC-MS/MS profile. At the protein level, MaxQuant identified proteins are 
compared for similarities and differences. Proteins commonly identified in multiple differentially 
tagged samples are considered as target candidates with higher analytical confidence.197 
On the other hand, the affinity enrichment of analytes can also be performed on probe-
modified peptides after the trypsin digestion instead of probe-labeled proteins before the trypsin 
digestion. In this case, the maxabpp data analysis is focused on probe-modified peptides; data of 
probe-modified peptides needs to be filtered from the background peptides, annotated, 
summarized, and compared across different samples. 
In summary, maxabpp is a powerful R package that integrates unique functions processing 
both qualitative and quantitative proteomics data, and thus provides a reliable software solution 





4.2 Chapter 4 Figures 
Figure 4.1 Overview of maxabpp workflows. 
 
Note: (A) Qualitative workflow performing cross-sample comparisons of identified proteins. (B) 
Quantitative workflow performing pairwise LFQ of probe-modified peptides from competitive ABPP 




Chapter 5 Conclusion and Impact 
Chemical proteomics is attracting a growing amount of attention chemical biology research 
and beyond. Over the years, various chemical tools and analytical methods have been developed 
for chemical proteomics and thus significantly expediting numerous studies of small molecule 
modes of action and protein functions. Compared to traditional ligand binding assays, chemical 
proteomics methods uniquely highlight the omics methodology of holism and create systemic 
solutions to complex problems in chemical biology. Chemical proteomics is a multidisciplinary 
subject. The rapid expansion of chemical proteomics depends on its multiplying knowledge base 
and evolving technology, which touches a wide range of scientific subjects. The technological 
advancement of chemical proteomics has been discussed in three domains: chemical tools, mass 
spectrometry-based analytical methods, and bioinformatics support. The domain of chemical tools 
contains both chemical probes for protein reactivity profiling and chemical reagents for enhancing 
analytical performance. The former is discussed independently while the latter is considered part 
of the method development in mass spectrometry-based analysis.  
This dissertation has presented the implementation of chemical proteomics and utilization 
of chemical probes for biochemical measurements in two disparate directions. The 2-nitro-ICG 
probe exemplifies a novel compound-centric chemical probe that answers how 2-nitroimidazole 
targets tumor hypoxia. This study concludes that 2-nitro-ICG and its reduced fragments modified 
mouse albumin as the primary protein target, but at two structurally distinct sites, possibly via two 
different mechanisms. The development and application of 2-nitro-ICG also demonstrates various 
analytical benefits, challenges, and pitfalls in the compound-centric methodological branch of 




In contrast to the 2-nitro-ICG probe, the MeLac-alkyne probe is an innovative activity-
based chemical probe with multiple electrophilic sites. This study of MeLac warhead and MeLac-
alkyne probe explores the significance of broad reactivity in activity-based probes for their 
analytical versatility. The characterization of MeLac reactions concludes it is reactive to amino, 
hydroxyl, and thiol groups on different types of amino acid residues. It also leads to the discovery 
of MeLac-alkyne glutathione adduct, which reveals a potential scalable route towards rapidly 
conversion of a multi-electrophile activity-based probe into a large variety of compound-centric 
probes. These traits make the multi-electrophile a feature of greater significance on novel warheads 
like MeLac. Chemical probes equipped with these warheads afford distinct advantages of being 
both activity-based probes and scaffolds for assembling compound-centric probes simultaneously.  
In addition to the exploration of chemical probes and their reactivity profiles, the 
development of analytical methods in mass spectrometry plays another crucial role in chemical 
proteomics. Mass spectrometry is intrinsically a qualitative analytical approach while biological 
inferences are often derived from quantitative analysis of small molecule-treated proteomes in 
chemical proteomics. Although label-free quantitation is a viable option in some cases of 
proteomics profiling, accurate quantitative mass spectrometry primarily relies on the introduction 
of various forms of stable isotope-based labels and internal standards. Quantitation-oriented 
sample preparation methodologies such as metabolic labeling on proteins, chemical tagging on 
peptides, and stable isotope dilution have made mass spectrometry technology amenable for 
accurate and precise quantitation of protein targets throughout the chemical proteomics pipeline. 
Another focus in analytical method development is reduction of sample complexity. 
Biological samples have complex matrices. The introduction of chemical probes and click 




the affinity capture technology can significantly reduce sample complexity and efficiently enrich 
analytes, the final proteomics profiling data may still contain a large number of ambiguous spectra. 
This spectrum ambiguity issue has been demonstrated and addressed in two aspects: sample 
preparation and bioinformatics. In the preparation of MeLac-treated protein samples, the affinity 
tagging triplication technique has exposed a novel methodology for enhancing the analytical 
implications. On the other hand, the modification-specific data processing principle has provoked 
awareness and thoughts on tailoring bioinformatics tools for chemical proteomics. 
Despite a few limitations, chemical proteomics has established its irreplaceable position in 
chemical biology. Researchers continue to exert efforts to make chemical proteomics technologies 
more universally applicable. The chemical tools, analytical workflows, and bioinformatics support 
continue to improve. As more innovations emerge at the cutting edge of chemical proteomics, we 
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